CN1976699A - Synthesis of epothilones, intermediates thereto, analogues and uses thereof - Google Patents
Synthesis of epothilones, intermediates thereto, analogues and uses thereof Download PDFInfo
- Publication number
- CN1976699A CN1976699A CN 200580013480 CN200580013480A CN1976699A CN 1976699 A CN1976699 A CN 1976699A CN 200580013480 CN200580013480 CN 200580013480 CN 200580013480 A CN200580013480 A CN 200580013480A CN 1976699 A CN1976699 A CN 1976699A
- Authority
- CN
- China
- Prior art keywords
- chemical compound
- aliphatic
- hydrogen
- aryl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930013356 epothilone Natural products 0.000 title claims description 75
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 title claims description 67
- 239000000543 intermediate Substances 0.000 title description 8
- 238000003786 synthesis reaction Methods 0.000 title description 7
- 230000015572 biosynthetic process Effects 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 204
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 148
- 238000000034 method Methods 0.000 claims abstract description 46
- 201000011510 cancer Diseases 0.000 claims abstract description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 35
- 238000011282 treatment Methods 0.000 claims description 143
- 125000001931 aliphatic group Chemical group 0.000 claims description 120
- 239000000203 mixture Substances 0.000 claims description 117
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 claims description 109
- -1 Cyclic acetal Chemical class 0.000 claims description 94
- 229910052799 carbon Inorganic materials 0.000 claims description 92
- 125000003118 aryl group Chemical group 0.000 claims description 87
- 229910052739 hydrogen Inorganic materials 0.000 claims description 80
- 239000001257 hydrogen Substances 0.000 claims description 80
- 125000001072 heteroaryl group Chemical group 0.000 claims description 68
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 66
- 229910052731 fluorine Inorganic materials 0.000 claims description 66
- 125000000217 alkyl group Chemical group 0.000 claims description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- 125000002015 acyclic group Chemical group 0.000 claims description 46
- 229910052736 halogen Inorganic materials 0.000 claims description 43
- 150000002367 halogens Chemical class 0.000 claims description 42
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 32
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 32
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 31
- 230000037396 body weight Effects 0.000 claims description 26
- 239000007787 solid Substances 0.000 claims description 25
- 229910052760 oxygen Inorganic materials 0.000 claims description 24
- 230000000903 blocking effect Effects 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 23
- 125000000304 alkynyl group Chemical group 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 12
- 229910052740 iodine Inorganic materials 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 229910052794 bromium Inorganic materials 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 239000011593 sulfur Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 238000006317 isomerization reaction Methods 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 239000007856 photoaffinity label Substances 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 229910052723 transition metal Inorganic materials 0.000 claims description 2
- 150000003624 transition metals Chemical class 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 229910052751 metal Inorganic materials 0.000 claims 3
- 239000002184 metal Substances 0.000 claims 3
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 229910010082 LiAlH Inorganic materials 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 159
- 210000004027 cell Anatomy 0.000 description 140
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 119
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 87
- 229960001592 paclitaxel Drugs 0.000 description 87
- 229930012538 Paclitaxel Natural products 0.000 description 86
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 86
- 239000003814 drug Substances 0.000 description 79
- 239000000243 solution Substances 0.000 description 74
- 238000002474 experimental method Methods 0.000 description 69
- 108090000623 proteins and genes Proteins 0.000 description 64
- 241000699670 Mus sp. Species 0.000 description 62
- 238000004364 calculation method Methods 0.000 description 62
- 235000019439 ethyl acetate Nutrition 0.000 description 59
- 206010035226 Plasma cell myeloma Diseases 0.000 description 58
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 53
- 239000011734 sodium Substances 0.000 description 51
- 239000000460 chlorine Substances 0.000 description 49
- 201000000050 myeloid neoplasm Diseases 0.000 description 45
- 238000005160 1H NMR spectroscopy Methods 0.000 description 43
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- 229940079593 drug Drugs 0.000 description 41
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 39
- 238000000746 purification Methods 0.000 description 35
- 125000001424 substituent group Chemical group 0.000 description 35
- 230000000694 effects Effects 0.000 description 34
- 102000014150 Interferons Human genes 0.000 description 33
- 108010050904 Interferons Proteins 0.000 description 33
- 229940079322 interferon Drugs 0.000 description 33
- 239000002585 base Substances 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 31
- 238000003756 stirring Methods 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 230000002829 reductive effect Effects 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- 206010059866 Drug resistance Diseases 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 150000002148 esters Chemical class 0.000 description 23
- 238000001990 intravenous administration Methods 0.000 description 23
- 229920006395 saturated elastomer Polymers 0.000 description 23
- 102000035195 Peptidases Human genes 0.000 description 22
- 108091005804 Peptidases Proteins 0.000 description 22
- 239000002253 acid Substances 0.000 description 22
- 238000011580 nude mouse model Methods 0.000 description 22
- 230000010412 perfusion Effects 0.000 description 22
- 235000019833 protease Nutrition 0.000 description 22
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- 238000004440 column chromatography Methods 0.000 description 21
- 230000001105 regulatory effect Effects 0.000 description 21
- 108091022875 Microtubule Proteins 0.000 description 20
- 230000001225 therapeutic effect Effects 0.000 description 20
- 238000005406 washing Methods 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 102000029749 Microtubule Human genes 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 19
- 210000004688 microtubule Anatomy 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 238000002560 therapeutic procedure Methods 0.000 description 19
- 229910004298 SiO 2 Inorganic materials 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 230000006907 apoptotic process Effects 0.000 description 18
- 230000003828 downregulation Effects 0.000 description 18
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 18
- 241000699660 Mus musculus Species 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 239000004519 grease Substances 0.000 description 16
- 239000000741 silica gel Substances 0.000 description 16
- 229910002027 silica gel Inorganic materials 0.000 description 16
- 229960001866 silicon dioxide Drugs 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 15
- 238000004043 dyeing Methods 0.000 description 15
- 238000003818 flash chromatography Methods 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 15
- 239000012141 concentrate Substances 0.000 description 14
- 238000006356 dehydrogenation reaction Methods 0.000 description 14
- 238000000605 extraction Methods 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 239000000376 reactant Substances 0.000 description 14
- 238000011160 research Methods 0.000 description 14
- 238000002689 xenotransplantation Methods 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 208000034578 Multiple myelomas Diseases 0.000 description 13
- 235000008504 concentrate Nutrition 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 206010009944 Colon cancer Diseases 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 125000004414 alkyl thio group Chemical group 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 12
- 238000005352 clarification Methods 0.000 description 12
- 239000011737 fluorine Substances 0.000 description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 12
- 238000004809 thin layer chromatography Methods 0.000 description 12
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 11
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 11
- 230000001093 anti-cancer Effects 0.000 description 11
- 239000002246 antineoplastic agent Substances 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 125000000623 heterocyclic group Chemical group 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 125000002769 thiazolinyl group Chemical group 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 10
- 206010025323 Lymphomas Diseases 0.000 description 10
- 206010033128 Ovarian cancer Diseases 0.000 description 10
- 102000004243 Tubulin Human genes 0.000 description 10
- 108090000704 Tubulin Proteins 0.000 description 10
- 239000003005 anticarcinogenic agent Substances 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 230000022131 cell cycle Effects 0.000 description 10
- 239000012230 colorless oil Substances 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 208000032839 leukemia Diseases 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 229940002612 prodrug Drugs 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 9
- 230000001640 apoptogenic effect Effects 0.000 description 9
- 150000003883 epothilone derivatives Chemical class 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 229960003048 vinblastine Drugs 0.000 description 9
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 101000840275 Homo sapiens Interferon alpha-inducible protein 27, mitochondrial Proteins 0.000 description 8
- 102100029604 Interferon alpha-inducible protein 27, mitochondrial Human genes 0.000 description 8
- 241001597008 Nomeidae Species 0.000 description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 201000008275 breast carcinoma Diseases 0.000 description 8
- 150000001993 dienes Chemical class 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000005649 metathesis reaction Methods 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 108090000672 Annexin A5 Proteins 0.000 description 7
- 102000004121 Annexin A5 Human genes 0.000 description 7
- 208000031648 Body Weight Changes Diseases 0.000 description 7
- 208000035126 Facies Diseases 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000004579 body weight change Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 150000002576 ketones Chemical class 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 102100027621 2'-5'-oligoadenylate synthase 2 Human genes 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 101150042183 GIP3 gene Proteins 0.000 description 6
- 101100218338 Gibberella zeae (strain ATCC MYA-4620 / CBS 123657 / FGSC 9075 / NRRL 31084 / PH-1) aurO gene Proteins 0.000 description 6
- 101001008910 Homo sapiens 2'-5'-oligoadenylate synthase 2 Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 6
- 239000005482 chemotactic factor Substances 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 230000008034 disappearance Effects 0.000 description 6
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 210000000582 semen Anatomy 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 238000010189 synthetic method Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 231100001274 therapeutic index Toxicity 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 229940099039 velcade Drugs 0.000 description 6
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 6
- 229960004982 vinblastine sulfate Drugs 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 5
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 5
- 102100033985 Heterogeneous nuclear ribonucleoprotein D0 Human genes 0.000 description 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 5
- 101001017535 Homo sapiens Heterogeneous nuclear ribonucleoprotein D0 Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 102100040021 Interferon-induced transmembrane protein 1 Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 102000011931 Nucleoproteins Human genes 0.000 description 5
- 108010061100 Nucleoproteins Proteins 0.000 description 5
- 206010034133 Pathogen resistance Diseases 0.000 description 5
- 102100034627 Phospholipid scramblase 1 Human genes 0.000 description 5
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 150000001336 alkenes Chemical class 0.000 description 5
- 125000005110 aryl thio group Chemical group 0.000 description 5
- 125000004104 aryloxy group Chemical group 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- PNPBGYBHLCEVMK-UHFFFAOYSA-N benzylidene(dichloro)ruthenium;tricyclohexylphosphanium Chemical compound Cl[Ru](Cl)=CC1=CC=CC=C1.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1 PNPBGYBHLCEVMK-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- AEAGZTSEFUFUKN-UHFFFAOYSA-N epothilone 490 Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CC=CC(C)=CCC1C(C)=CC1=CSC(C)=N1 AEAGZTSEFUFUKN-UHFFFAOYSA-N 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 238000011010 flushing procedure Methods 0.000 description 5
- 239000011984 grubbs catalyst Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 125000005553 heteroaryloxy group Chemical group 0.000 description 5
- 125000005368 heteroarylthio group Chemical group 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 206010022000 influenza Diseases 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- POPACFLNWGUDSR-UHFFFAOYSA-N methoxy(trimethyl)silane Chemical compound CO[Si](C)(C)C POPACFLNWGUDSR-UHFFFAOYSA-N 0.000 description 5
- 238000005497 microtitration Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000005760 tumorsuppression Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
- NPOAOTPXWNWTSH-UHFFFAOYSA-N 3-hydroxy-3-methylglutaric acid Chemical compound OC(=O)CC(O)(C)CC(O)=O NPOAOTPXWNWTSH-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 102100025828 Centromere protein C Human genes 0.000 description 4
- 101710088194 Dehydrogenase Proteins 0.000 description 4
- 101001034844 Homo sapiens Interferon-induced transmembrane protein 1 Proteins 0.000 description 4
- 101000609943 Homo sapiens Pecanex-like protein 1 Proteins 0.000 description 4
- 101001067396 Homo sapiens Phospholipid scramblase 1 Proteins 0.000 description 4
- 102100031802 Interferon-induced GTP-binding protein Mx1 Human genes 0.000 description 4
- 108010047956 Nucleosomes Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 102100039176 Pecanex-like protein 1 Human genes 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 238000005575 aldol reaction Methods 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- HFEHLDPGIKPNKL-UHFFFAOYSA-N allyl iodide Chemical compound ICC=C HFEHLDPGIKPNKL-UHFFFAOYSA-N 0.000 description 4
- 230000029918 bioluminescence Effects 0.000 description 4
- 238000005415 bioluminescence Methods 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 108010031373 centromere protein C Proteins 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 230000009274 differential gene expression Effects 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 208000003747 lymphoid leukemia Diseases 0.000 description 4
- 239000003120 macrolide antibiotic agent Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000001623 nucleosome Anatomy 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 150000002924 oxiranes Chemical class 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 201000008519 polycystic kidney disease 1 Diseases 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- GWYPDXLJACEENP-UHFFFAOYSA-N 1,3-cycloheptadiene Chemical compound C1CC=CC=CC1 GWYPDXLJACEENP-UHFFFAOYSA-N 0.000 description 3
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 3
- GTVAUHXUMYENSK-RWSKJCERSA-N 2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC=C)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GTVAUHXUMYENSK-RWSKJCERSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- XQCKXOKBWVXUJH-UHFFFAOYSA-N CCOC([O])=O Chemical compound CCOC([O])=O XQCKXOKBWVXUJH-UHFFFAOYSA-N 0.000 description 3
- 101001024441 Candida albicans (strain SC5314 / ATCC MYA-2876) Major facilitator superfamily multidrug transporter NAG3 Proteins 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 102100034597 E3 ubiquitin-protein ligase TRIM22 Human genes 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical class OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 3
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 3
- 101000848629 Homo sapiens E3 ubiquitin-protein ligase TRIM22 Proteins 0.000 description 3
- 101001082065 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 description 3
- 101000662690 Homo sapiens Trafficking protein particle complex subunit 10 Proteins 0.000 description 3
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 description 3
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 101150064138 MAP1 gene Proteins 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 108090000315 Protein Kinase C Proteins 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 102100037456 Trafficking protein particle complex subunit 10 Human genes 0.000 description 3
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 150000001540 azides Chemical class 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000007541 cellular toxicity Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000017858 demethylation Effects 0.000 description 3
- 238000010520 demethylation reaction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- FFHWGQQFANVOHV-UHFFFAOYSA-N dimethyldioxirane Chemical compound CC1(C)OO1 FFHWGQQFANVOHV-UHFFFAOYSA-N 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229940126701 oral medication Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 150000003254 radicals Chemical group 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 239000013585 weight reducing agent Substances 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- FCCNKYGSMOSYPV-DEDISHTHSA-N (-)-Epothilone E Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C FCCNKYGSMOSYPV-DEDISHTHSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- CRDZYJSQHCXHEG-XLBFCUQGSA-N (4Z,7Z,10S,11E,13Z,15E,17S,19Z)-10,17-dihydroxydocosahexaenoic acid Chemical compound CC\C=C/C[C@H](O)\C=C\C=C/C=C/[C@@H](O)C\C=C/C\C=C/CCC(O)=O CRDZYJSQHCXHEG-XLBFCUQGSA-N 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 2
- 102100027769 2'-5'-oligoadenylate synthase 1 Human genes 0.000 description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical class CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- QUTGXAIWZAMYEM-UHFFFAOYSA-N 2-cyclopentyloxyethanamine Chemical compound NCCOC1CCCC1 QUTGXAIWZAMYEM-UHFFFAOYSA-N 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 102100021308 60S ribosomal protein L23 Human genes 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 102100040084 A-kinase anchor protein 9 Human genes 0.000 description 2
- 102100033757 Acyl-coenzyme A thioesterase 11 Human genes 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 101100465060 Arabidopsis thaliana PRK4 gene Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 101100400452 Caenorhabditis elegans map-2 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000003846 Carbonic anhydrases Human genes 0.000 description 2
- 108090000209 Carbonic anhydrases Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000003909 Cyclin E Human genes 0.000 description 2
- 108090000257 Cyclin E Proteins 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical group C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102100035347 DmX-like protein 2 Human genes 0.000 description 2
- 101710105865 DmX-like protein 2 Proteins 0.000 description 2
- 102100029721 DnaJ homolog subfamily B member 1 Human genes 0.000 description 2
- 102100027085 Dual specificity protein phosphatase 4 Human genes 0.000 description 2
- 102100039922 E3 ISG15-protein ligase HERC5 Human genes 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 102100032864 General transcription factor IIH subunit 2 Human genes 0.000 description 2
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 2
- 108010093061 HLA-DPA1 antigen Proteins 0.000 description 2
- 102000016761 Haem oxygenases Human genes 0.000 description 2
- 108050006318 Haem oxygenases Proteins 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101001008907 Homo sapiens 2'-5'-oligoadenylate synthase 1 Proteins 0.000 description 2
- 101000675833 Homo sapiens 60S ribosomal protein L23 Proteins 0.000 description 2
- 101000890598 Homo sapiens A-kinase anchor protein 9 Proteins 0.000 description 2
- 101000801224 Homo sapiens Acyl-coenzyme A thioesterase 11 Proteins 0.000 description 2
- 101001057621 Homo sapiens Dual specificity protein phosphatase 4 Proteins 0.000 description 2
- 101001035145 Homo sapiens E3 ISG15-protein ligase HERC5 Proteins 0.000 description 2
- 101000655398 Homo sapiens General transcription factor IIH subunit 2 Proteins 0.000 description 2
- 101000839025 Homo sapiens Hydroxymethylglutaryl-CoA synthase, cytoplasmic Proteins 0.000 description 2
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 description 2
- 101100241084 Homo sapiens NRTN gene Proteins 0.000 description 2
- 101001094741 Homo sapiens POU domain, class 4, transcription factor 1 Proteins 0.000 description 2
- 101000583581 Homo sapiens Polyhomeotic-like protein 3 Proteins 0.000 description 2
- 101001074295 Homo sapiens Protein kinase C-binding protein 1 Proteins 0.000 description 2
- 101001095989 Homo sapiens RalBP1-associated Eps domain-containing protein 1 Proteins 0.000 description 2
- 101000650811 Homo sapiens Semaphorin-3D Proteins 0.000 description 2
- 101000679340 Homo sapiens Transformer-2 protein homolog alpha Proteins 0.000 description 2
- 101000838463 Homo sapiens Tubulin alpha-1A chain Proteins 0.000 description 2
- 102100028888 Hydroxymethylglutaryl-CoA synthase, cytoplasmic Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 229940119336 Microtubule stabilizer Drugs 0.000 description 2
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 102100021584 Neurturin Human genes 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 102100035395 POU domain, class 4, transcription factor 1 Human genes 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100030905 Polyhomeotic-like protein 3 Human genes 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 102100035697 Protein kinase C-binding protein 1 Human genes 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 102100037881 RalBP1-associated Eps domain-containing protein 1 Human genes 0.000 description 2
- 102000004208 Ribosomal protein L2 Human genes 0.000 description 2
- 108090000775 Ribosomal protein L2 Proteins 0.000 description 2
- 102100035947 S-adenosylmethionine synthase isoform type-2 Human genes 0.000 description 2
- 101000785134 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Probable phospholipid-transporting ATPase DNF3 Proteins 0.000 description 2
- 102100027746 Semaphorin-3D Human genes 0.000 description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 241000862997 Sorangium cellulosum Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 241000011102 Thera Species 0.000 description 2
- 102000006288 Transcription Factor TFIIH Human genes 0.000 description 2
- 108010083256 Transcription Factor TFIIH Proteins 0.000 description 2
- 102100022573 Transformer-2 protein homolog alpha Human genes 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 102100031638 Tuberin Human genes 0.000 description 2
- 108050009309 Tuberin Proteins 0.000 description 2
- 102100028968 Tubulin alpha-1A chain Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100028982 Vezatin Human genes 0.000 description 2
- 101710184950 Vezatin Proteins 0.000 description 2
- 238000007239 Wittig reaction Methods 0.000 description 2
- VRGWBRLULZUWAJ-XFFXIZSCSA-N [(2s)-2-[(1r,3z,5s,8z,12z,15s)-5,17-dihydroxy-4,8,12,15-tetramethyl-16-oxo-18-bicyclo[13.3.0]octadeca-3,8,12,17-tetraenyl]propyl] acetate Chemical compound C1\C=C(C)/CC\C=C(C)/CC[C@H](O)\C(C)=C/C[C@@H]2C([C@@H](COC(C)=O)C)=C(O)C(=O)[C@]21C VRGWBRLULZUWAJ-XFFXIZSCSA-N 0.000 description 2
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 238000005865 alkene metathesis reaction Methods 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 235000019994 cava Nutrition 0.000 description 2
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 108010087236 cobra venom endonuclease Proteins 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 239000000039 congener Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- DGXRZJSPDXZJFG-UHFFFAOYSA-N docosanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCCCCCCC(O)=O DGXRZJSPDXZJFG-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000009483 enzymatic pathway Effects 0.000 description 2
- FCCNKYGSMOSYPV-OKOHHBBGSA-N epothilone e Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 FCCNKYGSMOSYPV-OKOHHBBGSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- VRGWBRLULZUWAJ-UHFFFAOYSA-N fusaproliferin Natural products C1C=C(C)CCC=C(C)CCC(O)C(C)=CCC2C(C(COC(C)=O)C)=C(O)C(=O)C21C VRGWBRLULZUWAJ-UHFFFAOYSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000006772 olefination reaction Methods 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000002616 plasmapheresis Methods 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229930185346 proliferin Natural products 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000003335 steric effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 150000003557 thiazoles Chemical class 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 208000012991 uterine carcinoma Diseases 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- GNWBLLYJQXKPIP-ZOGIJGBBSA-N (1s,3as,3bs,5ar,9ar,9bs,11as)-n,n-diethyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,5a,8,9,9b,10,11-dodecahydro-1h-indeno[5,4-f]quinoline-1-carboxamide Chemical compound CN([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)N(CC)CC)[C@@]2(C)CC1 GNWBLLYJQXKPIP-ZOGIJGBBSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- JSLZUBLGGPEVQN-DIPNUNPCSA-N (2r)-4-methyl-2-propan-2-yl-2-[2-[4-[4-[2-(3,4,5-trimethoxyphenyl)ethyl]piperazin-1-yl]butoxy]phenyl]-1,4-benzothiazin-3-one Chemical compound COC1=C(OC)C(OC)=CC(CCN2CCN(CCCCOC=3C(=CC=CC=3)[C@@]3(C(N(C)C4=CC=CC=C4S3)=O)C(C)C)CC2)=C1 JSLZUBLGGPEVQN-DIPNUNPCSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- AUZFRDWTLAUNIR-ZIXYPWDKSA-N (4s,7r,8s,9s,10e,13e,16s)-4,8-dihydroxy-5,5,7,9-tetramethyl-16-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-13-(trifluoromethyl)-1-oxacyclohexadeca-10,13-diene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C\C(C(F)(F)F)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 AUZFRDWTLAUNIR-ZIXYPWDKSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 102100035389 2'-5'-oligoadenylate synthase 3 Human genes 0.000 description 1
- PRHXFAWRSMEJKZ-UHFFFAOYSA-N 2,3-dimethoxy-1h-pyrrole Chemical class COC=1C=CNC=1OC PRHXFAWRSMEJKZ-UHFFFAOYSA-N 0.000 description 1
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 1
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- IGMMTYZWNUSEEU-UHFFFAOYSA-N 3-(2-chloroethyl)-1-cyclohexyl-1-nitrosourea Chemical compound ClCCNC(=O)N(N=O)C1CCCCC1 IGMMTYZWNUSEEU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 108060000255 AIM2 Proteins 0.000 description 1
- 102100028777 AP-1 complex subunit sigma-1A Human genes 0.000 description 1
- 101150115055 ATG16 gene Proteins 0.000 description 1
- 102100022594 ATP-binding cassette sub-family G member 1 Human genes 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 101100330285 Arabidopsis thaliana OASA2 gene Proteins 0.000 description 1
- 101100462123 Arabidopsis thaliana OHP1 gene Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100040355 Autophagy-related protein 16-1 Human genes 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 108700009171 B-Cell Lymphoma 3 Proteins 0.000 description 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 1
- 102100021570 B-cell lymphoma 3 protein Human genes 0.000 description 1
- 101150072667 Bcl3 gene Proteins 0.000 description 1
- 101710125089 Bindin Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FAVAYIPFMLUGIT-UHFFFAOYSA-N C(C)(C)OC(C(C)(C)C)(OOC(C)(C)C)OCCCC Chemical compound C(C)(C)OC(C(C)(C)C)(OOC(C)(C)C)OCCCC FAVAYIPFMLUGIT-UHFFFAOYSA-N 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- VPIDXLJVGVBFOW-UHFFFAOYSA-N C=1C=[C-]PC=1 Chemical compound C=1C=[C-]PC=1 VPIDXLJVGVBFOW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 108050001186 Chaperonin Cpn60 Proteins 0.000 description 1
- 102000052603 Chaperonins Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 102100040428 Chitobiosyldiphosphodolichol beta-mannosyltransferase Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100029117 Coagulation factor X Human genes 0.000 description 1
- 102100024066 Coiled-coil and C2 domain-containing protein 1A Human genes 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Chemical class 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000015833 Cystatin Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108010000518 Dual-Specificity Phosphatases Proteins 0.000 description 1
- 102000002266 Dual-Specificity Phosphatases Human genes 0.000 description 1
- 101150071673 E6 gene Proteins 0.000 description 1
- 101150013359 E7 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 108010093099 Endoribonucleases Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102100029777 Eukaryotic translation initiation factor 3 subunit M Human genes 0.000 description 1
- 108010066805 F-Box Proteins Proteins 0.000 description 1
- 102000018700 F-Box Proteins Human genes 0.000 description 1
- 102100024516 F-box only protein 5 Human genes 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100031510 Fibrillin-2 Human genes 0.000 description 1
- 108010030242 Fibrillin-2 Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100037854 G1/S-specific cyclin-E2 Human genes 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 1
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
- 101150007870 HEMA3 gene Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 1
- 102100028006 Heme oxygenase 1 Human genes 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 101000597332 Homo sapiens 2'-5'-oligoadenylate synthase 3 Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000768000 Homo sapiens AP-1 complex subunit sigma-1A Proteins 0.000 description 1
- 101000964092 Homo sapiens Autophagy-related protein 16-1 Proteins 0.000 description 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000891557 Homo sapiens Chitobiosyldiphosphodolichol beta-mannosyltransferase Proteins 0.000 description 1
- 101000910423 Homo sapiens Coiled-coil and C2 domain-containing protein 1A Proteins 0.000 description 1
- 101000619536 Homo sapiens DNA-dependent protein kinase catalytic subunit Proteins 0.000 description 1
- 101000866018 Homo sapiens DnaJ homolog subfamily B member 1 Proteins 0.000 description 1
- 101001012700 Homo sapiens Eukaryotic translation initiation factor 3 subunit M Proteins 0.000 description 1
- 101001052797 Homo sapiens F-box only protein 5 Proteins 0.000 description 1
- 101000738575 Homo sapiens G1/S-specific cyclin-E2 Proteins 0.000 description 1
- 101001079623 Homo sapiens Heme oxygenase 1 Proteins 0.000 description 1
- 101000599573 Homo sapiens InaD-like protein Proteins 0.000 description 1
- 101001076680 Homo sapiens Insulin-induced gene 1 protein Proteins 0.000 description 1
- 101001032341 Homo sapiens Interferon regulatory factor 9 Proteins 0.000 description 1
- 101000980162 Homo sapiens Mediator of RNA polymerase II transcription subunit 18 Proteins 0.000 description 1
- 101001000091 Homo sapiens Nucleoporin-62 C-terminal-like protein Proteins 0.000 description 1
- 101000605434 Homo sapiens Phospholipid phosphatase 2 Proteins 0.000 description 1
- 101000701363 Homo sapiens Phospholipid-transporting ATPase IC Proteins 0.000 description 1
- 101000609211 Homo sapiens Polyadenylate-binding protein 2 Proteins 0.000 description 1
- 101000898093 Homo sapiens Protein C-ets-2 Proteins 0.000 description 1
- 101001068630 Homo sapiens Protein PRRC2B Proteins 0.000 description 1
- 101000822339 Homo sapiens Protein transport protein Sec24D Proteins 0.000 description 1
- 101000947881 Homo sapiens S-adenosylmethionine synthase isoform type-2 Proteins 0.000 description 1
- 101000836383 Homo sapiens Serpin H1 Proteins 0.000 description 1
- 101000666730 Homo sapiens T-complex protein 1 subunit alpha Proteins 0.000 description 1
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100037978 InaD-like protein Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100025887 Insulin-induced gene 1 protein Human genes 0.000 description 1
- 101710169201 Interferon alpha-inducible protein 6 Proteins 0.000 description 1
- 102100038251 Interferon regulatory factor 9 Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 101710087399 Interferon-induced transmembrane protein 1 Proteins 0.000 description 1
- 102100024064 Interferon-inducible protein AIM2 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 101150112867 MX1 gene Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100024280 Mediator of RNA polymerase II transcription subunit 18 Human genes 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 108010090314 Member 1 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 241000699729 Muridae Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 108010063737 Myristoylated Alanine-Rich C Kinase Substrate Proteins 0.000 description 1
- 102000015695 Myristoylated Alanine-Rich C Kinase Substrate Human genes 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102100036544 Nucleoporin-62 C-terminal-like protein Human genes 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 102000001107 Phosphatidate Phosphatase Human genes 0.000 description 1
- 108010069394 Phosphatidate Phosphatase Proteins 0.000 description 1
- 102100038120 Phospholipid phosphatase 2 Human genes 0.000 description 1
- 101710149609 Phospholipid scramblase 1 Proteins 0.000 description 1
- 102100030448 Phospholipid-transporting ATPase IC Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102100039427 Polyadenylate-binding protein 2 Human genes 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102100021890 Protein C-ets-2 Human genes 0.000 description 1
- 102100033953 Protein PRRC2B Human genes 0.000 description 1
- 102100022542 Protein transport protein Sec24D Human genes 0.000 description 1
- ULQISTXYYBZJSJ-UHFFFAOYSA-N R-12-HOA Natural products CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 102100038914 RalA-binding protein 1 Human genes 0.000 description 1
- 101150041852 Ralbp1 gene Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 101710167557 S-adenosylmethionine synthase isoform type-2 Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 108091006630 SLC13A1 Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 102100027287 Serpin H1 Human genes 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 102100036743 Solute carrier family 13 member 1 Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102000005262 Sulfatase Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 102100038410 T-complex protein 1 subunit alpha Human genes 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229920003180 amino resin Polymers 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001675 anti-mdr Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940044684 anti-microtubule agent Drugs 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000005998 bromoethyl group Chemical group 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229950005953 camsilate Drugs 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229950004783 cipionate Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 108050004038 cystatin Proteins 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- JZZIHCLFHIXETF-UHFFFAOYSA-N dimethylsilicon Chemical compound C[Si]C JZZIHCLFHIXETF-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 235000015177 dried meat Nutrition 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000005837 enolization reaction Methods 0.000 description 1
- FCCNKYGSMOSYPV-UHFFFAOYSA-N epothilone E Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2OC2CC1C(C)=CC1=CSC(CO)=N1 FCCNKYGSMOSYPV-UHFFFAOYSA-N 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000013415 human tumor xenograft model Methods 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 229950001891 iprotiazem Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical group [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229910000474 mercury oxide Inorganic materials 0.000 description 1
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 1
- 239000003863 metallic catalyst Substances 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000029115 microtubule polymerization Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 1
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 108010057248 oncogene proteins v-ets Proteins 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000005222 photoaffinity labeling Methods 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229950008885 polyglycolic acid Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 231100000814 pulsed exposure Toxicity 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000718 radiation-protective agent Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 101150015999 sec24 gene Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- OETNSIFETJNLBD-UHFFFAOYSA-M sodium;benzenesulfonate;hydrate Chemical class O.[Na+].[O-]S(=O)(=O)C1=CC=CC=C1 OETNSIFETJNLBD-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 108060007951 sulfatase Proteins 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000155 toxicity by organ Toxicity 0.000 description 1
- 230000007675 toxicity by organ Effects 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical compound OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 238000013298 xenograft nude mouse model Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides compounds of formula (I): as described generally and in classes and subclasses herein. The present invention additionally provides pharmaceutical compositions comprising compounds of formula (I) and provides methods of treating cancer comprising administering a compound of formula (I).
Description
Background of invention
Epothilones (Epothilone) A and B (2a and 2b, sketch map 1) be from the cellulose degradation mycobacterium, the n cell toxin macrolide of separating in the sorangium cellulosum (sorangium cellulosum) (people Angew.Chem. such as H fle, Int.Ed.Engl.1996,35,1567 and J.Antibiot.1996,49,560; Every piece of document is incorporated the present invention by reference into).Although their structure differs widely, Epothilones A and B have as paclitaxel (Taxol (Taxol)
) the mechanism of action, this mechanism comprises growth (people Cancer Res.1995 such as Bollag, 55,2325 of the anticancer by the stable of tubulin polymerization and microtubule assembling (microtubuleassemblies); Incorporate the present invention by reference into).Although it has unquestionable clinical value, Taxol as the front chemotherapeutant
It far not ideal medicament.But its dissolubility that is slightly soluble in water makes it must be by preparation vehicle Li Mofu (Cremophor) for example, and this causes himself danger and problem of management (people J.Allergy Clin.Immunol.1996 such as Essayan, 97,42; Incorporate the present invention by reference into).In addition, Taxol
Be easy to inactivation (people J.Biol.Chem.1997 such as Giannakakou, 272,17118 by multi-drug resistant (MDR); Incorporate the present invention by reference into).Yet this has illustrated that also Epothilones A and B have kept remarkable effectiveness (the people Mol.Biol.Cell 1995,6,2137 such as Kowalski of anti-MDR tumor cell; Incorporate the present invention by reference into).In addition, for the prescription ability (formulability) of Epothilones, it may be useful that the water-soluble of increase is compared with paclitaxel.Though native compound, epothilone B (2b, EpoB, in the sketch map 1), be the effective Epothilones family member of natural product, but at least in the xenotransplantation mice, unfortunate have narrow troublesomely therapeutic index (people Angew.Chem.Int.Ed.Engl.1997 such as Su, 36,1093; People J.Org.Chem.1999 such as Harris, 64,8434; Every piece of document is incorporated the present invention by reference into).
2a R
1=H, R
2=CH
3, Epothilones
A(EpoA)
2b R
1=CH
3, R
2=CH
3, Epothilones
1a R=Ph, paclitaxel (Taxol) B (EpoB)
1b R=t-Bu, Docetaxel (Taxotere) 2c R
1=H, R
2=CH
2OH, Epothilones
E(EpoE)
2d R
1=CH
3, R
2=CH
2OH, the dust slope is mould
Plain F (EpoF)
Sketch map 1: taxanes (Taxoids) and Epothilones
In view of EpoB has limited therapeutic index, people study other epothilone analogs, and particularly 12, the 13-NSC-703147, the ability that improved treatment characteristic (therapeuticprofile) is provided is (referring to United States Patent (USP) 6,242,469,6,284,781,6,300,355,6,369,234,6,204,388,6,316,630; Every piece of document is incorporated the present invention by reference into).Experimental results show that 12 in the body of on various mouse models, implementing, 13-NSC-703147 B (3b in the sketch map 2, dEpoB) in the mice xenograft, have anti-various sensitivities and drug-fast people's tumor treatment and render a service (people Proc.Natl.Acad.Sci.U.S.A.1998 such as Chou, 95,9642 and 15798; Incorporate the present invention by reference into).Recently, these NSC-703147 compare other anticarcinogen the treatment advantage by comparative study by final certification (people Proc.Natl.Acad.Sci.U.S.A.2001 such as Chou, 98,8113; Incorporate the present invention by reference into).Because its impressive body internal characteristic, dEpoB have passed through the intravital toxicity evaluation of Canis familiaris L. in advance, and now carrying out human trial as cancer therapy drug.
3a R
1=H, R
2=CH
3, deoxidation dust 4a R
1=H, R
2=CH
3, dehydrogenase 35 a R
1=H, R
2=CH
3, different
Slope mycin A (dEpoA) dEpoA (ddEpoA)-dEpoA
3b R
1=CH
3, R
2=CH
3, deoxidation 4b R
1=CH
3, R
2=CH
3, dehydrogenase 35 b R
1=CH
3, R
2=CH
3, different
Epothilone B (dEpoB) dEpoB (ddEpoB)-dEpoB
3c R
1=H, R
2=CH
2OH, deoxidation 4c R
1=H, R
2=CH
2OH, dehydrogenase 35 c R
1=H, R
2=CH
2OH, different
Epothilone E (-)-Epothilone E. (dEpoE) dEpoE (ddEpoE) dEpoE
3d R
1=CH
3, R
2=CH
2OH, 4d R
1=CH
3, R
2=CH
2OH takes off 5d R
1=CH
3, R
2=CH
2OH,
The different dEpoF of NSC-703147 F (dEpoF) hydrogen dEpoF (ddEpoF) (ddEpoF)
3e R
1=H, R
2=NH
2, demethylation 4e R
1=H, R
2=NH
2, demethylation ammonia 5e R
1=H, R
2=NH
2, demethylation
Amino-dEpoA (dadEpoA) base-ddEpoA amino-different-dEpoA
3f R
1=CH
3, R
2=NH
2, piptonychia 4f R
1=CH
3, R
2=NH
2, piptonychia 5fR
1=CH
3, R
2=NH
2, piptonychia
The basic amino of base amino-dEpoB (dadEpoB)-ddEpoB base amino-different-dEpoB
3g R
1=CH
2F, R
2=CH
3, 26-fluorine 4g R
1=CH
2F, R
2=CH
3, the 26-fluorine
-dEpoB -ddEpoB
3h R
1=CF
3, R
2=CH
3, 26-three 4h R
1=CF
3, R
2=CH
3, the 26-trifluoro
Fluoro-dEpoB-ddEpoB
Consider describedly 12, the promising treatment effectiveness of 13-NSC-703147 is necessary to study other analog and other synthetic method, be used for synthetic existing Epothilones, NSC-703147 and analog thereof with and novel analog.Especially, in view of on the treatment effectiveness of this compounds, becoming interested, be necessary to develop can provide the chemical compound described in a large amount of aforesaid any Epothilones or NSC-703147 or the present invention methodology, be used for clinical trial and mass preparation.
Description of drawings
Fig. 1 represents 12-trifluoromethyl-9, and 10-dehydrogenation NSC-703147 D's is synthetic.
Fig. 2 represents to prepare 12-trifluoromethyl-9 by Epo A, the several method of 10-dehydrogenation NSC-703147 D.
Fig. 3 represents to prepare 9 to the C9-C10 position, 10-dehydrogenation-epoD by Epo 490 by making the C10-C11 double-bond isomerization.
Fig. 4 has described 9, and the various epothilone analogs of modification are arranged on the 10-position.
Fig. 5 represents to adopt 9, the locational closed loop metathesis reaction of 10-and carry out various 9,10-dehydrogenation-epothilone analogs synthetic.
Fig. 6 represents experimental result, and wherein the MX-1 xenograft of super large is implanted in the nude mice.With MX-1 tumor tissues (50mg) subcutaneous implantation in the 0th day.When the tumor size reached 960 ± 132mg (be about body weight 3.4%), 6hr intravenous perfusion Fu Dilong (Fludelone) 25mg/kg was as shown by arrows in D22, D25, D28, D31 and D34 administration Q3D * 5 at the 22nd day (D22).Subsequently 9 days intermittences, carry out treatment second round in D43, D46, D49 and D52.The tumor size is treated in matched group (●) and the Fu Dilong treatment group () (every group of n=5) at excipient and is changed.Continue to observe Q3D until D180, at this moment stop experiment (after D52 stops to treat 128 days).Fig. 6 A represents to be reduced and the therapeutic effect of expression by the tumor size.Fig. 6 B represents that nude mice (being selected from a mouse of matched group and treatment group separately) is at photo that D25, D31, D37, D43 and D52 took.When stopping, the D180 experiment do not observe recurrence.Fig. 6 C represents body weight change.
Fig. 7 T-cell lymphoblastic leukemia (CCRF-CEM/ Taxol) (drug resistance to Taxol is 44 times) of representing to choose is implanted the experimental result of nude mice.Be implanted in the nude mice so that the 50mg/ mice is subcutaneous at the 0th day tumor tissues CCRF-CEM/ Taxol (44 times of drug resistance outside the organism).In D8 begin with Fu Dilong 15mg/kg () (n=3) and 30mg/kg (△) (n=4) carry out 6hr-intravenous perfusion therapy, or D16 begins, Q2D * 3 and then dosage is brought up to 40mg/kg, Q2D * 3 (D22-26) and 60mg/kg then, Q2D * 3 (D28-40).Figure 10 A represents to be reduced and the therapeutic effect of expression by the tumor size.Figure 10 B represents body weight change.
Figure 11 represents to adopt 26-three fluoro-9, and 10-dehydrogenation-dEpoB and Taxol are to the treatment (intravenous perfusion in 6 hours, Q3D * 11) of nude mice with people's pulmonary carcinoma (A549/ Taxol) (is 44 times to the Taxol drug resistance).Figure 11 A represents to be reduced and the therapeutic effect of expression by the tumor size.Figure 11 B represents body weight change.
Figure 12 represents to adopt 9, and 10-dehydrogenation-dEpoB is to the treatment (intravenous perfusion in 6 hours, Q4D * 5, * 3) of nude mice with Human Lung Cancer A549/ Taxol (is 44 times to the Taxol drug resistance).Figure 12 A represents to be reduced and the therapeutic effect of expression by the tumor size.Body weight change before and after Figure 12 B represents to treat.
Figure 13 represents to adopt 26-three fluoro-9, and 10-dehydrogenation-dEpoB, dEpoB and Taxol are adopting oral formulations (PO, Q2D * 7, * 5) to treat the comparison that has in the human breast carcinoma MX-1 xenograft nude mice.Figure 13 A represents to be reduced and the therapeutic effect of expression by the tumor size.Figure 13 B represents body weight change.
Figure 14 is the various treatments of summary epothilone derivate and the table of pharmacokinetic parameter.
Figure 15 represents to adopt 26-three fluoro-9, and 10-dehydrogenation-dEpoB and dEpoB treatment have the heteroplastic nude mice of Human Lung Cancer (A549) (intravenous perfusion in 6 hours, (Q2D * 6) * 2, * 2).Figure 15 A represents to be reduced and the therapeutic effect of expression by the tumor size.Figure 15 B is illustrated in the body weight change after the treatment neutralization treatment.
Figure 16 is illustrated in the stability that the microtubule under the 10 μ M medicines forms.The microtubule that will form in the presence of 10 μ M Taxols is defined as 100%.The tubulin that derives from Medulla Bovis seu Bubali is the product of Sigma.The tubulin assembling test is implemented according to the description of manufacturer.Tubulin (1mg among the 200 μ l) is with buffer agent (0.1M MES, 1mM EGTA, the 0.5mM MgCl of 790 μ
2, 0.1mM EDTA and 2.5M glycerol pH6.5) and with the medicine (ultimate density 10 μ M) of 10 μ l are cultivated.For assembling, implement down to cultivate 40 minutes and, implement down to cultivate 40 minutes at 4 ℃ for the dismounting of same sample at 35 ℃.Stable for microtubule, measure absorbance at the 350nm place.Solvent blank (DMSO) deducts from absorbance.
Figure 17 represents the effectiveness and relative therapeutic index of the external anticancer cell growth of Epothilones.
The cell cycle analysis of Figure 18 for determining by propidium iodide DNA dyeing.After treating with dEpoB (last figure) and Fu Dilong (figure below), cell cycle was ended and the blocking-up fully at 24 hours in the back 6 hours G2M stage of beginning for OPM-2 myeloma cell.Two kinds of medicines cause the pattern of same cell cycle termination.
Figure 19 represents that Annexin V fastens dyeing RPMI8226 myeloma cell.In the apoptotic cell, membrane phospholipid Phosphatidylserine (PS) translocates to the outer little page or leaf of cell membrane by the cell membrane endite, therefore PS is exposed to outside cellular environment in the early stage.Annexin V has the highly affine 35-36kD Ca to PS
+The phospholipids incorporate albumen that depends on, and utilize the PS that exposes to be attached on the cell.In conjunction with vital stain, 7-amino-D actinomycin D (7-AAD) for example, the dyeing dead cell, this test is used to identify viable apoptotic cell.Shown data show is in most cells or apoptosis or the death after 24 hours with dEpoB or Fu Dilong treatment.
Figure 20 represents with 24 hours the myeloma of Fu Dilong (125nM) treatment and the microphotograph of lymphoma cell line.Can see the feature circulus of the cell that terminates in G2/M.
Figure 21 represents the cell counting with the RPMI8226 myeloma cell of Fu Dilong and dEpoB (125nM) treatment.In different time points (1,2,4,8,24 hour),, and this cell continued to cultivate until 48 hours with the medicine eccysis.When noticing that being exposed to Fu Dilong is as short as 1 hour, tumor cell number promptly progressively reduces, and most cells experience apoptosis in the time of 24 hours simultaneously, and use dEpoB, and cell then still continues propagation.
Figure 22 represents RPMI8226 myeloma cell's alpha-tubulin dyeing.Fu Dilong has obviously stablized microtubule and has promptly increased the microtubule polymerization amount greatly in treatment early stage (treatment RPMI8226 myeloma cell 12 hours).After the Drug therapy 24 hours, the microtubule quality reduces and is destroyed, simultaneously cell experience apoptosis.
Figure 23 is the cell cycle analysis of being determined by propidium iodide DNA dyeing.Solid line is represented the value of G1 and G2, and the gray shade district is illustrated in the cell of S in the stage, and dotted lines goes out the master curve of double cell number, adopts Taxol especially obviously (the picture left above).Last row's explanation ovarian cancer cell line IGROV stops in the G2M stage after 24 hours with Fu Dilong (10nM), dEpoB (100nM) and Taxol (100nM) cultivation.Following row's explanation increases Fu Dilong concentration has increased stopping of HT-29 cell cycle.100nM cultivation with Fu Dilong causes a large amount of apoptosis after 24 hours, in comprising several cell lines of IGROV and HT-29, has hindered cell cycle analysis.
Figure 24 represents the Annexin V dyeing with 100nM Fu Dilong, Taxol or dEpoB cultivation Ovcar3 ovarian cancer cell line after 24 hours.The percentage ratio that provides at left lower quadrant is AnnexinV
+/ P1
-The percentage ratio of negative cells, this is with the apoptosis stages of cell is similar in early days.
Figure 25 is the cytospin (200 * amplification) with the HT-29 colon cancer cell of the painted treatment of HEMA3 after 24 hours.(a) control cells for the treatment of with solvent (DMSO).(b)-(d) expression increases concentration 1,10 and the 100nM of Fu Dilong.(e) the HT-29 cell after using the dEpoB of 100nM and (f) the HT-29 cell behind the Taxol of using 100nM.All three kinds of medicines all produced same phenotype after 24 hours, obviously be the class ring structure of the nuclear that causes apoptosis.
Figure 26 is illustrated in the xenotransplantation of diffusivity people tumor and shifts among the human tumor xenograft model experimental design of the system of the effect of evaluation Fu Dilong and dEpoB.
Figure 27 represents cell proliferation and IC50 (concentration that 50% cell suppresses) test.Cell proliferation adopts 3 '-[1-(phenylamino-carbonyl)-3,4-tetrazolium ]-two (4-methoxyl group-6-nitro) benzene sulfonic acid sodium salt hydrates (XTT) and measures, and it measures the conversion of tetrazolium chemical compound to first by the mitochondrial dehydrogenase in the living cells.The amount of first is with to be present in the test mixture quantity of living cells proportional.Each data is the meansigma methods of four independent measurements.(RPMI8226, CAG), the IC50 of Fu Dilong is about 7.6~36.67nM, and the IC50 of dEpoB is 36.67~61.34nM for myeloma cell line.For lymphoma system (SKIDLBCL and RL), the IC50 of Fu Dilong is about 60~80nM.
Figure 28 is illustrated in cell proliferation and the IC50 test on the normal stromal cell.Adopt as the identical method described in Figure 104.Human marrow-interstitial cell line, HS-27A and HS-5 do not go out by the E6/E7 gene, have the function of normal bone marrow matrix, and it has supported self renewal and the propagation of stem cell.For these substrate systems, the IC50 of Fu Dilong and dEpoB is about 90~100nM, and this and tumor cording have the population doubling time of equity.
Figure 29 represents the titration that the concentration cell cycle of Fu Dilong and dEpoB is stagnated.Adopt the CAG myeloma cell line.When concentration was 31.25nM, two kinds of medicines were all blocked cell cycle fully in G2M stage (data not shown that is lower than 31.25nM goes out).
Figure 30 represents the titration that the concentration cell cycle of Fu Dilong and dEpoB is stagnated.Adopt the RPMI8226 myeloma cell line.When concentration was 31.25nM, two kinds of medicines were all blocked cell cycle fully in G2M stage (data not shown that is lower than 31.25nM goes out).
Figure 31 represents the dyeing that Annexin V fastens CAG myeloma cell.In the apoptotic cell, membrane phospholipid Phosphatidylserine (PS) translocates to the cell membrane exite from the endite of cell membrane in the early stage, therefore PS is exposed to outside cellular environment.Annexin V has the highly affine 35-36kD Ca to PS
+The phospholipids incorporate albumen that depends on, and utilize the PS that exposes to be attached on the cell.Be incorporated into vital stain, 7-amino-D actinomycin D (7-AAD) for example, the cell that dyeing is dead, this test is used to identify viable apoptotic cell.Shown data show is with Fu Dilong or dEpoB treatment most cells or enter apoptosis or death after 24 hours.Notice that the X-axle is that Annexin dyeing and Y-axle are 7-ADD dyeing.
Figure 32 is the dna fragmentation test.The main biochemistry characteristics of apoptosis remove for nucleosome from chromatin.Nucleosome removes by the digestion of the Cobra venom endonuclease mediation of the DNA join domain that exposes between the nucleosome in chromatin and causes.Exempt from digestion owing to center on 180-200 the base of the DNA of histone nuclear on conformation, the nucleosome of this Cobra venom endonuclease mediation removes in agarose gel and can be viewed as dna ladder.Shown in data declaration after with Fu Dilong or dEpoB treatment RPMI8226 and CAG myeloma cell 24hr, detected typical dna ladder.This data declaration causes apoptosis by Epothilones by Guang winter peptidase (caspase) approach.
Figure 33 represents the alternate and the result behind Epothilones (20mg/kg) treatment diffusivity CAG xenotransplantation myeloma mice of body weight.Shown in the data show control mice dead and observe body weight in treatment after 20 days and significantly reduce in the time of about 30 days.Between mice for the treatment of with dEpoB and contrast, in the life-span, there is not the significance difference; Yet demonstrate the time-to-live of organizing equal significant prolongation than matched group and dEpoB with the mice of Fu Dilong treatment.The quantity of used mice is four in every group, and before injection CAG cell radiation 300Rad.
Figure 34 represents the treatment of diffusivity CAG xenotransplantation myeloma mice in the 4th week.With 10 * 10
6Mouse tail vein is gone in individual CAG myeloma cell's intravenous injection with the transformation of Luc-eGFP-TK fusion gene, and when the 7th day of implanting to suitable myeloma cell by the bioluminescence image detection begin treatment.This figure shows the bioluminescence image of the mice of using contrast or dEpoB or Fu Dilong treatment respectively.
Figure 35 be illustrated in (N=4) average tumor photo emissions in the CAG xenotransplantation mice quantitatively.This figure shows that the mice ratio with the Fu Dilong treatment has significantly reduced tumor photo emissions with excipient or the independent mice for the treatment of with dEpoB.Tumor photo emissions and tumor load positive correlation.
Figure 36 represents the alternate and the result behind Epothilones (20mg/kg) treatment diffusivity CAG xenotransplantation myeloma mice of body weight.This figure showed the feature similar as Figure 33 at first 30 days; But unique survival winding of Fu Dilong treatment mice is strengthened by the Velcade (6.25 μ g/ mices, intravenous perfusion) of other 5 dosage.
Figure 37 is illustrated in the treatment of the 18th day diffusivity CAG xenotransplantation myeloma mice.This figure demonstrates the remarkable difference of image between each group, and this reflects the tumor load in its place group.
Figure 38 be illustrated in the 18th day average tumor photo emissions in the treatment of diffusivity CAG xenotransplantation myeloma mice quantitatively.This figure demonstrates the remarkable difference of image between each group, and this reflects the tumor load in its place group.
Figure 39 is illustrated in the treatment of the 40th day diffusivity CAG xenotransplantation myeloma mice.This figure demonstrates the difference of image, reflects three groups of tumor loads in the mice.
Figure 40 be illustrated in the 40th day average tumor photo emissions in the treatment of diffusivity CAG xenotransplantation myeloma mice quantitatively.This figure demonstrates the difference of image, reflects three groups of tumor loads in the mice.
Figure 41 represents with Fu Dilong and Velcade combined treatment CAG xenotransplantation myeloma mice.(20mg/kg, Q2d) and with Velcade (6.25 μ g/ mices, intravenous 3/w) were treated mice from the 35th day to 45 days from the 0th day to 28 days with Fu Dilong.At the 10th day begin treatment, and behind the 59th day Fu Dilong 12 dosage and Velcade 5 dosage photographic images.With compare at the 40th day image, in three mices two all have significantly reduced tumor load at femur with in no vertebral column.
Figure 42 is the Kaplan-Meier survival curve with heteroplastic seven the NOD/SCID mices of CAG myeloma cell.Control mice is dead and dead in 50 days with the mice of dEpoB treatment in 40 days after transplanting the CAG cell.Dead in 70 days except a mice, the mice of the useful Fu Dilong treatment of institute survived above 80 days.
Figure 43 represents apoptotic approach.
Figure 44 is illustrated in inductive time dependent Guang winter peptidase 3 processes of Epothilones among the CAG myeloma cell, and it shows the cutting form that has increased the Guang winter peptidase 3 of 17kD along with the time lengthening of Drug therapy.
Figure 45 represents the immunohistochemical dyeing with the CAG myeloma cell that carries out of Guang winter peptidase-3 antibody of cutting, and it demonstrates Cytoplasm and the location in nuclear week (showing low and high amplification) in apoptotic cell.
Figure 46 represents the immunohistochemical dyeing with the CAG myeloma cell that carries out of Guang winter peptidase-3 antibody of cutting, and it demonstrates Cytoplasm and the location in nuclear week (showing low and high amplification) in apoptotic cell.
Figure 47 shows that the activity of Guang winter peptidase 8 has increased after the Epothilones treatment, and this increase can suppress by the special inhibitor of Guang winter peptidase 8.
Figure 48 shows that the activity of Guang winter peptidase 8 has increased after the Epothilones treatment, and this increase can suppress by the special inhibitor of Guang winter peptidase 8.
Figure 49 shows that the activity of Guang winter peptidase 9 has increased after the Epothilones treatment.
Figure 50 is illustrated in KL and does not exist or exist down, cultivates the Annexin V dyeing of the CB CD34+ cell of 24h with dEpoB or Fu Dilong.Then with the medicine eccysis and implement Annexin V dyeing.On behalf of excipient matched group and hollow area, solid area represent medication therapy groups.Short time is exposed to the apoptosis that Epothilones does not have obviously to increase acyclic people CD34+ cell.
Figure 51 is illustrated in during colony forms, and Epothilones is to the influence of acyclic people CD34+ cell.By the progenitor cell that the colony formation of 2 weeks is estimated, significantly not different between matched group and medication therapy groups.
Figure 52 is illustrated in during colony forms, and Epothilones is to the influence of acyclic people CD34+ cell.By the progenitor cell that the colony formation of 2 weeks is estimated, significantly not different between matched group and medication therapy groups.
Figure 53 represents the therapeutic effect (body weight reduction) by Fu Dilong and the chemical sproof human T-cell's lymphoblastic leukemia of paclitaxel antiradiation drug (CCRT-CEM/ paclitaxel) xenograft.Although reduce body weight significantly, there is not toxicity death for all treatments.
Definition
Chemical compounds more of the present invention and particular functional group's definition also is described in greater detail in down.For the purposes of the present invention, the chemical element root is according to the periodic table of elements (CAS version, Handbook ofChemistry and Physics (Chemical Physics handbook), the 75th edition, inside front cover) and determining, and the particular functional group is described General Definition therein.In addition, vitochemical general principle, and particular functional group part and reactivity are described in " Organic Chemistry (organic chemistry) ", Thomas Sorrell, University Science Books, Sausalito:1999, its full content is incorporated the present invention by reference into.In addition, it will be recognized by those of ordinary skill in the art that synthetic method has been utilized the kinds of protect group as described in the present invention.Term " blocking group " as used in the present invention, the meaning is meant special functional moiety, for example O, S or N are sealed so that can optionally react on another response location in the polyfunctional compound temporarily.In preferred embodiments, blocking group optionally reacts substrate to provide protected with good yield, this substrate to plan to carry out reaction be stable; Blocking group should optionally be removed with good yield, and its reagent by preferred nontoxic other functional group of not attack of easy acquisition carries out; Blocking group forms can be easy to isolating derivant (more preferably not forming new chiral centre); And blocking group has minimum additional functional to avoid the reaction of other position.As describing in detail in the present invention, oxygen, sulfur, nitrogen and carbon blocking group can be utilized.Though typical blocking group describes in detail in the present invention, what will recognize is that the present invention is not meant to and limited by these blocking groups; More properly, various other equal blocking group can easily be determined and is applied in the method for the present invention with above-mentioned standard.In addition, in " Protective Groups in Organic Synthesis (blocking group in the organic synthesis) " third edition, Greene, T.W. and Wuts, P.G. compiles, John Wiley ﹠amp; Sons has described the kinds of protect group among the New York:1999, its full content is incorporated the present invention by reference into.
Be that chemical compound described in the present invention can replace with any amount of substituent group or funtion part with what recognize.Usually, no matter whether term " replacement " add term " randomly " in front, and be contained in the substituent group in the molecular formula of the present invention, is meant with specifying substituent group to replace to the hydrogen group in the fixed structure.When in any given structure, replacing when being selected from the substituent group of specifying group, can be identical or different in each locational substituent group more than one more than a position.As used in the present invention, term " replacement " is conceived to comprise the admissible substituent group of all organic compound.Aspect generalized, admissible substituent group includes acyclic and cyclic, side chain and the substituent group unbranched, isocyclic and heterocyclic, aromatic and non-aromatic of organic compounds.For the purposes of the present invention, hetero atom such as nitrogen can have the substituent group of any admissible organic compound described in hydrogen substituent group and/or the present invention, as long as it satisfies this heteroatomic quantivalence.In addition, the present invention is not meant to by any way and is limited by the allowed substituent group of organic compound.Preferably cause forming those of stable chemical compound by the combination of the substituent group of the present invention imagination and variant, described chemical compound is used for the treatment of, and for example proliferative disease includes but not limited to cancer.Term " stable ", as used among the present invention, preferably refer to such chemical compound, it has is enough to allow the stability that is produced and its integrity that keeps this chemical compound with the detected sufficiently long time and be preferred for being specified in sufficiently long time of the purpose among the present invention.
Term " aliphatic " as used among the present invention, comprises saturated and (promptly unbranched), side chain, cyclic or polycyclic aliphatic hydrocarbon undersaturated, straight chain, and it randomly replaces with one or more functional groups.It will be recognized by those of ordinary skill in the art that " aliphatic " is intended to include but not limited among the present invention: alkyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkenyl group and cycloalkynyl radical part.Therefore, as used in the present invention, term " alkyl " comprises straight chain, side chain and cyclic alkyl.Similarly convention is applied to other general terms, for example " thiazolinyl ", " alkynyl " or the like.In addition, as used in the present invention, term " alkyl ", " thiazolinyl ", " alkynyl " etc. comprise replacement and unsubstituted group.In some embodiments, as used in the present invention, " low alkyl group " refers to that those have the alkyl of 1-6 carbon atom (cyclic, acyclic, that replace, unsubstituted, side chain or unbranched).
In some embodiments, used alkyl, thiazolinyl and alkynyl comprises 1-20 aliphatic carbon atom among the present invention.In other embodiments, used alkyl, thiazolinyl and alkynyl comprises 1-10 aliphatic carbon atom among the present invention.In some embodiments again, used alkyl, thiazolinyl and alkynyl comprises 1-8 aliphatic carbon atom among the present invention.In other embodiment, used alkyl, thiazolinyl and alkynyl comprises 1-6 aliphatic carbon atom among the present invention.In some embodiments again, used alkyl, thiazolinyl and alkynyl comprises 1-4 aliphatic carbon atom among the present invention.Therefore the aliphatic group that exemplifies includes but not limited to, for example, methyl, ethyl, n-pro-pyl, isopropyl, cyclopropyl ,-CH
2-cyclopropyl, pi-allyl, normal-butyl, sec-butyl, isobutyl group, the tert-butyl group, cyclobutyl ,-CH
2-cyclobutyl, n-pentyl, sec-amyl, isopentyl, tertiary pentyl, cyclopenta ,-CH
2-cyclopenta, n-hexyl, Sec-Hexyl, cyclohexyl, CH
2-cyclohexyl part or the like, it can have one or more substituent groups equally.Thiazolinyl includes but not limited to, for example, and vinyl, acrylic, cyclobutenyl, 1-methyl-2-butene-1-base etc.Typical alkynyl includes but not limited to acetenyl, 2-propynyl (propargyl), 1-propinyl etc.
Term " alkoxyl " or " alkylthio " refer to the alkyl as preceding definition as used in the present invention, are connected to parent molecular moiety by oxygen atom or by sulphur atom.In some embodiments, described alkyl comprises 1-20 aliphatic carbon atom.In other embodiments, described alkyl comprises 1-10 aliphatic carbon atom.In some embodiments again, used alkyl, thiazolinyl and alkynyl comprises 1-8 aliphatic carbon atom among the present invention.In other embodiment, described alkyl comprises 1-6 aliphatic carbon atom.In some embodiments again, described alkyl comprises 1-4 aliphatic carbon atom.The example of alkoxyl includes but not limited to, methoxyl group, ethyoxyl, propoxyl group, isopropoxy, n-butoxy, tert-butoxy, neopentyl oxygen and positive hexyloxy.The example of alkylthio includes but not limited to, methyl mercapto, ethylmercapto group, rosickyite base, iprotiazem base, positive butylthio etc.
Term " alkylamino " refers to have-group of NHR ' structure, and wherein R ' is alkyl as defined in the present invention.In some embodiments, described alkyl comprises 1-20 aliphatic carbon atom.In other embodiments, described alkyl comprises 1-10 aliphatic carbon atom.In some embodiments again, used alkyl, thiazolinyl and alkynyl comprises 1-8 aliphatic carbon atom among the present invention.In other embodiment, described alkyl comprises 1-6 aliphatic carbon atom.In some embodiments again, described alkyl comprises 1-4 aliphatic carbon atom.The example of alkylamino includes but not limited to, methylamino, ethylamino, isopropylamino or the like.
More substituent examples of the above-mentioned aliphatic of The compounds of this invention (and other) part include but not limited to, aliphatic, assorted aliphatic, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkoxyl, aryloxy group, assorted alkoxyl, heteroaryloxy, alkylthio group, arylthio, assorted alkylthio group, heteroarylthio, F, Cl, Br, I ,-OH ,-NO
2,-CN ,-CF
3,-CH
2CF
3,-CHCl
2,-CH
2OH ,-CH
2CH
2OH ,-CH
2NH
2,-CH
2SO
2CH
3,-C (O) R
x,-CO
2(R
x) ,-CON (R
x)
2,-OC (O) R
x,-OCO
2R
x,-OCON (R
x)
2,-N (R
x)
2,-S (O)
2R
x,-NR
x(CO) R
x, wherein each R that occurs
xInclude but not limited to independently, aliphatic, assorted aliphatic, aryl, heteroaryl, aralkyl or heteroarylalkyl, wherein above-mentioned and any aliphatic described here, assorted aliphatic, aralkyl or heteroarylalkyl substituent group can be that replace or unsubstituted, side chain or unbranched, ring-type or acyclic, and wherein above-mentioned and any aryl described here or heteroaryl substituent group can be to replace or unsubstituted.Common applicable substituent example is in addition illustrated by the particular in embodiments of the present invention.
Usually, term " aryl " and " heteroaryl " as used among the present invention, refer to have the stable monocycle of a preferred 3-14 carbon atom or multi-ring, heterocycle, the unsaturated part of multi-ring and many heterocycles, and wherein each all can be substituted or not replace.Substituent group includes but not limited to, any aforementioned substituent group, and promptly as disclosed substituent group that aliphatic portion is enumerated or the substituent group that other parts are enumerated among the present invention, this substituent group causes forming stable chemical compound.In some embodiments of the present invention, " aryl " refers to have the monocycle or the bicyclo-carbocyclic ring system of one or two aromatic rings, includes but not limited to phenyl, naphthyl, tetralyl, indanyl, indenyl etc.In some embodiments of the present invention, used term " heteroaryl " among the present invention refers to have the ring-type aromatic radical of five to ten annular atomses, and one of them annular atoms is selected from S, O and N; Zero, one or two annular atoms are the extra hetero atom that is independently selected from S, O and N; And remaining annular atoms is a carbon, this ring-type aromatic radical is connected to the other parts of molecule of the present invention, for example pyridine radicals, pyrazinyl, pyrimidine radicals, pyrrole radicals, pyrazolyl, imidazole radicals, thiazolyl, oxazolyl, isoxazolyl, thiadiazolyl group, oxadiazole base, thiophenyl, furyl, quinolyl, isoquinolyl or the like by any annular atoms.
To recognize that aryl and heteroaryl (comprising aryl bicyclic) can be unsubstituted or replace, wherein replace one, two, three or more hydrogen atoms comprising on it replace independently with any one or a plurality of as the lower part, include but not limited to: aliphatic, assorted aliphatic, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkoxyl, aryloxy group, assorted alkoxyl, heteroaryloxy, alkylthio group, arylthio, the alkylthio group of mixing, heteroarylthio, F, Cl, Br, I ,-OH ,-NO
2,-CN ,-CF
3,-CH
2CF
3,-CHCl
2,-CH
2OH ,-CH
2CH
2OH ,-CH
2NH
2,-CH
2SO
2CH
3,-C (O) R
x,-CO
2(R
x) ,-CON (R
x)
2,-OC (O) R
x,-OCO
2R
x,-OCON (R
x)
2,-N (R
x)
2,-S (O
2) R
x,-NR
x(CO) R
x, the R of each appearance wherein
xInclude but not limited to independently, aliphatic, assorted aliphatic, aryl, heteroaryl, aralkyl or heteroarylalkyl, wherein any above-mentioned and aliphatic described here, assorted aliphatic, aralkyl or heteroarylalkyl substituent group can be that replace or unsubstituted, side chain or unbranched, cyclic or acyclic, and wherein any above-mentioned and aryl described here or heteroaryl substituent group can be that replace or unsubstituted.Common applicable substituent example is in addition illustrated by the particular in embodiments of the present invention.
Used term " cycloalkyl " refers in particular to and has three to seven among the present invention, the group of preferred three to ten carbon atoms.The cycloalkyl that is fit to includes but not limited to, cyclopropyl, cyclobutyl, cyclopenta, cyclohexyl, suberyl or the like, as the situation in other aliphatic, assorted aliphatic or the heterocyclic moiety, its optional replacement includes but not limited to following group: aliphatic, assorted aliphatic, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkoxyl, aryloxy group, assorted alkoxyl, heteroaryloxy, alkylthio group, arylthio, assorted alkylthio group, heteroarylthio, F, Cl, Br, I ,-OH ,-NO
2,-CN ,-CF
3,-CH
2CF
3,-CHCl
2,-CH
2OH ,-CH
2CH
2OH ,-CH
2NH
2,-CH
2SO
2CH
3,-C (O) R
x,-CO
2(R
x) ,-CON (R
x)
2,-OC (O) R
x,-OCO
2R
x,-OCON (R
x)
2,-N (R
x)
2,-S (O
2) R
x,-NR
x(CO) R
x, the R of each appearance wherein
xInclude but not limited to independently, aliphatic, assorted aliphatic, aryl, heteroaryl, aralkyl or heteroarylalkyl, wherein any above-mentioned and aliphatic described here, assorted aliphatic, aralkyl or heteroarylalkyl substituent group can be that replace or unsubstituted, side chain or unbranched, cyclic or acyclic, and wherein any above-mentioned and aryl described here or heteroaryl substituent group can be that replace or unsubstituted.Common applicable substituent example is in addition illustrated by the particular in embodiments of the present invention.
Term " assorted aliphatic " used among the present invention refers to aliphatic portion, comprises one or more oxygen, sulfur, nitrogen, phosphorus or silicon atom, for example, substitutes carbon atom.Assorted aliphatic portion can be side chain, unbranched, cyclic or acyclic and comprise saturated and undersaturated heterocycle for example morpholinyl, pyrrolidinyl etc.In some embodiments, the one or more hydrogen atoms of assorted aliphatic portion on it substitute independently with one or more parts, include but not limited to, aliphatic, assorted aliphatic, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkoxyl, aryloxy group, assorted alkoxyl, heteroaryloxy, alkylthio group, arylthio, assorted alkylthio group, heteroarylthio, F, Cl, Br, I ,-OH ,-NO
2,-CN ,-CF
3,-CH
2CF
3,-CHCl
2,-CH
2OH ,-CH
2CH
2OH ,-CH
2NH
2,-CH
2SO
2CH
3,-C (O) R
x,-CO
2(R
x) ,-CON (R
x)
2,-OC (O) R
x,-OCO
2R
x,-OCON (R
x)
2,-N (R
x)
2,-S (O
2) R
x,-NR
x(CO) R
x, the R of each appearance wherein
xInclude but not limited to independently, aliphatic, assorted aliphatic, aryl, heteroaryl, aralkyl or heteroarylalkyl, wherein any above-mentioned and aliphatic described here, assorted aliphatic, aralkyl or heteroarylalkyl substituent group can be that replace or unsubstituted, side chain or unbranched, cyclic or acyclic, and wherein any above-mentioned and aryl described here or heteroaryl substituent group can be that replace or unsubstituted.Common applicable substituent example is in addition illustrated by the particular in embodiments of the present invention.
The atom that used term " halo " and " halogen " refer to be selected from fluorine, chlorine, bromine and iodine among the present invention.
Term " haloalkyl " refers to alkyl as defined above, and it has one, two or three halogen atoms connect on it and be illustrated as group as chloromethyl, bromoethyl, trifluoromethyl or the like.
Term " Heterocyclylalkyl " or " heterocycle " used among the present invention refer to that 5 yuan, 6 yuan or 7 yuan of non-aromatic are encircled or multi-ring group, include but not limited to bicyclo-or three cyclic groups, comprise condensed hexatomic ring with one to three hetero atom (being independently selected from oxygen, sulfur and nitrogen), wherein (i) each 5 yuan of ring have 0 to 1 two key and have 0 to 2 two key with each 6 yuan of ring, (ii) nitrogen and sulfur heteroatom can be randomly oxidized, (iii) nitrogen heteroatom can randomly can be fused on the phenyl ring by quaternized and (iv) any above-mentioned heterocycle.Typical heterocycle includes but not limited to pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidyl, piperazinyl, oxazolidinyl, isoxazole alkyl, morpholinyl, thiazolidinyl, isothiazole alkyl and tetrahydrofuran base.In some embodiments, " Heterocyclylalkyl of replacement or heterocycle " group is available and as using among the present invention, it refers to Heterocyclylalkyl or heterocyclic group as defined above, be substituted by substitute on it one, two or three hydrogen atoms independently with following group, described group includes but not limited to, aliphatic, assorted aliphatic, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkoxyl, aryloxy group, assorted alkoxyl, heteroaryloxy, alkylthio group, arylthio, assorted alkylthio group, heteroarylthio, F, Cl, Br, I ,-OH ,-NO
2,-CN ,-CF
3,-CH
2CF
3,-CHCl
2,-CH
2OH ,-CH
2CH
2OH ,-CH
2NH
2,-CH
2SO
2CH
3,-C (O) R
x,-CO
2(R
x) ,-CON (R
x)
2,-OC (O) R
x,-OCO
2R
x,-OCON (R
x)
2,-N (R
x)
2,-S (O
2) R
x,-NR
x(CO) R
x, the R of each appearance wherein
xInclude but not limited to independently, aliphatic, assorted aliphatic, aryl, heteroaryl, aralkyl or heteroarylalkyl, wherein any above-mentioned and aliphatic described here, assorted aliphatic, aralkyl or heteroarylalkyl substituent group can be that replace or unsubstituted, side chain or unbranched, cyclic or acyclic, and wherein any above-mentioned and aryl described here or heteroaryl substituent group can be that replace or unsubstituted.Common applicable substituent example is in addition illustrated by the particular in embodiments of the present invention.
" labelling ": used term " labelling " is intended to represent that chemical compound has at least one element, isotope or the chemical compound that connect on it and makes this chemical compound to detect among the present invention.Usually, label typically is divided into three classes: a) isotopic label, and it can be radioactive or heavy isotope, includes but not limited to,
2H,
3H,
32P,
35S,
67Ga,
99mTc (Tc-99m),
111In,
123I,
125I,
169Yb and
186Re; B) immune marker, it can be antibody or antigen, it can be incorporated into enzyme (for example horseradish peroxidase) but go up to make detectable; And c) dyestuff colour developing, luminous, phosphorescence or fluorescence.With what recognize be, this label can be incorporated in the The compounds of this invention on any position, as long as the biological activity or the characteristic of detected chemical compound are not disturbed in this position.In some embodiments of the present invention, utilize the directly intermolecular interaction (for example, epothilones bind position in detection tubulin dimer) of explanation in living things system of photoaffinity labeling.Available various known luminescent substance, major part depend on diazonium compound, nitrine or Azimethylene. (diazirine) to the conversion of the light of nitrene or Cabbeen (referring to, Bayley, H., Photogenerated Reagents in Biochemistry and MolecularBiology (1983), Elsevier, Amsterdam.), its full content is incorporated the present invention by reference into.In some embodiments of the present invention, used photoaffinity label for the neighbour that partly replaces with one or more halogens-,-and right-azido benzoyl base, include but not limited to 4-azido-2,3,5, the 6-tetrafluorobenzoic aid.
" polymer ": used term " polymer " among the present invention " refer to comprise the compositions of chain, described chain can be a repetitive (monomer) that open, closed, straight chain, side chain or crosslinked, described repetitive can be identical or different.With what recognize be, term polymer refers to biopolymer in some embodiments, and used in the present invention biopolymer is intended to refer to natural polymeric material or based on those natural materials, includes but not limited to nucleic acid, peptide and analog thereof.In other embodiments, term polymer refers to synthetic polymer, biological example degradable polymer or other polymeric material.With what recognize is that the polymeric solid phase support also is included in the polymer of the present invention.Chemical compound of the present invention can be connected on the polymer support and therefore can carry out synthetic modification on solid phase.Term " solid support " used among the present invention refers to include but not limited to, polystyrene bead, graft copolymerization pearl, polyacrylamide pearl, the latex particle of granule, pan, capillary tube, doughnut, spicule, spicule, solid fiber, cellulose bead, Bio-Glas, silica gel, optional and divinylbenzene crosslink, choose wantonly and N, DMAA that N '-two-acryloyl ethylenediamine is crosslinked and the glass particle that applies with hydrophobic polymer.The selection that it will be recognized by those of ordinary skill in the art that specific solid support will be subject to the compatibility of support and the reactive chemistry that is utilized.Typical solid support is a Tentagel amino resins, by 1) with the polystyrene bead and 2 of divinyl benzene crosslinked) complex formed of PEG (Polyethylene Glycol).Tentagel is useful especially solid support, because it is the common support that is used for (off-bead) test under granule (on-bead) or the granule, and it also has the good swellability in the solvent from toluene to water.
The description of some embodiments of the present invention
Recognize the needs of development of new and effective cancer therapy, the novel method for synthesizing that the invention provides the macro ring that can obtain to have wide biological activity and pharmacologically active is learned, and have these active new compounds, novel therapeutic compositions and use these chemical compounds and method for compositions.
In some embodiments, The compounds of this invention is used for the treatment of cancer.Compound exhibits more of the present invention go out the cytotoxicity of cancerous cell line or growth inhibited effect, demonstrate the ability of polymerization tubulin and stabilize microtubules assembling, and/or cause dwindling or disappearing of in cancerous cell xenograft models tumor.In some embodiments, The compounds of this invention can have side effect minimizing or minimized, comprises critical organ toxicity, nausea,vomiting,diarrhea, alopecia, body weight reduction, weight increase, liver toxicity, dermatosis etc.The compounds of this invention also may be owing to the water solublity that increases, the toxicity of reduction, the therapeutic domain of increase, enhanced effect etc. are easy to make preparation.
The generality explanation of The compounds of this invention
Chemical compound of the present invention comprises chemical compound and its pharmaceutically acceptable derivates of general formula further defined below (0); With its pharmacy acceptable derivates:
R wherein
0For replacing or unsubstituted aryl, heteroaryl, aralkyl, arylalkenyl, sweet-smelling alkynyl, heteroarylalkyl, impure aromatic ene base or hetaryne base section; In some embodiments, R
0Be aralkyl, arylalkenyl, heteroarylalkyl or impure aromatic ene base section; In other embodiments, R
0Be the impure aromatic ene base section; In some embodiments, R
0Be the heteroarylalkyl part; In other embodiments, R
0Aryl or heteroaryl moieties for 5-7 unit; In some embodiments again, R
0Be 8-12 unit's aryl bicyclic or heteroaryl moieties; In other embodiment, R
0Be two loop sections, wherein phenyl ring is fused on heteroaryl or the aryl moiety; In other embodiments, R
0Be the dicyclo part, wherein phenyl ring is fused on thiazole, oxazole or the imidazoles part; In some embodiments again, R
0For replacing or unsubstituted phenyl moiety;
R
3And R
4Be hydrogen independently of one another; Or replace or not replacement, straight or branched, ring-type or acyclic aliphatic, assorted aliphatic, aryl, heteroaryl, aralkyl or heteroarylalkyl part, the optional replacement: the alkyl of hydroxyl, protected hydroxyl, alkoxyl, carboxyl, carboxaldehyde radicals, straight or branched or cyclic acetal, fluorine, amino, protected amino, the amino, N-oxyimino or the N-Alkoximino that partly replace with one or two alkyl or aryl with one or more following groups; In some embodiments, R
3And R
4Be hydrogen, fluorine or low alkyl group independently of one another; In other embodiments, R
3And R
4Be hydrogen or methyl independently of one another; In other embodiment, R
3Be methyl and R
4Be hydrogen;
R
5And R
6Be hydrogen or blocking group independently of one another; In some embodiments, R
5And R
6All be hydrogen;
X is O, S, C (R
7)
2Or NR
7, the R under every kind of situation wherein
7Be hydrogen or low alkyl group independently; In some embodiments, X is O; In other embodiments, X is NH;
Y is O, S, NH, C (R
7)
2, CH
2, N (R
7) or NH, the wherein R under every kind of situation
7Be hydrogen or low alkyl group independently; Y is O in some embodiments; In other embodiments, Y is NH; In some embodiments again, Y is CH
2
Each R
8Be hydrogen independently; Halogen, hydroxyl, alkoxyl, amino, dialkylamino, alkylamino, fluorine, cyano group, or replace or do not replace, straight or branched, ring-type or acyclic aliphatic, assorted aliphatic, aryl, heteroaryl, aralkyl, arylalkenyl, sweet-smelling alkynyl or heteroarylalkyl, the impure aromatic ene base, the hetaryne base section, the optional replacement: hydroxyl with one or more following groups, protected hydroxyl, alkoxyl, carboxyl, carboxaldehyde radicals, the alkyl of straight or branched or cyclic acetal, fluorine, amino, protected amino, the amino that partly replaces with one or two alkyl or aryl, N-oxyimino or N-Alkoximino; In some embodiments, R
8Be hydrogen; In other embodiments, R
8Be hydroxyl; In some embodiments again, R
8Be fluorine; In other embodiment, R
8Be low alkyl group methyl for example; In other embodiments, R
8For-CF
3,-CF
2H or CFH
2In other embodiments, R
8Be fluoridized or fluorinated alkyl; In some embodiments again, R
8Be halogenated or fully halogenated alkyl;
R
9And R
10Be hydrogen independently of one another; Or replace or not replacement, straight or branched, ring-type or acyclic aliphatic, assorted aliphatic, aryl, heteroaryl, aryl, aralkyl, arylalkenyl, sweet-smelling alkynyl, heteroarylalkyl, impure aromatic ene base or hetaryne base section optional the replacement: the alkyl of hydroxyl, protected hydroxyl, alkoxyl, carboxyl, carboxaldehyde radicals, straight or branched or cyclic acetal, fluorine, amino, protected amino, the amino, N-oxyimino or the N-Alkoximino that partly replace with one or two alkyl or aryl with one or more following groups; In some embodiments, R
9And R
10One of be methyl; In other embodiments, R
9And R
10Be methyl; In some embodiments again, R
9And R
10One of be methyl, and another is a hydrogen; In other embodiments, R
9And R
10All be hydrogen;
A-B represents CR
A=CR
B-, C (R
A)
2-C (R
B)
2-or-C ≡ C-;
C-D represents CR
C=CR
D-,-C (R
C)
2-C (R
D)
2-or-C ≡ C-;
The R under every kind of situation wherein
ABe hydrogen independently; Halogen;-OR
A '-SR
A '-N (R
A ')
2-C (O) OR
A '-C (O) R
A '-CONHR
A '-O (C=O) R
A '-O (C=O) OR
A '-NR
A '(C=O) R
A 'N
3N
2R
A 'Cyclic acetal; Or the aliphatic of ring-type or acyclic, straight or branched, assorted aliphatic, aryl or heteroaryl, the optional replacement: hydrogen with one or more following groups; Halogen;-OR
A '-SR
A '-N (R
A ') 2;-C (O) OR
A '-C (O) R
A '-CONHR
A '-O (C=O) R
A '-O (C=O) OR
A '-NR
A '(C=O) R
A 'N
3N
2R
A 'Cyclic acetal; Or the replacement of ring-type or acyclic, straight or branched or unsubstituted aliphatic, assorted aliphatic, aryl or heteroaryl moieties;
For the R under every kind of situation
BBe hydrogen independently; Halogen;-OR
B '-SR
B '-N (R
B ')
2-C (O) OR
B '-C (O) R
B '-CONHR
B '-O (C=O) R
B '-O (C=O) OR
B '-NR
B '(C=O) R
B 'N
3N
2R
B 'Cyclic acetal; Or the aliphatic of ring-type or acyclic, straight or branched, assorted aliphatic, aryl or heteroaryl, the optional replacement: hydrogen with one or more following groups; Halogen;-OR
B '-SR
B '-N (R
B ') 2;-C (O) OR
B '-C (O) R
B '-CONHR
B '-O (C=O) R
B '-O (C=O) OR
B '-NR
B '(C=O) R
B 'N
3N
2R
B 'Cyclic acetal; Or the replacement of ring-type or acyclic, straight or branched or unsubstituted aliphatic, assorted aliphatic, aryl, or heteroaryl moieties; In some embodiments, R
BFor hydrogen,
Methyl, ethyl, propyl group, butyl, amyl group, hexyl, cyclopropyl, cyclobutyl, cyclopenta or cyclohexyl do not replace or the optional following group that replaces with one or more appearance separately: halogen ,-OH ,-OR
B ', NH
2Or N (R
B ')
2Or its combination in any, the wherein R under every kind of situation
B 'Be hydrogen, alkyl, aryl or blocking group independently, in other embodiments, R
BBe hydrogen, methyl or ethyl, in other embodiment, R
BBe methyl, in other embodiments ,-CY
3,-CHY
2,-CH
2Y, wherein Y is F, Br, Cl, I, OR
B ', NHR
B ', N (R
B ')
2Or SR
B 'In some embodiments again, R
BFor-CF
3,-CH
2F or CHF
2In other embodiments, R
BBe perfluorinate or fluorinated alkyl; In some embodiments again, R
BBe halogenated or fully halogenated alkyl;
For the R under every kind of situation
CBe hydrogen independently; Halogen;-OR
C '-SR
C '-N (R
C ')
2-C (O) OR
C '-C (O) R
C '-CONHR
C '-O (C=O) R
C '-O (C=O) OR
C '-NR
C '(C=O) R
C 'N
3N
2R
C 'Cyclic acetal; Or the aliphatic of ring-type or acyclic, straight or branched, assorted aliphatic, aryl or heteroaryl, the optional replacement: hydrogen with one or more following groups; Halogen;-OR
C '-SR
C '-N (R
C ')
2-C (O) OR
C '-C (O) R
C '-CONHR
C '-O (C=O) R
C '-O (C=O) OR
C '-NR
C '(C=O) R
C 'N
3N2R
C 'Cyclic acetal; Or the replacement of ring-type or acyclic, straight or branched or unsubstituted aliphatic, assorted aliphatic, aryl or heteroaryl moieties; In some embodiments, R
CBe halogen, alkyl, hydroxyl or amino; In other embodiments, R
CBe fluorine; In some embodiments again, R
CBe hydroxyl;
For the R under every kind of situation
DBe hydrogen independently; Halogen;-OR
D '-SR
D '-N (R
D ')
2-C (O) OR
D '-C (O) R
D '-CONHR
D '-O (C=O) R
D '-O (C=O) OR
D '-NR
D '(C=O) R
D 'N
3N
2R
D 'Cyclic acetal; Or the aliphatic of ring-type or acyclic, straight or branched, assorted aliphatic, aryl or heteroaryl, the optional replacement: hydrogen with one or more following groups; Halogen;-OR
D '-SR
D '-N (R
D ')
2-C (O) OR
D '-C (O) R
D '-CONHR
D '-O (C=O) R
D '-O (C=O) OR
D '-NR
D '(C=O) R
D 'N
3N
2R
D 'Cyclic acetal; Or the replacement of ring-type or acyclic, straight or branched or unsubstituted aliphatic, assorted aliphatic, aryl, or heteroaryl moieties; Perhaps
R wherein
A, R
B, R
COr R
DIn any two lump together and can form annulus and can pass through oxygen, sulfur, carbon or the nitrogen-atoms connection, perhaps any two adjacent R
A, R
B, R
COr R
DLump together, can form replacement of 3-6 unit or unsubstituted aliphatic, assorted aliphatic, aryl or heteroaryl ring; In some embodiments, R
AAnd R
BLump together and form 3 yuan of rings that connect by oxygen, sulfur, carbon or nitrogen-atoms; In other embodiments, R
CAnd R
DLump together and form 3 yuan of rings that connect by oxygen, sulfur, carbon or nitrogen-atoms;
The R under every kind of situation wherein
A ', R
B ', R
C 'Or R
D 'Be hydrogen independently; Blocking group; Straight or branched, replacement or not replacement, ring-type or acyclic, aliphatic, assorted aliphatic, aryl, heteroaryl, aralkyl, arylalkenyl, sweet-smelling alkynyl, arylalkenyl, sweet-smelling alkynyl or heteroarylalkyl, impure aromatic ene base, hetaryne base section.
The compounds of this invention comprises the chemical compound of general formula further defined below (I):
R wherein
1Be hydrogen or low alkyl group; In some embodiments, R
1Be methyl; In some embodiments, R
1For-CF
3,-CF
2H or CH
2F; In other embodiments, R
1Be fluoridized or fluorinated alkyl; In some embodiments again, R
1Be halogenated or fully halogenated alkyl;
R
2For replace or unsubstituted aryl, heteroaryl, aralkyl or heteroarylalkyl part; In some embodiments, R
2For replacing or not replacing the De oxazole; In other embodiments, R
2For replacing or unsubstituted thiazole; With
A, B, C, D, R
3, R
4, R
5, R
6As above define with X.
In some embodiments, The compounds of this invention comprises the chemical compound with stereochemical general formula (II) as giving a definition:
Wherein A, B, C, D, R
1, R
2, R
3, R
4, R
5, R
6As above define with X.
In some embodiments, The compounds of this invention comprises the chemical compound of general formula as follows (III):
Wherein Z be oxygen atom, sulphur atom ,-NR
Z-or-C (R
Z)
2-; And A, B, R
1, R
2, R
3, R
4, R
5, R
6As above define with X.In some preferred embodiments, Z is an oxygen.In other embodiments, Z is-NH-.In some embodiments again, Z is-CH
2-.In other embodiments, R
ZBe hydrogen, alkyl, halogen or acyl group.In some embodiments, R
ZBe fluorine.
In some embodiments, The compounds of this invention comprises the chemical compound with stereochemical general formula (IV) as giving a definition:
Wherein A, B, R
1, R
2, R
3, R
4, R
5, R
6, X and Z as above define.In some embodiments, R
BBe methyl.In other embodiments, R
BFor-CF
3
In some embodiments, The compounds of this invention comprises logical formula V as follows or chemical compound (VI):
Wherein Z be oxygen atom, sulphur atom ,-NR
Z-or-C (R
Z)
2-; And A, B, R
1, R
2, R
3, R
4, R
5, R
6As above define with X.In some preferred embodiments, Z is an oxygen.In other embodiments, Z is-NH-.Z is-CH in some embodiments again
2-.In other embodiments, R
ZBe hydrogen, alkyl, halogen or acyl group.In some embodiments, R
ZBe fluorine.
In some embodiments, The compounds of this invention comprises the chemical compound of general formula as follows (VII):
Wherein A, B, R
C, R
D, R
1, R
2, R
3, R
4, R
5, R
6As above define with X.In some preferred embodiments, each R
CBe hydrogen, halogen or low alkyl group independently.In other embodiment, each R
DBe hydrogen, halogen or low alkyl group independently.
In some embodiments, X is O.In other embodiments, X is NH.In other embodiments, X is CH
2
In some embodiments, R
2Be that replace or unsubstituted thiazole.In some embodiments, R
2Be 2-methyl-thiazole-4-base.In other embodiments, R
2Be 2-methylol-thiazole-4-base.In some embodiments again, R
2Be 2-aminomethyl-thiazole-4-base.In other embodiments, R
2Be 2-thiol methyl-thiazole-4-base.
In some embodiments, R
2For replace or do not replace the De oxazole.In some embodiments, R
2Be 2-methyl-oxazoles-4-base.In other embodiments, R
2Be 2-methylol-oxazoles-4-base.In some embodiments again, R
2Be 2-aminomethyl-oxazoles-4-base.In other embodiments, R
2Be 2-thiol methyl-oxazoles-4-base.
In some embodiments, R
BFor hydrogen, methyl, ethyl ,-CF
3,-CH
2F ,-CF
2H.In some embodiments, R
BBe methyl.In some embodiments again, R
BFor-CF
3In some embodiments, R
BBe hydrogen.In other embodiments, R
BBe ethyl.
Some preferred chemical compounds comprise, for example:
The compounds of this invention comprises that as above specifically illustrate and those chemical compounds described herein, and by in the present invention other local disclosed various types of, belong to and plant and partly illustrate.Do not wish to be bound by any concrete theory, chemical compounds more of the present invention are modified to force molecular conformation with the mode that carbon-carbon double bond is identical on the C9-C10 position on C9 and C10.Electronic effect, steric effect, hydrogen bond, dipole effect or their combination can be used to set up this conformation and force.For example, cyclic rings system oxirane, cyclopropyl and the aziridine conformation that can be used for forcing this molecule for example.In other embodiments, 4,5 or 6 yuan of rings are used to the effect that reaches same.This effect can also be by conjugated p-track system, for example is found in the system in ester, thioester or the amide and finishes.This effect also can be passed through delocalization π system, for example be found in the aromatic rings system those and finish.In other embodiments, utilize near the substituent steric effect in C9 and C10 position to force the same way as of molecule to force molecular conformation with carbon-carbon double bond on the C9-C10 position.
It will be recognized by those of ordinary skill in the art that asymmetric center can be present in the The compounds of this invention.Therefore, The compounds of this invention and pharmaceutical composition thereof can be the forms of single enantiomer, diastereomer or geometric isomer, perhaps can be the form of mixtures of stereoisomer.In some embodiments, The compounds of this invention is an enantiopure compound.The mixture of stereoisomer or diastereomer is provided in other embodiments.
Be that the class of some aforesaid compounds and subclass can exist with various isomeric form with what recognize.Inclusion compound of the present invention is as the individual isomer of essentially no other isomer with alternatively as various mixture of isomers, for example the racemic mixture of stereoisomer.In addition, the present invention comprises (Z) and (E) both double bond isomers, unless spell out in addition.Therefore, be described in usually The compounds of this invention in the structure of the present invention comprise those wherein double bond structure be (Z) or chemical compound (E).In some preferred embodiments, be cis or Z configuration at locational pair of key of C12-C13.In some embodiments, be trans or the E configuration at locational pair of key of C9-C10.In other embodiment, be cis or Z configuration at locational pair of key of C12-C13, and be trans or the E configuration at locational pair of key of C9-C10.The present invention also comprises the tautomer of aforesaid specific compound.
In addition, the invention provides The compounds of this invention pharmacy acceptable derivates and use described these chemical compounds, its pharmaceutical composition or one of them and one or more other therapeutic agents combinations and the method for treatment target.Used term " pharmaceutically acceptable derivates " refers to the salt of any pharmaceutically acceptable salt, ester or this ester of this chemical compound among the present invention, or any other addition product or derivant, it is when giving patient's medication, can provide (directly or indirectly) as other local chemical compound of describing among the present invention, or its metabolite or residual.Pharmaceutically acceptable derivates is therefore particularly including prodrug.Prodrug is the derivant of chemical compound, has significantly reduced pharmacologically active usually, and it comprises other part, and this part is easy in vivo remove and generates parent molecule as pharmacological active substance.The example of prodrug is an ester, and it can cut in vivo and generate the purpose chemical compound.The prodrug of all cpds and material and the being used to parent compound of deriving forms the method for prodrug, is known and can be suitable for the present invention.Some typical pharmaceutical compositions and pharmacy acceptable derivates will be discussed below of the present invention in detail.
Interested especially The compounds of this invention comprises:
● demonstrate cytotoxicity or growth inhibited effect to cancerous cell line, described cell line maintains in the zooscopy of acceptable cancerous cell heteroplastic transplantation model on external or the employing science;
● demonstrate the ability of polymerization tubulin and stabilize microtubules assembling;
● demonstrate the minimum toxic level of vitals;
● cause the disappearance of the tumor in the acceptable cancerous cell heteroplastic transplantation model on science;
● cause the contraction of the tumor in the acceptable cancerous cell heteroplastic transplantation model on science;
● cause on science the tumor in the acceptable cancerous cell heteroplastic transplantation model to disappear and stopping to delay after the treatment/or do not cause tumor recurrence;
● on science, demonstrate in the acceptable cancerous cell heteroplastic transplantation model in short-term and to reduce with reversible body weight and demonstrate therapeutic effect;
● demonstrate the water solublity that is better than Epothilones A, B, C or D or paclitaxel, but or demonstrate enough dissolubilities additionally or alternati with in the water-bearing media that is formulated in the Li Mofu that uses the reduction ratio; And/or
● demonstrate the treatment characteristic (for example effect of Zui Jia safety and healing) that is better than epothilone B, epothilone d or paclitaxel
The analog of various Epothilones described above is as institute of the present invention illustration and be produced, characterize and test.Have been found that 9,10-dehydrogenation-epothilone analogs can be used for treatment for cancer, and particularly chemical compound has been produced and has found that it has one or more above-named characteristics of wanting.
Synthetic method
Some Epothilones, NSC-703147 and analog thereof synthetic be described in the past (referring to, United States Patent (USP) 6,242,469,6,284,781,6,300,355,6,204,388,6,316,630 and 6,369,234; U.S. Patent application 09/797,027,09/796,959 and 10/236,135; With PCT open WO 99/01124, WO 99/43653 and WO 01/64650, full content is incorporated the present invention by reference into).Recognize and to improve or to replenish the synthetic method that effectively generates Epothilones, NSC-703147 and analog thereof in large quantities, the invention provides effective canonical path and be used for synthetic Epothilones, NSC-703147 and analog thereof.Although some exemplary compounds synthetic is described among the embodiment of this paper, is that this methodology can be common to the analog and the conjugate of generation each class as above described in the present invention and subclass with what recognize.
Particularly, of the present invention 9,10-dehydrogenation epothilone compounds can prepare with the number of ways of the synthetic method that is used for synthetic Epothilones.In some embodiments, adopt the convergent synthesis approach to prepare these chemical compounds.For example synthetic Epothilones can form the chemical compound of wanting by preparing two or three intermediate and bonding them together.In one embodiment, one of intermediate is the acyl moiety that comprises 1-9 carbon, and another intermediate comprises 10-15 carbon and can also comprise the thiazole side chain.The intermediate of these two Epothilones about equally can utilize esterification and combine, and this esterification occurs in C1 and sloughs between the C15 of oxygen.Can utilize carbon carbon coupled reaction then, for example Suzuki coupling or closed loop metathesis reaction are closed into macro ring.In one embodiment, final closed loop step forms 9 by the closed loop metathesis reaction, and the two keys of 10-also are closed into macro ring and finish.The closed loop metathesis reaction is by using organo-metallic catalyst, for example is shown in the Grubbs catalyst of following sketch map 8 and finishes.In some embodiments, with this 9, the two keys of 10-are reduced or oxidation, perhaps can with this 9, the two keys of 10-are further functionalized to prepare other epothilone derivate.In some embodiments, by with Cabbeen or carbenoid reagent such as CH
2N
2Handle 9, the two keys of 10-and with this 9, the two keys of 10-are converted into the cyclopropyl part.
In some embodiments, described 9,10-dehydrogenation epothilone compounds by with two keys from 10,11-position (for example, Epo490) isomerization to 9,10-position and preparing.This isomerization can be by the transition metal such as the palladium catalysis that exist.
In other embodiments, final closed loop step forms 12 by adopting the closed loop metathesis reaction, and the two keys of 13-also are closed into macro ring and finish.In some embodiments, with this 12, two keys reduction of 13-or oxidation.In other embodiments, form macro ring with macro ring aldolisation or macrolide reaction.
The compounds of this invention is provided in drawings and Examples, and some are typically synthetic.Persons of ordinary skill in the art will recognize that and adopt the synthetic method that is described among the present invention can prepare multiple analog and derivant.For example, can realize a lot of synthesis steps with different blocking groups or the different substituent groups on 16 yuan of rings.
Pharmaceutical composition
The present invention also provides pharmaceutical preparation, its comprise at least a as mentioned above with chemical compound described here, or its pharmaceutically acceptable derivates, described chemical compound can anticancer growth or kill cancer cell, and in some embodiments, interested especially is that described chemical compound can suppress the growth of multi-drug resistant cancerous cell or kill them.In some embodiments, pharmaceutical preparation of the present invention also comprises solubilizing agent or emulsifying agent, but for example Li Mofu (CREMOPHORE EL) or Solutol (Polyethylene Glycol 660 12-hydroxy stearic acid esters).
As mentioned above, the invention provides and have anticancer and new compound antiproliferative activity, and therefore The compounds of this invention can be used for treatment for cancer.Therefore in another aspect of the present invention, provide pharmaceutical composition, wherein these compositionss comprise any one in the chemical compound described in the present invention, and the optional medicine acceptable carrier that comprises.In some embodiments, these compositionss randomly further comprise one or more other therapeutic agents.In other embodiments, as being described in further detail in the present invention, this other therapeutic agent is an anticarcinogen.
What also will recognize is that chemical compounds more of the present invention can exist with free form and be used for the treatment of, or suitable place, as the form of its pharmaceutically acceptable derivates.According to the present invention, pharmaceutically acceptable derivates includes but not limited to, the salt of pharmaceutically acceptable salt, ester, this ester or any other addition product or derivant, it is when giving the patient's medication that needs, can provide (directly or indirectly) as other local chemical compound of describing among the present invention, or its metabolite or residual, for example prodrug.
As used in the present invention, term " pharmaceutically acceptable salt " refers to those salt, it is suitable for contacting with the lower animal tissue with the people and not having unsuitable toxicity, zest, allergy etc., and has rational benefit/risk ratio in rational medical judgment scope.Pharmaceutically acceptable salt is known in the art.For example, the acceptable salt of pharmacy is described in detail in J.Pharmaceutical Sciences by people such as S.M.Berge, among the 66:1-19 (1977), incorporates the present invention by reference into.Described salt can original position generate in last separation of The compounds of this invention and purge process, or by free alkali functional group is separated preparation with suitable organic acid reaction.The example of the acceptable nontoxic acid-addition salts of pharmacy is the amino salt that forms with mineral acid or organic acid, wherein mineral acid is for example hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid and perchloric acid, organic acid is for example acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid, perhaps by adopting available other method in this area, for example ion exchange.The acceptable salt of other pharmacy comprises adipate, alginate, Ascorbate, aspartate, benzene sulfonate, benzoate, disulfate, borate, butyrate, camphorate, camsilate, citrate, cipionate, digluconate, dodecane sulfonate, ethane sulfonate, formates, fumarate, gluceptate, glycerophosphate, gluconate, hernisulfate, enanthate, caproate, hydriodate, 2-hydroxyl-ethane sulfonate, Lactobionate, lactate, laruate, lauryl sulfate, malate, maleate, malonate, mesylate, the 2-naphthalene sulfonate, nicotinate, nitrate, oleate, oxalates, palmitate, embonate (pamoate), pectate (pectinate), persulfate, 3-phenylpropionic acid salt, phosphate, picrate, Pivalate, propionate, stearate, succinate, sulfate, tartrate, rhodanate, tosilate, the hendecane hydrochlorate, valerate or the like.Typical alkali metal salt or alkali salt comprise sodium, lithium, potassium, calcium, magnesium or the like.The more acceptable salt of pharmacy comprises, in the time of suitably, nontoxic ammonium, quaternary ammonium and the amine cation that forms with the ion with anti-electric charge, described ion with anti-electric charge is halogen ion, hydroxide ion, carboxylic acid ion, sulfate ion, phosphate anion, nitrate ion, low alkyl group sulfonate ion and aryl sulfonic acid radical ion for example.
In addition, as used in the present invention, term " pharmaceutically acceptable ester " refers to the ester of hydrolysis in vivo, and is included in easy those esters that discharge parent compound or its salt that decompose in the human body.The ester group that is fit to comprises that for example, those are derived from the ester of the acceptable aliphatic carboxylic acid of pharmacy, particularly alkanoic acid, alkenoic acid, aphthenic acids and chain docosandioic acid, and wherein each alkyl or alkenyl part advantageously has no more than 6 carbon atoms.The example of concrete ester comprises formic acid esters, acetas, propionic ester, butyrate, acrylate and ethyl succinate.
In addition, " pharmaceutically acceptable prodrug " refers to those prodrug of The compounds of this invention as used in the present invention, it is in rational medical judgment scope, be applicable to and contact with the lower animal tissue with the people and do not have unsuitable toxicity, zest, allergy etc., and has a rational benefit/risk ratio, with effectiveness, and as long as, refer to zwitterionic form to the The compounds of this invention possibility to their desired use.Term " prodrug " refers in vivo conversion fast to form the as above parent compound of general formula, for example by hydrolysis in blood.At T.Higuchi and V.Stella, Pro-drugs as Novel Delivery Systems, in the A.C.S.Symposium Series the 14th volume, with the BioreversibleCarriers in Drug Design that compiles at Edward B.Roche, American Pharmaceutical Association andPergamon Press, carried out in 1987 discussing completely, two pieces of documents are all incorporated the present invention by reference into.
As mentioned above, pharmaceutical composition of the present invention comprises pharmaceutically acceptable carrier in addition, it is as used in the present invention, comprise any and all solvent, diluent or other liquid vehicle, dispersion or suspension aids, surfactant, isotonic agent, thickening agent or emulsifying agent, antiseptic, solid binder, lubricant or the like, as the concrete form of medication that is suitable for wanting.Remington ' s Pharmaceutical Sciences, the 15th edition, E.W.Martin (MackPublishing Co., Easton, Pa., 1975) discloses variety carrier and the known technology of preparing thereof that is used to form pharmaceutical composition.With inconsistent all the conventional mounting mediums of anticancer compound of the present invention, for example produce any unwanted biological effect or with pharmaceutical composition in any other one or more components interact in deleterious mode, in addition, the expection of the purposes of this mounting medium is incorporated in the scope of the present invention.Some can be used as the examples of material of pharmaceutically acceptable carrier, and the judgement according to formulator includes but not limited to, saccharide is lactose, dextrose plus saccharose for example; Starch based is corn starch and potato starch for example; Cellulose and derivant thereof be sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate for example; Powdered tragakanta; Fructus Hordei Germinatus; Gelatin; Pulvis Talci; But Li Mofu; Solutol; Excipient is cocoa butter and suppository cured (suppository waxes) for example; Oils is Oleum Arachidis hypogaeae semen, Oleum Gossypii semen, safflower oil, Oleum sesami, olive oil, Semen Maydis oil and soybean oil for example; Di-alcohols is propylene glycol for example; Esters is ethyl oleate and ethyl laurate for example; Agar; Buffer agent is magnesium hydroxide and aluminium hydroxide for example; Alginic acid; Apirogen water; Deng oozing salt; Ringer's mixture; Ethanol and phosphate buffered solution, and other nontoxic compatible lubricant for example sodium lauryl sulphate and magnesium stearate, and coloring agent, releasing agent, coating agent, sweeting agent, flavoring agent and aromatizing agent (perfuming agents), antiseptic and antioxidant also can be present in the present composition.
The purposes of chemical compound and pharmaceutical composition
The present invention further provides the method that is used to suppress tumor growth and/or neoplasm metastasis.In some interested especially embodiments,, the invention provides by suppressing tumor growth and/or neoplasm metastasis and treat method for cancer for the multidrug resistant cancerous cell of tumor.This method comprises the treatment The compounds of this invention of effective dose or its pharmacy acceptable derivates its object of needs (including but not limited to the human or animal) medication.In some embodiments, be used in particular for treating the cancer that comprises the multidrug resistant cancerous cell, described treatment effective dose is such amount: it is enough to kill or suppresses the multidrug resistant cancerous cell line.In some embodiments, The compounds of this invention is used for the treatment of solid tumor.
The compounds of this invention and pharmaceutical composition can be used for treatment or prevent any disease or symptom, comprise proliferative disease (for example cancer), autoimmune disease (for example rheumatoid arthritis) and infectious disease (for example infectious disease such as antibacterial, fungus).But The compounds of this invention and pharmaceutical composition medication be in animal, preferred mammal (for example domestic animal, cat, Canis familiaris L., mice, rat), and more preferably people.Can use the chemical compound of any administrated method to animal delivering drugs compositions.In some embodiments, The compounds of this invention or pharmaceutical composition are with parenterai administration.
More on the one hand, as described herein, according to Therapeutic Method of the present invention, the kill tumor cell or suppress their growth by tumor cell is contacted with The compounds of this invention or compositions.Therefore in still another aspect of the invention, be provided for treating method for cancer, it comprises is wanted result's amount and time medication to the object that needs it The compounds of this invention of treatment effective dose or the pharmaceutical composition that comprises The compounds of this invention to reach.In some embodiments of the present invention, " the treatment effective dose " of The compounds of this invention or pharmaceutical composition is such amount: it is kill cancer cell or anticancer growth effectively.The method according to this invention, chemical compound of the present invention and compositions can be with any amount and any administrations of effective kill cancer cell or anticancer growth.Therefore, statement as used in the present invention " the effectively amount of kill cancer cell or anticancer growth " refers to the reagent of the q.s of kill cancer cell or anticancer growth.Required definite amount will change with object is different, its depend on object species, age and comprehensive state, the seriousness of infection, concrete antitumor and anticancer agent, application method or the like.Anticancer compound of the present invention is preferably prepared to be easy to medication and dosage homogeneous with dosage unit form.Used statement " dosage unit form " refers to be suitable for treat the physically separated unit of patient's antitumor and anticancer agent among the present invention.Yet this will be interpreted as that the whole day consumption of The compounds of this invention and compositions will reasonably determined in the medical judgment scope by the attending doctor.The effective dosage level of particular treatment that is used for any concrete patient or organism will depend on various factors, comprise the seriousness of the disease of being treated and this disease; The activity of used specific compound; Used particular composition; Patient's age, body weight, comprehensive health state, sex and diet; The time of the medication of used specific compound, route of administration and drainage rate; The persistent period of treatment; The medicine that combines or use simultaneously with used specific compound; And in the known similar factor of medical domain.
In addition, after preparing with the dosage of wanting with suitable pharmaceutically acceptable carrier, pharmaceutical composition of the present invention can be to people and the administration as follows of other animal: oral administration, rectal administration, non-enterally administer, pond innerlich anwenden, intravaginal medication, intraperitoneal administration, local application's (as by powder, ointment or drop), through cheek medication such as oral cavity or nasal cavity spray or the like, it depends on the seriousness of the infection of being treated.In some embodiments of the present invention, chemical compound described in the present invention is prepared by combining with water-soluble chelator or water-soluble polymer, wherein said water-soluble polymer is for example: Polyethylene Glycol is as poly-(1-glutamic acid) or poly-(1-aspartic acid), as at United States Patent (USP) 5,977, described in 163 like that, its full content is incorporated the present invention by reference into.In some embodiments, The compounds of this invention can oral or non-intestinal with enough dosage level medications, described dosage level is enough to reach about 0.001mg/kg of object body weight every day to about 100mg/kg for the medicine of delivering, about 0.01mg/kg is to about 50mg/kg, preferred about 0.1mg/kg is to about 40mg/kg, preferred about 0.5mg/kg is to about 30mg/kg, about 0.01mg/kg is to about 10mg/kg, about 0.1mg/kg is to about 10mg/kg, and more preferably from about 1mg/kg is to about 25mg/kg, once a day or repeatedly, to obtain desirable therapeutic effects.Can with per two days once, per three days once, jede Woche once, every fortnight once, per three weeks once or every four stars phase the dosage of wanting once is provided.In some embodiments, can provide the dosage of wanting (for example, twice, three times, four times, five times, six times, seven times, eight times, nine times or ten administrations) with multiple dosing.
Be used for oral and liquid dosage form parenterai administration and include but not limited to the acceptable Emulsion of pharmacy, microemulsion, solution, suspension, syrup and elixir.Except reactive compound, liquid dosage form for example also can comprise inert diluent commonly used in this area, water or other solvent, solubilizing agent and emulsifying agent be ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzylalcohol, benzyl benzoate, propylene glycol, 1 for example, the fatty acid ester of 3-butanediol, dimethyl formamide, oils (particularly Oleum Gossypii semen, Oleum Arachidis hypogaeae semen, Semen Maydis oil, germ oil, olive oil, Oleum Ricini and Oleum sesami), glycerol, tetrahydrofurfuryl alcohol, Polyethylene Glycol and sorbitan, and their mixture.Except inert diluent, Orally administered composition also can comprise adjuvant for example wetting agent, emulsifying agent and suspending agent, sweeting agent, flavoring agent and aromatizing agent.Be used for the embodiment of parenterai administration at some, The compounds of this invention mixes with solubilizing agent, but for example Li Mofu, alcohols, oils, modification oils, glycols, polysorbate esters, cyclodextrin, polymer class, and their compositions.In some embodiments, The compounds of this invention and alcohol, but for example ethanol and Li Mofu (Oleum Ricini of polyethoxylated) mixing.
Injection, for example aseptic injection water or oily suspension, dispersant that can be fit to according to use known in the art or wetting agent and suspending agent are prepared.Aseptic injection also can be aseptic injectable solution, suspension or the emulsion in nontoxic non-intestinal acceptable diluent or solvent, for example solution in 1,3 butylene glycol.Spendable in these acceptable excipient and the solvent have water, Ringer's mixture, U.S.P. and an isotonic sodium chlorrde solution.In addition, aseptic not volatile oil is commonly used for solvent or suspension media.For this reason, available any non-stimulated fixed oil comprises synthetic monoglyceride or diglyceride.In addition, fatty acid for example oleic acid be used to injection.
Injection of the present invention can be sterilized in the following way: for example, keep filter by antibacterial and filter, or add sterilization solid composite form disinfectant, described disinfectant can be dissolved or dispersed in sterilized water or other aseptic injection medium before use.
In order to prolong drug effect, wish to delay from the absorption of the medicine of subcutaneous injection or intramuscular injection.This can finish by the liquid suspension that use has relatively poor water miscible crystallization or an amorphous material.So the infiltration rate of medicine depends on its dissolution rate, this may depend on crystallite size and crystal habit again.Perhaps, by in the oils excipient, medicine dissolution or suspension being reached the purpose that the medicament forms that delays parenterai administration absorbs.Injection storage storehouse dosage form, for example forms little encapsulation capsule substrate in polylactic acid-poly-glycolic acid lactide and prepares in biodegradable polymer by medicine.Depend on medicine to the ratio of polymer and the character of used concrete polymer, can control drug release speed.The example of biodegradable polymer comprises poe and polyanhydride.Storage storehouse injection is also caught medicine by liposome compatible with bodily tissue or microemulsion and is prepared.
The compositions that is used for rectum and vagina medicinal is preferably suppository, it can pass through The compounds of this invention and the non-irritating excipient or the carrier that are fit to, the for example cured mixing of cocoa butter, Polyethylene Glycol or suppository and preparing, described excipient or carrier at room temperature are solid, and be liquid under body temperature, and therefore fusing and discharge active medicine in rectum or vaginal canal.
The solid dosage forms of oral administration comprises capsule, tablet, pill, powder and granule.In these solid dosage formss, reactive compound and at least a inert, acceptable excipient of pharmacy or carrier mix, for example sodium citrate or calcium hydrogen phosphate and/or a) filler or extender starch for example, lactose, sucrose, glucose, mannitol and silicic acid, b) binding agent carboxymethyl cellulose for example, alginate, gelatin, polyvinylpyrrolidone, sucrose and Radix Acaciae senegalis, c) wetting agent glycerol for example, d) disintegrating agent agar--agar for example, calcium carbonate, potato starch or tapioca, alginic acid, some silicate and sodium carbonate, e) dissolve for example paraffin of delayer, f) absorption enhancer quarternary ammonium salt compound for example, g) for example monostearate spermaceti alcohol ester and glyceryl monostearate of wetting agent, h) for example Kaolin and bentonite and i of absorbent) lubricant Pulvis Talci for example, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulphate and composition thereof.Under the situation of capsule, tablet and pill, these dosage forms also comprise buffer agent.
The solid composite of similar type also can be used as the filler in soft filling and the hard gelatine capsule agent of filling, and the used excipient of described capsule is lactose and high molecular weight polyethylene glycol or the like.These solid dosage formss of tablet, dragee, capsule, pill and granule can be used at the known coating of pharmacy formulation art and shell and prepare, for example casing and other coating.These dosage forms can be chosen wantonly and comprise tranquilizer and also can be the compositions that only discharges one or more active components, or preferably, some part at intestinal randomly discharges in the time-delay mode.The example of available embedding composition comprises polymer material and wax.The solid composite of similar type also can be used as the filler in soft filling and the hard gelatine capsule agent of filling, and the used excipient of described capsule is as lactose and high molecular weight polyethylene glycol or the like.
Reactive compound also can with have one or more as above illustrated excipient in little packaging plastic cap dosage.These solid dosage formss of tablet, dragee, capsule, pill and granule can be used the known coating of pharmacy formulation art and shell and prepare, for example casing, controlled release coat and other coating.In this solid dosage forms reactive compound can with for example sucrose, lactose or the starch blending of at least a inert diluent.This dosage form also can comprise, as normal way, and except the other material of inert diluent, for example tablet lubricants and other sheet agent aid such as magnesium stearate and microcrystalline Cellulose.Under the situation of capsule, tablet and pill, described dosage form also can comprise buffer agent.These dosage forms can be chosen wantonly and comprise emulsifying agent and also can be the compositions that only discharges one or more active components, or preferably, in some part of intestinal, randomly the mode with time-delay discharges.The example of available embedding composition comprises polymer material and wax.
The dosage form that is used for part or percutaneous dosing of The compounds of this invention comprises ointment, paste, cream, lotion, gel, powder, solution, spray, inhalant or patch.Described active component under aseptic condition with the pharmaceutically acceptable carrier that may need and any required antiseptic or buffer agent blending.Ophthalmic preparation, ear drop and eye drop are also expected to fall in the scope of the invention.In addition, the present invention relates to use transdermal patch, it has the additional advantage that the controlled release chemical compound is provided to health.This dosage form can prepare by The compounds of this invention is dissolved or dispersed in the suitable medium.Also can use absorption enhancer to increase the flux that The compounds of this invention passes skin.Can be by the speed controlling film being provided or controlling transdermal speed by dispersion The compounds of this invention in polymeric matrix or gel.
As discussed above, the The compounds of this invention useful asticancer agents, and therefore by making the growth of cancer cell death or anticancer be used for the treatment of cancer.Usually, the cancer that anticarcinogen of the present invention can be used for treating and other proliferative disease include but not limited to, breast carcinoma, the brain cancer, skin carcinoma, uterus carcinoma, colon and rectal cancer, leukemia, pulmonary carcinoma, melanoma, multiple myeloma, non-Hodgkin lymphoma, ovarian cancer, cancer of pancreas, carcinoma of prostate and gastric cancer only give some instances.In some embodiments, anticarcinogen of the present invention is effective to leukaemia and melanoma cells, and therefore (for example can be used for treating leukemia, bone marrow, lymphocytic, promyelocyte, myelocytic and lymphoblastic leukemia, no matter acute or chronic form) and malignant melanoma.In other embodiment, anticarcinogen of the present invention is effectively to solid tumor and can also kills multidrug resistant cell (MDR cell) and/or suppress its growth.In some embodiments, anticarcinogen of the present invention is to the chemical sproof cancer of other known antineoplastic agent or have been found that to the clinical nonreactive cancer of other known antineoplastic agents be effective.In other embodiments, for the chemical sproof cancer of other antitumor microtubule stabilizer (for example paclitaxel), anticarcinogen of the present invention is effective.
What also will recognize is, The compounds of this invention and pharmaceutical composition can be used to combined therapy, chemical compound promptly of the present invention and pharmaceutical composition can be simultaneously, prior to or medication subsequently in one or more other required therapy or medical procedures.The concrete therapeutic combination (therapeutics or rules) that is used for assembled scheme should be considered required therapeutics and/or rules and the compatibility of the required therapeutic effect that will reach.What also will recognize is, used therapy can reach the effect wanted (for example, The compounds of this invention can be simultaneously and another kind of anticarcinogen medication) for identical disease, or used therapy can obtain different effect (for example, controlling any adverse effect).
For example, can comprise surgical operation with other therapy or anticarcinogen of anticarcinogen applied in any combination of the present invention, radiotherapy (some of them example, γ-radiation, the neutron beam radiotherapy, the electron beam radiotherapy, proton therapeutic, brachytherapy and body radioactivity isotope, only give some instances), incretotherapy, biological respinse therapy (interferon, interleukin and tumor necrosis factor (TNT), only give some instances), overheated and cryotherapy, reduce the medicament (for example Bendectin) of any side reaction, chemotherapy drugs with other approval, include but not limited to alkylating agent (chlormethine, chlorambucil, cyclophosphamide, phenyalamine mustard, ifosfamide), antimetabolite (methotrexate), purine antagonist and pyrimidine antagonist (Ismipur, 5-fluorouracil, Cytarabile, gemcitabine (Gemcitabine)), spindle poisonous substance (vinblastine, vincristine, Herba Catharanthi Rosei, paclitaxel, Docetaxel (Docetaxel)), podophyllinic acid lactone (etioposide, Irinotecan, hycamtin), antibiotic (amycin, bleomycin, mitomycin), nitroso ureas (carmustine, chlorethyl cyclohexyl nitrosourea), inorganic ions (cisplatin, the Carboplatin), enzyme (asparaginase) and hormones (tamoxifen, bright dried meat Li Te, flutamide and megestrol), only give some instances.For the more fully discussion of up-to-date cancer therapy referring to http://www.nci.nih.gov/, the tabulation of the tumour medicine of FDA approval is at http://www.fda.gov/cder/cancer/druglistframe.htm, with The Merck Manual, in the 17 edition 1999, its full content is incorporated the present invention into by application.
On the other hand, the present invention also provides drug packages or test kit, it comprises one or more containers of filling with one or more compositions of pharmaceutical composition of the present invention, and in some embodiments, it comprises the therapeutic agent as combination treatment of other approval.Randomly accompany with such one or more containers, it can be bulletin with government organs' true-to-shape, manufacturing, use or the sale of described government organs standard drug products, wherein said bulletin have reflected the approval of government organs for production, use or the sale of people's medication.
Coordinate
Below the embodiment of the invention be intended to help to understand the present invention, and they are not meant to, and also they should be construed as limiting the invention.In fact, from full content of the present invention, comprise in the list of references of the science quoted among the following examples and the present invention and patent documentation, to those skilled in the art, except those illustrate in the present invention and describe those, various modifications of the present invention and its many further embodiments will be conspicuous.Be that the content of the document that those are cited is incorporated the present invention into by reference to help to understand prior art with what further recognize.The following examples comprise important additional information, illustration and guidance, and they can various embodiments of the present invention and coordinate and be suitable for practice of the present invention.
Embodiment
Embodiment 1:26-three fluoro-9,10-is trans-and the oral and non-enterally administer treatment of dehydrogenation-epothilone d implants the intravital people's tumor of nude mice
In the present embodiment, proved the microtubule stabilizer of 16 membered macrolide things of structural design, 26-three fluoro-9,10-is trans-dehydrogenation-epothilone d, and giving the perfusion of 6hr intravenous or when oral, tumor is being shunk, cause tumor to disappear, and reach the effect that does not recur for a long time.Mice with large scale tumor (Fig. 6) or Taxol resistant tumors xenograft (Fig. 7) is used to explanation can use 26-three fluoro-9, and 10-is trans-and dehydrogenation-epothilone d cures as single medicament single therapy.The therapeutic domain of curing comprises leukemia and breast carcinoma, colon cancer and pulmonary carcinoma (Fig. 6,9 and 13).Here the interior experiment of Bao Gao all chemotherapeutics bodies of laws is all adopted the people's tumor xenogeneic graft in the immunodeficiency nude mice and is carried out.This animal model was usually used in estimating antitumoral compounds before to the cancer patient clinical trial.
MX-1 and HCT-116 experiment carries out 5.5 and 6.5 months (Fig. 6 and 9) respectively.Tumor is all less than recurrence in two experiments, eliminated 3.8 and 5.2 months respectively stopping to treat the back tumor.For HCT-116 experiment (Fig. 9), paclitaxel and 26-three fluoro-9,10-is trans-and dehydrogenation-epothilone d all uses and all realized the tumor disappearance with 20mg/kg.Yet the paclitaxel treatment group recurs after stopping to treat back 1.1 months, and 26-three fluoro-9, and 10-is trans-and the animal tumor of dehydrogenation-epothilone d treatment disappears above 5.2 months.Suppose that the long twice time of tumor is 4 days (based on vehicle treatment contrast), the paclitaxel treatment of HCT-116 tumor causes 99.7% tumor suppression or the cell of 2.56-log to kill, yet when experiment stops, by 26-three fluoro-9,10-is trans-cell that dehydrogenation-epothilone d kills in MX-1 and HCT-16 experiment is respectively>8.5-log and>11.6log.Based on by treatment mice health, active state, weight recovery level before the treatment simultaneously if implement the treatment that prolongs or increase treatment cycle, estimates that this " healing " can guarantee to run through 2 year life-span of mice.Should obtain such result, although in fact this " healing " more is difficult to obtain in immunodeficient mouse than in immunocompetent mice is arranged.As far as our knowledge goes, this is the longest xenograft treatment research of implementing on nude mice in biomedical document, also is with the parenteral administration or with the longest the returning to one's perfect health of being reported in the oral administration for single anti-tumor agents.This is relevant with following statement: the chemical compound of finding the inhibition tumor growth is relatively easy, but finds that the chemical compound that tumor is dwindled is uncommon relatively.The compounds of this invention 26-three fluoro-9,10-is trans-dehydrogenation-epothilone d, it has realized making fully in all mices tumor to disappear, and recurrence does not reach 5.2 months, this discovery was never reported as far as our knowledge goes, this shows 26-three fluoro-9, and 10-is trans-and dehydrogenation-epothilone d is for the great potential of therapeutics progress.
But the other remarkable advantage of oral medication is the severe allergic reaction that can avoid using the Li Mofu prescription to cause.But use Li Mofu to cause that thorny anaphylaxis is known in Taxol, deoxidation-EpoB and 15-aza-Epo 13 preparations, this makes and must use antihistaminic and/or steroid to carry out pretreatment.
26-three fluoro-9,10-is trans-oral result of dehydrogenation-epothilone d and its in external mice plasma and in people's liver microsomes S9 fragment significant metabolic stability consistent.Described metabolic stability is owing to fluoridizing (Figure 14) in three of C-26 position in this Epothilones molecule.On the C9-C10 position, introduce two keys and also increased metabolic stability (Figure 14).26-three fluoro-9,10-is trans-and dehydrogenation-epothilone d is used for intravenous perfusion (20-30mg/kg, Q2D) and be used for oral administration (20mg/kg, QD or 30mg/kg Q2D), its optimal dose can be well absorbed and have good bioavailability in vivo near this chemical compound of explanation.
It should be noted that the invention process many parallel with Taxol (one of Chang Yong most important anticancer therapeutic agent clinically) carry out about the interior therapeutics of the anti-xenograft of Fu Dilong researchs (Figure 13,7,9,10,11 and 16).The important discovery of Fu Dilong is compared with Taxol, has shown that this chemical compound is used for the treatment of the promising potentiality of cancer.
Material and method
Chemical products: all Epothilones are synthetic like that as described in the present invention.Paclitaxel (Taxol
) and vinblastine sulfate (VBL) available from Sigma.All these compound dissolutions are used in vitro tests in dimethyl sulfoxine, (except VBL is dissolved in saline).For studying in the body, but all Epothilones and paclitaxel all are dissolved in Li Mofu/ethanol (1: 1) vehicle and be used for utilizing the microtubular of autonomous Design and program-controlled pump to carry out the perfusion of 6hr intravenous (people (1998) Proc.Natl.Acad.Sci.USA 95 such as Chou, 15798-15802 by the tail vein with the saline dilution then; People such as Chou (2001) Proc.Natl.Acad.Sci.USA 98,8113-8118; Every piece of document is incorporated the present invention by reference into).The medicine of oral administration prepares in the following way: compound dissolution in ethanol and be suspended in isopyknic tween 80, is diluted the saline of this suspension with 5 times of volumes before giving the nude mice medication.Use the animal feeding pin of the spherical band of 1ml syringe and standard # 22 medicated cap to implement gavage (Popper﹠amp; Sons, Inc.New HydePark, NY).
Tumor and cell line: CCRF-CEM people's lymphoblast leukaemia and its vinblastine drug resistance subbreed (CCRF-CEM/VBL
100, 720 times of drug resistance) derive from William doctor Beck of Chicago Illinois university, and CCRF-CEM/ Taxol (44 times of drug resistance) by six middle of the month with the CCRF-CEM cellular exposure in ever-increasing to lethal concentration (IC
50-IC
90) paclitaxel in and prepare.The drug resistance degree is shown among Figure 14.People's breast carcinoma (MX-1), human lung carcinoma cell (A549) and human colon carcinoma (HCT-116) derive from American type culture collection (ATCC, Rockville, MD).
Animal: the nude mouse with nu/nu gene derives from NCI, Frederick, and MD also is used for the xenotransplantation of the somebody of institute tumor.Use 6 weeks above with body weight 20-22g or heavier male nude mouse.By using homemade microtubule and the limiter tube inculcated by perfusion administration in 6 hours in the tail cava vein.Have multichannel program-controlled Harvard PHD2000 syringe pump and be used to the intravenous perfusion.But inculcated volume in typical 6 hours is the Li Mofu/ethanol (1: 1) that contains every kind of medicine of 100 μ l in the 2.0ml saline.For oral administration, Fu Dilong and Taxol all are dissolved in the ethanol and with tween 80 and dilute 5 times.Taxol solution should use in 5min to avoid precipitation.Gross tumor volume is estimated by measure long * wide * high (or wide) with caliper.For the nude mice that has tumor, its body weight is meant that gross weight deducts the weight of tumor in the experimentation.All zooperies are all implemented according to the guideline of National Institute of Health Guide for the Care and Use of Animals with by the agreement of Memorial Sloan-Kettering Cancer Center ' s InstitutionalAnimal Care and Use Committee approval.
Cell toxicity test: for preparing the vitro cytotoxicity test, cell culture is 2-5 * 10 in initial density
4Every milliliter in individual cell.They are stored in 5%CO
2In 37 ℃ the RPMI culture medium 1640 (GIBCO/BRL) of-moistening atmosphere, described RPMI culture medium 1640 comprises penicillin (100 units/mL), streptomycin (100 μ g/mL GIBCO/BRL) and 5% heat-inactivated FBS.For the solid tumor cell of in monolayer, growing (for example HCT-116 and A549), the cytotoxicity of medicine is by using lissamine rhodamine B method (people (1990) J.Natl.CancefInst.82 such as Skehan, 1107-1112 incorporates the present invention by reference into) on the microtitration plate of 96-hole, measure.For the cell (for example CCRF-CEM and subbreed thereof) that grows in the suspension, by using 2,3-is two-(2-methoxyl group-4-nitro-5-sulfophenyl)-5-N carboxanilides)-2H-terazodium hydroxide (XTT) microtubule method (people (1988) Cancer Res.48 such as Scudiero, 4827-4833; Incorporate the present invention by reference into) on the microtitration plate of 96-hole, measure in duplicate.For two kinds of methods, (Winooski VT) measures the absorbance in each hole for Power Wave XS, Bio-Tek with the micro plate plate reading machine.The relation data of dosage-effect is by 6 to 7 concentration of every kind of medicine, and is duplicate, by the program of using a computer (people (1997) CalcuSyn for Windows such as Chou (and Biosoft, Cambridge, U.K.); Wherein each all incorporates the present invention by reference into) analyze with middle effect figure.
Epothilones is in mice and the stability in people's liver S9 fragment: carry out stability study with full-automatic HPLC system, described HPLC system comprises Prospekt-2 (SparkHolland, Netherlands) sample preparation system and Agilent 1100 HPLC systems.In brief, Prospekt 2 selects the C8 extraction column and uses acetonitrile and water washing.The Agilent automatic sampler is set at 37 ℃, draws 20 μ l samples, and it is loaded on the extraction column, washes with water, and Prospekt 2 turns to mobile phase to flow by extraction column to analytical column then.(PA) Reliance Stable Bond C8 4 * 80mm and eluent are monitored at the 250nm place for MacMod, Chadds Ford to have guard column.Mobile phase is made up of 53 or 65% acetonitrile/0.1% formic acid, flow velocity 0.4ml/min, so the retention time of purpose chemical compound is about 6 minutes.Sample preparation comprises isopyknic blood plasma is joined among the PBS, obtains cumulative volume 400 μ l, filter, and this substrate (20mM) that adds 0.5-2 μ l is to obtain in HPLC analyzes at the about 30-50mAU in 250nm place.(Xeno Tech, Lenex KS), mix the S9 fragment of 20 μ l (400 μ g) and to carry out step as mentioned above then with the PBS of 280 μ l for people's liver microsomes S9 fragment of merging.Sampling period is by automatic sampler control and gather the peak area data to compare the rate of disappearance of parent compound.
The result
The structure-activity relation of external anti-human leukemia, Taxol drug resistance and vinblastine drug resistance leukaemia and solid tumor cell.According to IC
50(in μ M) lists in the table of Figure 17 for the effectiveness of the anti-following cell growth of 12 kinds of typical Epothilones: the subbreed of human leukemia CCRF-CEM cell and their vinblastine drug resistance CCRF-CEM/VBL and taxol resistance CCRF-CEM/ Taxol.Also show the IC of two people's reality oncocyte systems simultaneously
50Value: pulmonary carcinoma A549 and colon cancer HCT-116.This shows that deH-EpoB has replaced EpoB as the most virtuous known Epothilones.What also show is: i) at dEpoB, dEpoF or F
3-dEpoF is last 9, and the 10-dehydrogenation is modified and always caused the remarkable increase renderd a service, has but reduced described effectiveness to a certain extent yet fluoridize at C-26 locational three, yet metabolic stability is but fluoridized greatly by three and increased (Figure 14); Ii) most of Epothilones is to vinblastine, and a kind of have the typical substrate of multiple drug resistance not have cross resistance to the P-glycoprotein, also not to the cross resistance of Taxol.Taxol is the good substrate of a kind of MDR phenotype, but the Taxol drug resistance also can produce by the sudden change in microtubule protein gene.15-azepine-EpoB is an exception, and 15-azepine-deH-EpoB demonstrates significant cross resistance to vinblastine and paclitaxel.DEpoF and derivant thereof demonstrate the cross resistance of some and vinblastine and paclitaxel are not had.The iii) almost same influence that is subject to Epothilones of leukemia CCRF-CEM cell and solid tumor A549 and HCT-116.Iv) F
3-deH-dEpoB, deH-dEpoB and deH-EpoB, they are novel lead compound that the present invention is used for further pharmacological evaluation, have not a particle of the cross resistance to vinblastine, and paclitaxel is not had yet.
(people (1979) Nature (London) 277 such as Schiff, 665-667 in the research in early days; People such as Meng (1997) J.Am.Chem.Soc.119,2733-2734; Every piece of document is incorporated the present invention by reference into), sum up the Epothilones molecule and can be divided into three parts.Therefore, in the acyl moiety of C-1~8,, do not allow structural change according to vitro cytotoxicity and microtubule stabilisation ability.This side aryl moiety with the O-moieties of C-9~15 and C-15 is opposite, and wherein both structures of back can allow to change significantly (people (1996) Biochemistry 35 such as Haar, 243-250; People such as Kowalski (1997) J.Biol.Chem.272,2534-2541; Every piece of document is incorporated among the present invention by reference).
Have 12, the Epothilones of 13-epoxy radicals part, for example EpoB and deH-EpoB, although be the most virtuous medicament in the Epothilones series, they are stood in maximum only has the therapeutic index of being on duty mutually under the dosage.This hypothesis can illustrate with the treatment data that are shown in Figure 14 table.
The physicochemical properties of epothilone derivate, metabolisming property, pharmacological property and therapeutic outcome.The serial Epothilones of different nature that is mutually related has promoted the understanding to the factor at the treatment home to return to that contributes to leading chemical compound.Table among Figure 14 has been summed up the feature of nine kinds of epothilone derivates.Structure-cytotoxic external activity relation provides based on the initial assessment of rendeing a service.For example, 9, the new class that the 10-dehydrogenation is modified has increased in the body and external effectiveness greatly.In the chemical compound of these preliminary elections, be difficult to structure-microtubule stability is renderd a service and is associated, because this renders a service all very high (that is, being similar to the effectiveness of paclitaxel).Water-soluble and lipotropy play a part different in therapeutic effect and are important for the design of preparation.DeH-dEpoF, F3-deH-dEpoF and deH-dEpoB have the water solublity of remarkable increase with respect to other Epothilones.F
3-deH-dEpoB is orally active, but this discovery reduced water solublity in pharmaceutical preparation necessity and can avoid using and cause Li Mofu hypersensitive.
External, deH-EpoB, deH-dEpoF, EpoB and deH-dEpoB have the IC of inferior nanomole in proper order with this
50Yet, F
3-deH-dEpoF, dEpoF, F
3-deH-dEpoB, dEpoB and F
3-dEpoB with this order, has IC
50Scope be 1.3 to 9.3nM (Figure 17).DeH-EpoB and EpoB are the most virtuous known Epothilones in vitro and in vivo, but they do not produce best therapeutic index.Obviously, the epoxy radicals part on C-12~13 of EpoB and deH-EpoB contributes to the toxicity for the host greatly, reduces (and not dead) lower value obviously visible (Figure 14) by weight limit percentage ratio.On the contrary, F
3-deH-dEpoB and dEpoB allow body weight to reduce peak and they all show the good curing result, for example eliminates tumor in all animals fully.Usually, with 6hr intravenous perfusion therapy, vitro efficacy and best therapeutic dose have shown good relatedness.Interesting especially is in listed Epothilones, F
3-deH-dEpoB (Fu Dilong) has the wideest healing therapeutic dose scope (10-30mg/kg) (people (2003) Angew Chem.Int.Ed.Engl.42 such as Chou, 4762-4767 incorporates the present invention by reference into), fabulous metabolic stability and best overall therapeutic outcome (Figure 14).In addition, F
3-deH-dEpoB provides the therapeutic effect of curing by oral administration route.In a word, the most virtuous Epothilones might not have better curative effect as anti-tumor agents, and F
3-deH-dEpoB is used for the treatment of the leading drug candidate of learning development.
Treatment for super large MX-1 tumor xenogeneic graft.As shown in Fig. 6 A, 25mg/kg, 6hr intravenous perfusion Q3D * 5, tumor is implanted back D22 and is begun to use F
3-deH-dEpoB causes significant tumor to shrink (>97.4%) to the treatment MX-1 xenograft of body weight 3.4% greatly.In 9 day intermission of not treatment (D34-D43), the tumor size continues to shrink (>99.3%) and has 2 mouse tumors to disappear in 5 mices that are studied, however the level (Fig. 6 B) of the body weight of treatment group before identical tempus intercalare all returns to treatment.Resume treatment at D43, Q3D * 4 cause disappearing at D50, D50 and D51 tumor in remaining 3 mices.Behind the D52 (promptly taking medicine the date at last), observed animal once in per three days, when the D165 test stops.All 5 animals all do not have tumor recurrence at D165 (promptly stopping to treat back 3.7 months).
A mice is shown among Fig. 6 B at the photo of this test nude mice of D25, D31, D37, D43 and D52 shooting from matched group and treatment group.
By oral administration by the healing treatment of cancer of Fu Dilong to the MX-1 xenograft.As shown in FIG. 13A, per two days orally give F
3-deH-dEpoB 30mg/kg 7 times, cause the MX-1 tumor shrink and 4 mices in 2 tumors disappear.Two other dosage (dosage skip back) in 4 mices 4 all cause tumor to disappear.On the contrary, suppress the MX-1 growth of tumor with the oral medication of the Taxol that carries out under same dose and the identical progress but do not cause tumor to be shunk.In the end two days (D36) behind the potion Taxol, it causes tumor suppression 66.9%.F
3-deH-dEpoB treatment is induced moderate but persistent body weight reduces maximum 15% body weight (Figure 13 B) that reduces.Very little body weight change is induced in the Taxol treatment, illustrates that the oral administration Taxol is obviously because drug metabolism inactivation or the bioavailability of difference rather than suitable treatment.Opposite with oral administration route, the present inventor's earlier report (people (2001) Proc.Natl.Acad.Sci.USA 98 such as Chou, 8113-8118; Incorporate the present invention by reference into), the MX-1 tumor can cause tumor to be shunk and the tumor disappearance with the 20mg/kg Taxol through 6hr intravenous perfusion therapy.
The healing therapeutic effect of the chemical sproof CCRF-CEM/ Taxol of the anti-Taxol of Fu Dilong xenograft.(people (2003) AngewClient.Int.Ed.Engl.42 such as Chou, 4762-4767 in the nearest report of the present inventor; Incorporate the present invention by reference into), the present inventor has illustrated F
3-deH-dEpoB is at 20mg/kg, Q2D * 7, and the 6hr intravenous causes tumor growth to suppress fully when being poured in anti-Taxol drug resistance people pulmonary carcinoma A549/ Taxol (external to 44 times of drug resistance of paclitaxel), but does not reach vanishing tumor.The present inventor uses another kind of taxol resistance xenograft in the present invention, CCRF-CEM/ Taxol (external to 44 times of drug resistance of paclitaxel).As shown in Figure 7, Fu Dilong is in 30mg/kg Q2D * 7, and the perfusion of 6hr intravenous causes having in 4 mices 2 tumors to disappear.Other Q2D * 5 (dosage doubles) cause having in 4 mices 3 tumors to disappear, and final tumor suppression is 99.8% (Fig. 7 A).At the dosage that reduces is 15mg/kg, has only the 5th a day generation tumor disappearance after two cycle therapy in 4 mices.In the final tumor suppression of D34 is 98.8%.The parallel laboratory test of carrying out at 20mg/kg with Taxol has caused tumor growth to suppress but seldom or has not at all dwindled tumor.In the final tumor suppression of D34 is 75.6%.
F
3Both all continue to reduce body weight-deH-dEpoB (at 15mg/kg and 30mg/kg) and Taxol (20mg/kg) in the period 1 therapeutic process of dabbling 7 treatments by the 6hr intravenous in per two days.Skip seance at D22 and cause in all mices weight increase immediately.Treatment second round of Q2D * 5 is same to continue to reduce body weight, but all are tested mices all less than deadly (Fig. 7 B).
Healing treatment by the anti-human colon carcinoma HCT-116 of Fu Dilong xenograft.Shown in Fig. 9 A, F
3-deH-dEpoB at 20mg/kg and 30mg/kg or Taxol at 20mg/kg, Q2D * 4, in 6hr intravenous 3 cycles of perfusion, 4 all cause tumor to disappear in 4 mices.Implant back D9 begin treatment in tumor.Between first and second cycles, skip a dosage, and between the second and the 3rd circulation, skip two dosage at D27 and D29 at D17.D9-D37 is that 3 cycle therapy stages and D37-D200 are follow-up period.This Therapy lasted 200 days, it is for surpassing 1/4th of mice average life.
For F at 30mg/kg
3-deH-dEpoB, tumor disappears at D21,23,33 and 41, and at 20mg/kg, tumor disappears at D31,35,41 and 45.F for two kinds of dosage
3-deH-dEpoB, when the D200 experiment finished, 4 did not all have tumor recurrence in 4 mices.At 20mg/kg, tumor disappears at D33,33,41 and 45 for Taxol, this and F at 20mg/kg
3Observed similar among the-deH-dEpoB.Yet in Taxol treatment group, at D71,75,81 and 81 tumor recurrences.
The treatment program that comprises tempus intercalare is represented by body weight reduction and the physical state of mice.For F at 30mg/kg
3-deH-dEpoB treatment, maximum body weight are reduced to 30% and do not cause death, and this betides the second treatment cycle end (being D29) (Fig. 9 B).For the Taxol of 20mg/kg and the F of 20mg/kg
3-deH-dEpoB, the reduction of body weight and recovery are in pattern and measure all similar.
Embodiment 2: determine Fu Dilong (F
3-deH-dEpoB) the mechanism of action with and how to be different from the mechanism of action of EpoD; These different therapeuticss hints
The drug susceptibility of multiple myeloma of people (MM) and non-Hodgkin lymphoma (NHL) tumor cell line
MM account for all cancers 1% and malignant hematologic disease 10%, 15,500 newly-increased diagnosed SARS cases and>15 were arranged, 000 example death in 2002.MM is incurable with the traditional chemical therapy for treating, and existence time limit median is about 3 years (people " Treatment of multiplemyeloma " Blood 2004 such as Barlogie; 103:20-32; Incorporate the present invention by reference into).Although the high dose chemotherapy with the hematopoietic stem cell carrier has increased the ratio that complete symptom goes down and do not have the incident life span, almost each patient can be recurred, and requires for rescuing pressing for of selection scheme.Paclitaxel has been used to treat multiple myeloma and non-Hodgkin lymphoma (people " Paclitaxel as the initial treatment of multiple myeloma:an EasternCooperative Oncology Group Study (E1A93) " Am.J.Clin.Oncol.1998 such as Miller; 21:553-556; People such as Jazirehi " Resveratrol modifies the expression of apoptoticregulatory proteins and sensitizes non-Hodgkin ' s lymphoma and multiplemyeloma cell lines to paclitaxel-induced apoptosis " Mol.Cancer Ther.2004; 3:71-84; Every piece of document is incorporated the present invention by reference into).Yet this application is but because its high toxicity and multi-drug resistant and restricted.The present inventor has estimated Fu Dilong and anti-lineup MM of dEpoB and NHL system, they use in many researchs recently that are used for estimating the NOD/SCID heteroplastic transplantation model of novel therapies, comprise 10-propargyl-10-denitrogenation assorted-aminopterin (PDX) (people such as Wang " Activity of a novel anti-folate (PDX, 10-propargyl-10-deazaaminopterin) against human lymphoma issuperior to methotrexate and correlates with tumor RFC-1geneexpression " Leukemia ﹠amp; Lymphoma 2003,44:1027-1035), anti-telomerase (people " Telomerase inhibition with an oligonucleotidetelomerase template antagonist:in vitro and in vivo studies in multiplemyeloma and lymphoma " Blood 2004 such as Wang; 103:258-66; Incorporate the present invention by reference into) and anti-VEGFR Mab (people " Targeting autocrine and paracrineVEGF receptor pathways regresses human lymphoma xenographs in vivo " Blood such as Wang is in the printing; Incorporate the present invention by reference into).Fu Dilong and dEpoB all can suppress myeloma and lymphoma cell propagation significantly.Myeloma cell line is very responsive to Fu Dilong with ultralow IC50 and dEpoB, and two kinds of NHL tie up to and are suppressed (table 2-1) when Fu Dilong dosage exceeds among the MM effective dose 5-10 times simultaneously.
The cell enlargement of anti-one group of normal person's tumor of table 2-1. Fu Dilong and dEpoB and normal cell population suppresses and IC50, by XTT bisazo salt (tetrazonium) test determination.
IC50(nM) | IC50(nM) | |||
Tumor cell line | The histology | dEpoB | Fu Dilong | |
RPMI?8226 | Myeloma | 36.67±2.0 | 7.6±1.2 | |
CAG | Myeloma | 61.34±4.2 | 12.04±1.8 | |
OPM-2 | Myeloma | 38.89±3.3 | 8.2±2.2 | |
H929 | Myeloma | 42.75±4.5 | 9.2±1.9 | |
MOLP-5 | Myeloma | 68.56±5.5 | 14.4±2.6 | |
| Lymphoma | 90±11 | 80±11 | |
SKI- | Lymphoma | 72±9.8 | 60±4.2 | |
HS-27A | | 100±10 | 102±8 | |
HS-5 | | 100±8 | 96±7 | |
MRC-5 | Embryo lung fibroblast (people) | 8.2±4.3 | 7.4±2.7 | |
HT-29 | Colon cancer | 7.2±2.2 | 4±1.7 | |
HCT-116 | Colon cancer | 7.5±3.1 | 3.6±1.3 | |
MDA?MB435 | Breast carcinoma | 7.8±4.2 | 5.8±2.8 | |
IGROV | | 15±3.8 | 2±1.2 | |
SKOV3 | | 13±4.7 | 1.6±0.5 | |
Ovcar-3 | | 14±3.6 | 1.1±0.4 | |
Ovcar-4 | | 16±2.5 | 1.8±0.7 |
Normal marrow stromal cell (HS-27A and HS-5 system) shows the relative drug resistance to these chemical compounds, shows that Fu Dilong and dEpoB have the safe treatment window (table 2-1) to MM.Fu Dilong has about 5 times of big effectiveness than dEpoB to MM cell line, and these two kinds of medicines all have the toxicity of equity to normal marrow stromal cell simultaneously.Human fetal lung fibroblast (MRC-5) is responsive to dEpoB and Flu, but for Flu, treating window clearly is significantly, even for these highstrung normal cells.Fu Dilong and dEpoB cause myeloma and lymphoma cell to stagnate (Figure 18) and inducing apoptosis of tumour cell (Figure 19 and 20) in the G2M stage.The present inventor has estimated the persistent period that causes the essential external drug exposure of myeloma cell's apoptosis.Pulsed exposures 1,2,4,8 and 24 hours, eccysis medicine and continuation subsequently cultivated and reached 48 hours.Cellular exposure causes all cells in 48hr dead (Figure 21) in Fu Dilong or dEpoB 24hr.Cultivate 4-8hr with dEpoB and delayed cell proliferation, being exposed to the identical persistent period of Fu Dilong has then reduced about 50% of initial cell quantity.Be exposed to dEpoB and reduced in 48hr in one hour but do not stop tumor cell proliferation, and use Flu, tumor quantity has reduced by 50% (Figure 21).Fu Dilong is the same with paclitaxel with dEpoB, all has after exposure soon, increases that microtubule fasolculus forms and the ability (Figure 22) that do not have the microtubule quality in this cell of slight modification in cancerous cell.Destroyed and the generation apoptosis at time (about 24hr) microtubule after a while.Fu Dilong and dEpoB for comparison available from the nascent CD138MM cell of parent marrow in, the present inventor illustrates Fu Dilong induced tumor apoptosis in 24hr, and dEpoB does not have.
Drug susceptibility to human solid tumor's cell line
The IC of Fu Dilong and dEpoB
50Go up mensuration (table 2-1) in lineup's solid tumor system (colon, breast and ovary).In each example, the IC of Fu Dilong
50All be lower than the IC of dEpoB
50There is the IC of average out to 1.6nM in ovarian cancer system to the ovary cording of Fu Dilong sensitivity especially and 4/5
50, the IC of dEpoB Comparatively speaking
50Be 16.5nM.These two kinds of medicines all cause tumor cell to stagnate (Figure 23) and rapid induction apoptosis (Figure 24 and 25) in the G2M stage.
RPMI-8226 myeloma cell ties up to dEpoB or Fu Dilong with * 10 full genomic expressions behind IC50 dosage treatment 6 and the 18hr separately
The comparison of full genomic expression (Affymetric chip AU133 2.0) and differential gene expression in the multiple myeloma cell line of RPMI-8226 people is with dEpoB or Fu Dilong treatment 6 or the 18hr (IC * 10
50Dosage) carry out after.The RPMI-08226 of Fu Dilong treatment and the untreated cell of contrast relatively in, in the time of 6 hours 5 genes just regulated and control (table 2-2) and during at 18hr 48 genes just regulated and control (table 2-3).JUN is all just regulated and control (+3.25 ,+2.64) at twice.When 6hr 3 genes by negative regulation (table 2-2) and when the 18hr 16 genes by negative regulation (table 2-3).HNRPD (allos nuclear nucleoprotein D analog) two times all by negative regulation (2.46 ,-3.25).The RPMI-08226 of dEpoB treatment and the untreated cell of contrast relatively in, in the time of 6 hours 21 genes just regulated and control (table 2-2) and during at 18hr 26 genes just regulated and control (table 2-3).JUN (+5.66 ,+3.73) and tubulin α 3 (+2.64 ,+2.30) were all just regulated and control two times.When 6hr 3 genes by negative regulation (table 2-2) and when the 18hr 16 genes by negative regulation (table 2-3).HNRPD two times all by negative regulation (4.92 ,-2.00).So the present inventor has compared the gene expression (table 2-2 and 2-3) that dEpoB is changed by Fu Dilong.
Table full genomic expression of 2-2. (Affymetrix chip-AU133 2.0) and the comparison of differential gene expression in RPMI-8226 (the multiple myeloma cell line of people).Control cells and 6 hours the comparison of cell (at 10 times of IC50 dosage) for the treatment of with Fu Dilong or dEpoB.
Fu Dilong 6hr | Multiple changes | NSC-703147 B 6hr | Multiple changes |
? JUNSKIL (class SKI) BASP1 (brain abundance symphysis signal) APP(amyloid precursor protein) HMGCS1(3-hydroxy-3-methylglutaric acid list acyl coenzyme synthase) | +3.25 +2.83 +2.83 ? +2.14 ? +200 ? ? ? ? ? ? ? ? ? ? ? ? ? ? | IFI27 (but interferon-' alpha ' induced protein) JUN G1P3 *(but interferon-' alpha ' induced protein) IFITM1 *(interferon-induced transmembrane protein 1) APP(amyloid precursor protein matter) CCL5 (Rantes chemotactic factor (CF)) TUBA3 (tubulin α 3) INSIG1 (insulin-induced gene) TRIM22 (containing tripartition motif 22) HLA-DPA1*(histocompatibility classification II DP α 1) IFIT1 *(having the multiple interferon inducible protein of tetratricopeptide) HMGCS1(3-hydroxy-3-methylglutaric acid list acyl coenzyme A) MARCKS (being rich in meristoylated alanine PKC substrate) ABCG1 (ABC transports activity) | +18.38 +5.66 +5.28 +4.92 ? ? +2.83 +2.64 ? +2.64 +2.46 +2.30 +2.30 ? +2.30 ? +2.30 ? +2.14 ? +2.14 |
MX1 *(myxovirus drug resistance, interferon can be induced p78) OAS1 *(2 ' 5 '-oligoadenylate synthetase) PLSCR1 (phosphatide translocase (phospholid scramblase)) STS (steoid sulfatase) DUSP4 (two special phosphate) AP1S1 (joint GAP-associated protein GAP compound 1) ARHE (the Ras homologue E of family) | +2.00 ? +2.00 +2.00 ? +2.00 +2.00 +2.00 +2.00 +2.00 | ||
? HNRPD(allos nuclear nucleoprotein D). SUV39 H2. (inhibitive factor of raggle-taggle homologous chromosome). HIST1 (histone 1) | -2.46 ? -2.00 ? ? -2.00 | ? RNRPD(allos nuclear nucleoprotein D) HMOX1 (heme oxygenase) HASA1A (heat shock 70kDa albumen) MAT2A (methionine adenosyltransferase II α) | -4.92 ? -2.30 -2.14 ? -2.00 |
Underscore :-gene is just being regulated and control or negative regulation, in the cell of Fu Dilong or dEpoB treatment during 6hr.
*But interferon induced gene.
Table full genomic expression of 2-3. (Affymetrix chip-AU133 2.0) and the comparison of differential gene expression in RPMI-8226 (the multiple myeloma cell line of people).Control cells and 18 hours the comparison of cell for the treatment of (at * 10 times of IC50 dosage) with Fu Dilong or dEpoB.
Fu Dilong 18hr | Multiple changes | NSC-703147 B 18hr | Multiple changes |
PRKDC (double-strand break reparation) | +21.11 ? +12.3 +9.85 ? +7.46 | REPS1 (the Eps zone that RALBP1 is relevant) PKD1(polycystic kidney disease 1) JUN? ? SEMA3D(Ig sema zone) | +9.85 ? +5.6 +3.73 ? +3.73 |
?
TRIO(Triple functn zone amidino groups NEF) FLJ20241 (NFkB activated protein)
CCL3(chemotactic factor MIP-1 α)
PCNX(Pecanex homologue)
KIAA1025Albumen
TRA2A( | +4.29 ? +3.73 +3.48 +3.48 +3.25 +3.03 ? +3.03 ? +3.03 +2.83 +2.83 +2.64 +2.64 +2.64 ? +2.64 ? +2.46 +2.46 +2.30 +2.30 ? +2.30 ? +2.30 +2.30 +2.14 ? | ?
PRKCBP1(Protein kinase C combination)
PCNX(Pecanex homology) GTF2H2 (general transcription factor IIH)
KIAA1025Albumen
TRIO(Triple functn zone guanyl-NEF)
CCL3(chemotactic factor MIP-1 α)
VEZATIN(transmembrane protein)
TRA2A( | +3.03 +3.03 +2.83 +2.83 +2.83 ? +2.64 +2.46 +2.46 ? +2.46 ? +2.46 +2.30 +2.30 +2.30 +2.30 +2.14 ? +2.14 ? +2.14 +2.14 ? +2.00 +2.00 +2.00 +2.00 ? ? |
ZFY (zinc finger protein-Y-connects) AIP1 (atropine-1 interaction protein)
RPL23( | +2.14 +2.14 +2.14 +2.14 +2.14 +2.00 ? +2.00 +2.00 ? +2.00 ? +2.00 +2.00 ? +2.00 ? +2.00 +2.00 ? +2.00 | ||
?
ZF(HCF-is in conjunction with transcription factor) Clorf29, ( | -6.50 -6.06 -5.66 ? -4.00 -3.73 -3.25 ? | ? ZF(HCF-is in conjunction with transcription factor) cyclin E2 MARS(methionine-tRNA synzyme) POU4F1(Pou district transcription factor) NRTN(neuturin) PABPN1 poly-(A) is conjugated protein, nuclear) | -6.06 -3.03 -2.83 ? -2.46 -2.14 -2.00 ? |
?
CyclinE2 FLJ20045 (hypothetical albumen) CEB1 (cyclin E is in conjunction with ubiquitin ligase) FBXO5 (the | -2.64 ? -2.46 -2.30 ? -2.30 -2.3 -2.14 -2.14 -2.00 -2.00 -2.00 | ? HNRPD(allos nuclear nucleoprotein D-analog) | -2.00 ? ? ? ? ? ? ? ? ? ? ? |
Underscore :-gene is just being regulated and control or negative regulation, in the cell of Fu Dilong or dEpoB treatment during 18hr.
But interferon induced gene *.
At 6 hours, just regulating and control 5 genes by Fu Dilong, just regulating and control 21 by dEpoB, and the two is all just regulating and control 3 genes, simultaneously by 3 genes of Fu Dilong negative regulation,, and there is not the two all gene of negative regulation by 4 of dEpoB negative regulations.At 18 hours, just regulating and control 48 genes by Fu Dilong, just regulating and control 26 by dEpoB, and the two is all just regulating and control 18 genes, simultaneously by 16 genes of Fu Dilong negative regulation, by 7 of dEpoB negative regulations, and the two 6 gene of negative regulation all.Specifying this scheme to test enhanced antitumor efficacy that following hypothesis: Fu Dilong is better than dEpoB and former Epothilones is because except microtubule stability, other cancer target mechanism.Therefore the present inventor has determined which kind of gene just regulated and control and negative regulation by Flu difference ground, simultaneously with the MM cell of dEpoB-treatment relatively (table 2-4).
The table full genomic expression of 2-4. (Affymetrix chip-AU133 2.0) and differential gene expression are with the comparison among 6 or 18 hours the RPMI-8226 (the multiple myeloma cell line of people) of dEpoB or Fu Dilong (at * 10 times of IC50 dosage) treatment.Shown in those of gene Wei You Fu Dilong selectively changing.
6 hours gene differences | |
18 hours gene differences | Multiple changes |
The BCL3 Heme oxygenase | + 3.25+2.30 | HMT-1 (transmethylase-analog-1) | + 11.3 |
IFI27 *(derivable interferon (IFN) α) GIP3 *(derivable IFN α) T RIM34 (containing the tripartition motif) IFTM1 *(the inductive film of striding of IFN) HLA-II DP α *AIM2 *(in melanoma, lacking) PTPL (tyrosine phosphatase-analog) TRIM22 (containing the tripartition motif) CA4 (carbonic anhydrase) MX1 *(myxovirus drug resistance, IFN is derivable). | -7.46 -6.06 -5.66 -4.00 -3.73 -2.64 -2.46 -2.46 -2.14 -2.00 | IFI27 *(derivable interferon (IFN) α) GIP3 *(derivable IFN α) IFITM1 *(the inductive film of striding of IFN) MX1 *(myxovirus drug resistance, IFN is derivable) DUSP4 (two special phosphatase) PPAP2C (phosphatidic acid phosphatase) PLSCR1 *(phospholipid translocase) IFIT1 *(the inductive albumen tetra-tricopeptide of IFN repeats) OAS2 *(2 '-5 '-oligoadenylate synthetase-2) TRIM22 (containing tripartition motif-22) CEB1 (cyclin E is conjugated protein) | -5.28 -5.28 -3.25 -2.30 -2.14 -2.14 -2.00 -2.00 -2.00 -2.00 -2.00 |
Underscore :-negative gene regulation and control, in the cell of Fu Dilong or dEpoB treatment 6 with during 18hr.
*But interferon induced gene.
At 6 hours, just regulating and control two genes, and, just regulating and control a gene at 18 hours.At 6 hours, negative regulation ten genes, and at 18 hours, negative regulation 11 genes, and at two time negative regulations four gene (IFI27,-7.46 ,-5.28), GIP3 (6.06 ,-5.28), IFTM1 (4.00 ,-3.25), MX-1 (2.00 ,-2.30).These are the derivable genes of all interferon.The gene expression figure of ovary 1A9 and 1A9PTX22 ovary xenograft is reported, be shown as IFN responsive genes (GIP3 after 24 hours with paclitaxel treatment, IFI27, IFITM1, IFII6, (people " Gene expressioncorrelating with response to paclitaxel in ovarian carcinoma xenografts " the Mol.Cancer Thera.2004 such as Bani of expression decreased ISG15); 3:111-121; Incorporate the present invention by reference into).Three (GIP3 in these genes, IFI27, IFITM1), at dEpoB rather than after 6 hours with the RPMI-8226 cell of Fu Dilong treatment, by overexpression consumingly, and these also are that it expresses the gene of distinguishing Fu Dilong and dEpoB gene map the most consumingly.The overexpression of IFN-responsive genes (for example, IFR9) with in the tumor cell line drug resistance of paclitaxel is linked together recently, and such probability has been supported in these discoveries: be the response that the medium of INF signal is involved in paclitaxel, rather than INF self (people such as Luker, " Overexpression of IRF9confers resistance to antimicrotubule agents in breast cancer cells " CancerRes.2001; 61:6540-7; Incorporate the present invention by reference into).In the chemical sproof development of antagonism microtubule agent, the report of this Novel IFN independent action of IRF9 accounts near half of breast carcinoma and uterus carcinoma (people such as Luker, " Overexpression of IRF9confers resistance toantimicrotubule agents in breast cancer cells " Cancer Res.2001; 61:6540-7; Incorporate the present invention by reference into).But the microarray analysis of the chemical sproof tumor of eEpoA or Taxol system shows in the EpoA resistant tumors most gene codes of in the Taxol resistant tumors, highly not expressed interferon induced gene (people " Geneexpression profiling of epothilone A-resistantcells " Novartis Found Symp.2002 such as Atadja; 243:119-32; Incorporate the present invention by reference into).Obviously, the present inventor finds that (just regulated and control, neither one changes (showing 2-2 to 2-4) by the Flu treatment in derivable and these genes for IFN for all genes of 8/21 (38%) after dEpoB treatment RPMI-8226.But IFN induced gene subsequently demonstrates in the 8226MM cell with the dEpoB treatment just to be regulated and control after 6 hours or 18 hours and do not change when treating with Fu Dilong.By the degree ordering that dEpoB is just regulating and control, they are 1.) interferon (IFN) α-derivable IFI 27 (increasing+18.83).But this belongs to the family of little interferon-' alpha '-induced gene, and its unknown function is for just being regulated and control (people " Interferon alpha-inducibleprotein 27 (IFI27) is upregulated in Psoriatic skin and certain epithelialcancers " J Invest.Dermatol.2004 such as Suomela in dermatosis, epithelial cancer and the wound repair of inflammation; 122:717-721; Incorporate the present invention by reference into).2.) but IFN α-induced protein (clone IFI-6-16) GIP3 (people " Gene expressioncorrelating with response to paclitaxel in ovarian carcinoma xenografts " Mol.Cancer.Thera.2004 such as Bani; 3:111-121; Incorporate the present invention by reference into) (increasing+5.28).3.) IFN-induces transmembrane protein 1, IFTM1 people such as () Bani (increasing+4.92).4.) mucosal virus drug resistance, IFN is derivable, MX1 (increasing+2.3 increase+2 in 6 hours with at 18 hours).This MX1 gene is given the optionally congenital drug resistance of influenza virus (Staeheli, Ad.Viral Res.38:147,1990; Incorporate the present invention by reference into).They also may as gtp binding protein take on basic cell function (Arnheiter H and Meier E. " Mx proteins:antiviral proteins by chance or necessity? " New Biol.1990; 90 851; Incorporate the present invention by reference into).5.) phospholipid translocase 1 gene PLSCR1.The response element that the control of this gene transcription is stimulated by the single IFN-that is positioned at first exon and regulation and control fully (people " Transcriptional control of the human plasma membrane phospholipidscramplase 1 gene is mediated by interferon-alpha " Blood 2000 such as Zhou; 95:2593-2599; Incorporate the present invention by reference into).PLSCR1 relates to the motion to cell surface of reconstruction membrane plasmapheresis phospholipid and Phosphatidylserine.It can help the film of striding fast of membrane plasmapheresis phospholipid to move, this can be in being exposed to the rising cell Ca
++Injured and apoptotic cells in observe.Studies show that it can also make the nuclear transposition and can be used as transcription factor (people " PhospholipidScramblase 1 is imported into the nucleus by a receptor-mediated pathwayand interacts with DNA " Biochem.2004 such as Ben-Efraim; 43:35181; Incorporate the present invention by reference into).6.) has the multiple interferon inducible protein of tetracopeptide, IFITI (increasing+2.3).Its relevant with the whole body lupus erythematosus and protein-protein studies show that it can activate Rho albumen (people " Protein interaction for an interferon-inducible syste-3526mic lupusassociated gene, IFIT1 " Rheumatology 2003 such as Ye by interacting with the Rho/Rac guanine nucleotide exchange factor; 42:1155-63; Incorporate the present invention by reference into).7.) 2 '-5 ' oligoadenylate synthetase-2, OAS2 (increasing+2).(OAS1, OAS2, OAS3, interferon-induced gene OAS4) relate to stress and are important (Chebath, Nature 330:587,1987 for the antiviral activity of interferon in this gang; People J.Virol.66:5804 such as Meurs, 1992; Every piece of document is incorporated the present invention by reference into).OAS2 catalysis adenosine oligomer (2-5A) synthetic.So these oligomer have activated RNase L, hide endoribonuclease in most of mammalian cells, it can make RNA inactivation (the people Eur.J.Biochem.2004 such as Anderson of virus (picornoviruses is encephalomyocardis virus for example) and cell conversely again; 271:628-36; Incorporate the present invention by reference into).8.) histocompatibility class II DP α 1, HLA-DPA1 (increasing+2).MHC-class II is medium (people " the Molecular cloning of a new Interferon-induced factorthat represses human immunodeficiency virus Type 1long terminal repeatexpression " Biol.Chem.1995 such as Tissot of known IFN biological function; 270:14891-14898; Incorporate the present invention by reference into).
Sum up
The CAG myeloma cell line has shown many features of clinical multiple myeloma, and described multiple myeloma has graft in phenotype (CD38+CD138+CD45-) and the body.Set up xenotransplantation NOD-SCID myeloma mouse model by 10~1,500 ten thousand CAG cells of intravenous perfusion with the transformation of fusion HSV-TK-eGFP-luciferase gene.Therefore the whole animal imaging that is formed by the luciferase bioluminescence can be used for real-time, Noninvasive report and estimates tumor load and efficacy of drugs in the mice of work.The myeloma mice shows bone marrow infiltration and the molten bone infringement of pathology at tumor injection after 7 to 20 days.Behind the implantation tumour cell, mice is divided into vehicle control group, dEpoB treatment group and Fu Dilong treatment group randomly.The dosage of dEpoB and Fu Dilong is 20mg/kg, and these medicines are all by the intraperitoneal administration.The meansigma methods of dosage number of times: in first 30 days of treatment, being 10 times for dEpoB, is 12 times for Fu Dilong.In addition, initially with 3 in 7 mices of Fu Dilong treatment, the Velcade of five dosage of administration between 35 to 45 days (6.25 μ g/ Mus, intravenous perfusion).The result shows, estimates by the bioluminescence imaging, and compares with control mice with the mice of dEpoB treatment, significantly reduces with its tumor load of the myeloma mice of Fu Dilong treatment.All mice in control group are dead in 30 days after initial therapy, yet the time-to-live of the mice of Fu Dilong treatment is at least the twice of matched group.Matched group and do not have difference with the time-to-live between two groups of the mices of dEpoB treatment.With proteasome inhibitor Velcade combination, can significantly reduce to be arranged in the tumor of vertebrates gray columns and femur, this shows this combination even also can attack the myeloma cell under the bone marrow microenvironment protection.
The data of front show that the myeloma with the Epothilones treatment demonstrates typical apoptosis feature.Whether it be unclear that Guang winter peptidase involves in this process.At first, the present inventor has studied the activity of Guang winter peptidase 3 in the myeloma cell (a kind of effector Guang winter peptidase in Guang winter peptide enzymatic pathway) by the Western trace.With dEpoB or Fu Dilong treatment, the myeloma cell demonstrates the cracked Guang winter peptidase 3 that has increased 17kd, and this is active relevant with it.The antibody of the Guang winter peptidase 3 that is specific to cut-out has been adopted in the immunohistochemical dyeing of CAG myeloma cell, is used for being illustrated in the apoptotic cell Cytoplasm and the local feature in nuclear week.These data acknowledgement Guang winter peptidases are activated in the cell of Epothilones treatment.Secondly, the present inventor attempts having tested by fluorometric method the activity of Guang winter peptidase 8 and Guang winter peptidase 9 (the initiator Guang winter peptidase in Guang winter peptide enzymatic pathway).Equally, find that in the myeloma cell Guang winter peptidase 8 and Guang winter peptidase 9 activity all have been increased.The specific activity Guang winter peptidase 8 of the Guang winter peptidase 9 that attention increases is more outstanding.Cause Guang winter peptidase 8 or 9 activatory signals just in active research.
Drug cell toxicity to hematopoietic stem cell is people's major concern always.From Cord blood, isolate people CD34+ stem cell and or with dEpoB or with Fu Dilong single culture 24 hours.Behind the eccysis medicine, carry out apoptosis test and the test of the origin in 2 week to estimate the influence of Epothilones to stem cell.Data show dEpoB of the present invention or Fu Dilong do not have remarkable toxicity to acyclic stem cell.
Embodiment 3:(E)-9,10-dehydrogenation Epothilones: the novel microtubule of a class that has fine foreground features in the Muridae heteroplastic transplantation model is stablized antitumor agent
The 26-F that comprises common 16 yuan of rings
3-[16] dEpoB (2) synthetic can compile strategy by height finishes, and this strategy is for being applied to 27-F
3Relevant strategy in-[17] ddEpoB (19) synthetic.This strategy is estimated to form E-9 by closed loop metathesis reaction as follows, 10-alkene (example that RCM is cyclized into complex structure greatly that passes through in the past is, referring to: Sinha, S.C.; Sun, J.Angew.Chem.Int.Ed.2002,41,1381; Incorporate the present invention by reference into).The present inventor estimates 28 and 29 E-9, the 26-F that the chemical selective reduction of 10-alkene will provide dEpoB (1) and want
3-dEpoB (2).The precursor of this RCM is by preparing in conjunction with two fragments (21 or 24) and 123 by esterification.Coupling companion 123 is connected in the methylene spacer groups (seeing in the early stage approach of the present inventor, referring to chemical compound 18) of C8 secondary methyl by elimination and makes up.As above illustrated, comprise the discovery of external level of the Epothilones (referring to 18) of 17 yuan of rings that diene at interval arranges, emphasized needs for the corresponding research of the biological results of diene such in the 16 membered ring lactone structures of being familiar with.In view of the cis among the dEpoB among the present invention 12, the existence of 13-diene, such interval diene should comprise 9, the two keys of 10-.
9,10-dehydrogenation Epothilones and 26-F
3The retrosynthesis of-dEpoB
With being easy to synthetic trifluoro allyl iodide and methacrylic iodine (being respectively 8 and 124) Wan Jiization oxazolidone 7 (people such as Lee, J.Am.Chem.Soc.2001,123,5249; Incorporate the present invention by reference into), allow in the absolute configuration that is fit to, to set up the three-dimensional center of C15 (Evans, D.A. with high diastereomeric excess (referring to product 9 or 125); Morrissey, M.M.; Dorow, R.L.J.Am.Chem.Soc.1985,107,4346; Paterson, I.; Bower, S.; Mcleod, M.D.Tetrahedron lett.1995,36,175; Every piece of document is incorporated the present invention by reference into).The latter is converted to corresponding Weinreb amide (people Tetrahedron Lett.1981 such as Nahm, 22,3815; People Synth.Commun.1982 such as Levin, 12,989; Every piece of document is incorporated the present invention by reference into), and be converted into 126 and 42 thus, then by nucleophilic methylate (MeMgBr) become olefination (people such as Lythgoe, Tetrahedron lett.1975,40,3863 with the Homer Wittig that is fit to; Lythgoe, Chem.Soc.Rev.1981,449; People Org.Chem.1983 such as Toh, 48,1414; People J.Org.Chem.1986 such as Baggiolini, 51,3098; Every piece of document is incorporated the present invention by reference into) be converted into 24 and 21.Although use this as chirality adminicle De oxazolidone by Evans and colleague (people J.Am.Chem.Soc.1985 such as Evans, 107,4346; People Tetrahedron Lett.1995 such as Paterson, 36,175; Every piece of document is incorporated the present invention by reference into) initiative, but its application by the glycolate of alkylation (rather than passing through hydroxylating) synthesizing optical definition is not developed as yet.
The synthetic of many propionic esters fragment 25 can realize that it has set up the relative configuration at C3, C6 and the three-dimensional center of C7 by the aldol reaction of two keys.First aldol reaction relates to the ethyl ketone 30 of Z-enolization and 31 reactions of Roche aldehyde (people Org.Chem.1976 such as Cohen, 41,3505; People Tetrahedron such as Nagaoka 1981,37,3873; People J.Am.Chem.Soc.1990 such as Roush, 112,6348; Every piece of document is incorporated the present invention by reference into) with provide want have the height non-enantiomer selectivity 32.Should synthesize by means of 31, its remarkable advantage is to be better than using former aldehyde, and former aldehyde need solve the source problem that comes of optical voidness initiation material.
Protection C7-alcohol provides the aldehyde of wanting 34 by the acetal hydrolysis subsequently and is that aldol reaction creates conditions for the second time.34 with the reaction of DAG (diketone glucose) the Ti-enolate of Duthaler (people Angew.Chem.Int.Ed.Engl.1989 such as Duthaler, 28,495; Incorporate the present invention by reference into) provide want have the height (>95%) non-enantiomer selectivity hydroxyl tertiary butyl ester 35.Then the latter is converted into the acid of wanting 25.
Synthesizing of acid 25
By corresponding methodology, the present inventor has synthesized 9, and 10-dehydrogenation-dEpoF (57) vide infra.Imidodicarbonic diamide reduction E-9 optionally, 10-alkene has confirmed the structure of aforesaid various synthetic intermediates, therefore impels the distribution before evaluating in the document once more.
9,10-dehydrogenation-Epothilones synthetic
Synthetic analog (28,29 and 57), inspection in cell culture system (referring to [) demonstrates them various responsive things and the generation of MDR tumor cell line is better than the inhibitory action that the present drug candidate dEpoB (1) of the present inventor is had.The impressive cell growth inhibition that Epothilones 28,29 and 57 is had covers the scope of various resistant tumors, and this has impelled measures the plasma stability of these novel (E)-9,10 congeners.The present inventor remembers (E)-10, and 11-dehydrogenation-dEpoB (Epo490) has the plasma stability of non-constant.In fact, this just blood plasma unstability has hindered the further exploitation of Epo490 (6).On the contrary, when being exposed to Mus blood plasma with 28,29 and 57, the present inventor observes with dEpoB (1) and compares very slow drug degradation (factor is about 7).From drug utilization degree aspect, with respect to dEpoB (1), say nothing of epo490 (6), this stability has constituted substantial progress.Based on preliminary (E)-9,10-dehydro derivatives 28 and 29 cell culture and pharmacokinetic data are further used for them that research is suitable in the body.Such research is certainly than the availability of more emphasizing medicine in vitro study (people J.Am.Chem.Soc.2003 such as Rivkin, 125,2899; People Angew.Chem.Int.Ed.Engl.2003 such as Chou, 42,4761-4767; People Angew.Chem.Int.Ed.Engl.2003 such as Yoshimura, 42,2518-2521; Every piece of document is incorporated the present invention by reference into.For the example of nearest in addition effectively epothilone analogs referring to people Bioorg.Med.Chem.Lett.2000 such as Altmann, 10,2765; People Chem.Biol. such as Nicolaou, 2000,7,593; Every piece of document is incorporated the present invention by reference into).
This demand and in fact may need prepare 9 of number gram amount at last, the 10-dehydro derivatives is used for further research, impels the complete synthesis route of the present invention is carried out significant revaluing.Certainly, unique the most serious problem is that 39b, the 40b and 56 that the RCM reaction on 26,27 and 54 produces only is secondary product.The main path strictness that relates to the RCM reaction is limited to 26,27 and 54 O-moieties, causes mainly producing undesired 39b and 40b.Therefore, decision is attempted (videing infra) after the RCM postponed till in the introducing (passing through olefination) of thiazole.
The handlabilities of final number gram magnitudes as target of the present invention, have therefore been rebuild alkyl and the acyl group fragment that enters the RCM reaction.Chemical compound 86 as illustrated being easy to are synthesized.Use it for alkylation height enantiomeric excess De oxazolidone 7.Carry out subsequently the OTES group go the protection and the nucleophilic methylation, obtain chemical compound 90.This alpha-alcohol ketone is in the formation of the important ester for preparing all key RCM, as acyl acceptor.The possible weakness of making us obvious concern is, but such hydroxy-ketone is as the acyl acceptor partial racemizationization or change into the α-keto-alcohol of position isomery.
Accessible synthetic fragment 90
The serious problems of the synthetic in the past acid fragment 25 of the present inventor are very high and technical Duthaler chemistry (people Angew.Chem.Int.Ed.Engl.1989 such as Duthaler, 28,495 of needing of cost; Incorporate the present invention by reference into) on the C3 position, produce the S spatial chemistry want.In order to avoid this problem, need not any chirality adminicle and carry out aldol reaction so that 1: 1 mixture of corresponding beta-hydroxy ketone to be provided.The reagent of control institute's deutero-ketone (referring to chemical compound 69) asymmetric reduction, employing Noyori condition (people J.Am.Chem.Soc.1987 such as Noyori, 109,5856; Incorporate the present invention by reference into) on the C3 position, produced the S spatial chemistry of wanting with the excessive form of high antimer.Now available beta-hydroxy esters 70 was converted into acid 25 (people Proc.Natl.Acad.Sci.U.S.A.2001 such as Chou, 98,8113 according to former scheme in several steps; Incorporate the present invention into by application).
Accessible synthetic sour 25
Significantly, the hydroxy-ketone 43 and 44 that obtains is used C
1-C
9Acid fragment 25 esterifications provide corresponding RCM cyclisation precursor 45 and 46, and do not have obvious raceme on C15, lose the integrity of initial α keto-alcohol Cheng Jian in other words.45 and 46 closed loop metathesis reaction is by adopting RCM catalyst (people Tetrahedron Lett.1999 such as Scholl, 40,2247; People Acc.Chem.Res.1995 such as Grubbs, 28,446; People Acc.Chem.Res.2001 such as Trnka, 34,18; Alkene Metathesis in Organic Chemistry Ed.F ü rstner, A; Springer, Berlin, 1998; F ü rstner, A.Angew.Chem.Int.Ed.Engl.2000,39,3012; Schrock, Top.Organomet.Chem.1998,1,1; Every piece of document is incorporated the present invention by reference into) in toluene, carry out.This reacts, and is also uncomplicated owing to the double decomposition approach that substitutes now, and the complete transisomer 47 and 48 of high yield is provided.Introduce the thiazole part by Wittig reaction with high E/Z selectivity and high yield, obtain 28 and 29 after with two monosilane ether deprotections (people Tetrahedron Lett.2000 such as Hindupur, 2,7341; Incorporate the present invention by reference into.Attempt using the product of scheme introducing thiazole of Avery, the low and E/Z poor selectivity of productive rate) to obtain to want.This approach meets a large amount of synthetic standards of obeying.
The present inventor whether consider epothilone B (51, introduce C9-C10 alkene in EpoB) and will change its biological nature, with its 12, the identical direction of 13-deoxidation homologue situation.For this reason, the present inventor studied and adopted 2,2 '-dimethyldioxirane (DMDO) carries out epoxidation to 28.This is reflected on the more polysubstituted C12-C13 alkene and carries out with highly-solid selectively really.Obtain productive rate and be 87% ratio and be 1: 2.6 (E)-9,10-dehydrogenation epothilone B (49) and its have α-12, the diastereomer of 13-oxirane (structure is not shown).In vitro study 49 (it is established at C12 and C13 configuration, provides EpoB with its reduction) shows that it than parent compound EpoB (51) to the powerful 2-4 of being about of various cell lines doubly.Although chemical compound 49 is proved to be the most virtuous Epothilones in the program that the present inventor carries out, it is for the narrow therapeutic index of xenograft, with and be difficult to acquired (on seeing) and hindered it in preclinical further research.What is interesting is that non-natural α-oxirane does not almost have activity.
Accessible synthetic (E)-9,10-dehydrogenation Epothilones
Synthetic another advantage of aforesaid (second filial generation) that rebulids is: can various heterocycles be introduced by ketone intermediate 39a and 40a.This point is by 9, and 10-dehydrogenation-dEpoF's is synthetic and well outstanding.Wittig that ketone and He Shi De phosphonium salt ylide carry out reaction with high yield and high E/Z selectivity provide want 9,10-dehydrogenation-dEpoF chemical compound 57 and 59.In addition, the present inventor can be converted into 21-hydroxyl 59 derivant of 96 and 97 types effectively, is included in the C21 position and carries out aminofunctional, and a few step reactions are as described below.
(E)-9, the variation of the C21 of 10-dehydrogenation Epothilones
Aspect anti-various kinds of cell type, estimated the complete synthesis Epothilones homologue of the present invention, renderd a service with the antitumor of determining them.
The most outstanding feature of the present inventor's discovery is as follows: by with E-12,13 pairs of keys substitute C12-C13 β epoxide, can predict order of magnitude of about reduction (to the CCRF-CEM cell line of sensitivity relatively EpoB and dEpoB).What another can be expected is: comprise E-9,10 pairs of keys add Z-12,13 alkene, and its cytotoxicity that causes covering several cell lines significantly increases.
Another useful trend is found in 12-three fluoro-E-9,10-dehydrogenation-dEpoB (29) (Fu Dilong) with corresponding E-9, in the comparison of 10-dehydrogenation compound 28.With respect to (1), on C26, comprise three fluorine atoms and weakened cytotoxicity and be up to the factor 4.The effect that weakens of this 12-trifluoromethyl functional group also is found in and lacks 9, in the chemical compound of 10-unsaturated bond (relatively dEpoB (1) and 12-three fluoro-dEpoB (2)).
In view of these data and in view of these 9,10-dehydrogenation compound (comprising 12-trifluoro congener) is by the available of chemosynthesis, the present inventor begins to carry out testing in the body with the most promising chemical compound of the present invention.The inventor this described with some of chemical compound 29 (Fu Dilong) surprising especially with promising result, chemical compound 29 demonstrated the exciting probability that is used for further clinical evaluation.In the immunodeficiency nude mice, utilize people's tumor xenogeneic graft to carry out testing in the body.Although their shortcoming is arranged, this model in the oncology still is widely used in estimating (Fiebig, H.H.; Berger, D.P.; Preclinical Phase II trials.At Boven, among the The Nude Mouse in Oncology Research that E. and Winograd, B. edit, CRC Press, Boca Raton (1995), 318; Incorporate the present invention into by application) possible antitumor lead compound to be to carry out clinical research.
Significantly, with the Fu Dilong treatment MX-1 xenograft of 30mg/kg dosage, it causes the tumor complete obiteration and did not have any recurrence (referring to Fig. 6 A) in back 2 months stopping to treat.The most important thing is that these successful treatments can or be finished (referring to Fig. 6 B and 10A) by the perfusion of 6 hours intravenouss or by oral administration.On the other hand, do not influence this tumor (referring to Fig. 6 B and 10A) by oral Taxol treatment MX-1 xenograft.Self-evident, if transfer in people's the clinical setting, it will be significantly useful obtaining Orally active.
Taxol resistant tumors xenograft (Fig. 7 A) and human colon carcinoma (HCT-116, Fig. 9 A) also can be cured by the intravenous perfusion with Fu Dilong.The experiment that breast carcinoma of choosing in nude mice (MX-1) and human colon carcinoma (HCT-116) xenograft carry out continues 6.0 and 6.6 months respectively.After stopping treatment, do not have tumor recurrence each comfortable 4.3 and 5.3 middle of the month in two experiments.For the HCT-116 experiment, under 20mg/kg, compare Taxol and Fu Dilong, the both makes the group of tumor disappearance Taxol treatment end recurrence in back 1.1 months in treatment, however the animal tumor that Fu Dilong treats disappeared above 5.3 months.
These results relate to research especially long and that run through whole treatment, and described research is adopted xenograft and remarkably reported with the medication of single antitumor agent parenteral or oral medication and the disease that disappears fully for a long time.
Experimental example:
General pharmacological method:
Tumor and cell line.CCRF-CEM people's lymphoblastic leukemia cell and the chemical sproof subbreed (CCRF-CEM/VBL of its vinblastine
100, 720 times of drug resistance) derive from Chicago, William doctor Beck of Illinois university, and CCRF-CEM/ Taxol (external 44 times of drug resistance) by six middle of the month with the CCRF-CEM cellular exposure in ever-increasing to lethal concentration (IC
50-IC
90) paclitaxel in and prepare.People's breast carcinoma (MX-1), human lung carcinoma cell (A549) and human colon carcinoma (HCT-116) cell derive from American type culture collection (ATCC, Rockville, MD).
Animal.The nude mouse that has the nu/nu gene derives from NCI, Frederick, and MD also is used for the xenotransplantation of the somebody of institute tumor.Except pointing out female nude mice in addition, use above body weight 20-22g of 6 weeks or heavier male nude mouse.Use homemade microtubule and the limiter inculcated by perfusion administration in 6 hours in the tail cava vein.Have multichannel program-controlled HarvardPHD2000 syringe pump and be used to the intravenous perfusion.Inculcated volume in typical 6 hours every kind of medicine in can sharp good fortune/ethanol (1: 1) is contained 100 μ l in for 2.0ml saline.For oral administration, Fu Dilong and Taxol all are dissolved in the ethanol and with tween 80 and dilute 5 times.Taxol solution should use in 5min to avoid precipitation.Gross tumor volume is measured long * wide * high (or wide) and is estimated by caliper.For the nude mice that has tumor, its body weight is meant that gross weight deducts the weight of tumor in the experimentation.All zooperies are all implemented according to the guideline of National Institute of HealthGuide for the Care and Use of Animals with by the rules of MemorialSloan-Kettering Cancer Center ' s Institutional Animal Care and UseCommittee approval.
Cell toxicity test.For preparing the vitro cytotoxicity test, cell culture is 2-5 * 10 in initial density
4Every milliliter in individual cell.They are stored in 5%CO
2In 37 ℃ the RPMI medium 1640 (GIBCO/BRL) of-moistening atmosphere, described RPMI medium 1640 comprise penicillin (100 units/mL), streptomycin (and 100 μ g/mL, GIBCO/BRL) and 5% heat-inactivated FBS.For the solid tumor cell of in monolayer, growing (for example HCT-116 and A549), the cytotoxicity of medicine is by using sulphonyl rhodamine B method (people J.Natl.Cancer Inst. (1990) 82 such as Skehan, 1107-1112 incorporates the present invention by reference into) on the microtitration plate of 96-hole, measure.For the cell (for example CCRF-CEM and subbreed thereof) that grows in the suspension, by using dimethoxy azoles sulphur (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-5-carboxanilide)-2H-terazodium hydroxide (XTT)) microtubule method (people Cancer Res. (1988) 48,4827 such as Scudiero; Incorporate the present invention by reference into) on 96 hole microtitration plates, measure in duplicate.For two kinds of methods, (Winooski VT) measures the absorbance in each hole for PowerWave XS, Bio-Tek with the microtitration plate plate reading machine.The relation data of dosage-effect is by 6 to 7 concentration of every kind of medicine, and is duplicate, by the program of using a computer (Chou, T.-C.﹠amp; Talalay, P.T.Adv.Enzyme Reg.1984,22,27; Chou, T.-C.﹠amp; Hayball, M.CalcuSyn for Windows (Biosoft, Cambridge, U.K.) (1997); Wherein every piece of document is incorporated the present invention by reference into) analyze with middle effect figure.
General chemical method: use the reagent that derives from commercial suppliers to be further purified, except as otherwise noted.Following solvents is obtained by dry solvent system (by the alumina column of pre-filling), and need not further dry and be used: oxolane, dichloromethane, ether, benzene and toluene.From calcium hydride, distill triethylamine, N, N-diisopropylethylamine, diisopropylamine, pyridine and 2,6-lutidines.All to the reaction of air and water sensitive all in flame-dried glass drying oven under the positive pressure of ultrapure nitrogen or argon and carry out.NMR (
1H and
13C) spectrum on Bruker AMX-400MHz or Bruker Advance DRX-500MHz as respectively the explanation record, with reference to CDCl
3(for
1H 7.27ppm and for
13C 77.1ppm).Infrared spectrum (IR) obtains on Perkin-Elmer FT-IR model 1600 spectrogrphs.Optical rotation obtains in the polarimeter of JASCO model DIP-370 numeral.Low resolution (electrojet) mass spectrum record on PESCIEX API 100.Analyzing thin layer chromatography carries out on E.Merck silica gel 60F254 plate.To ultraviolet do not have active chemical compound by silica gel plate being impregnated in alcoholic acid P-methoxybenzal-dehyde solution, alcoholic acid phosphomolybdic acid or the cerous molybdate ammonia or/and heating develop.The preparation of lamina chromatograph is at Whatman
Use specified solvent on (LK6F silica gel 60A) TLC plate and carry out.Silica gel chromatography is at Davisil
Use specified solvent to carry out on (1740 grades, 60A type, 170-400 order) silica gel.
Chemical shift is with the δZhi report with respect to chloroform (NMR is for proton δ 7.24 with for carbon δ 77.0).
At room temperature to 4,4, the 4-trifluoroacetic ethyl acetoacetate (24.0mL, (3: 1=V: V adds allyl bromide, bromoallylene (20.0mL to THF-water 0.164mol) in solution 320mL), 1.4 equivalent), add indium (powder ,-100 orders, 25g subsequently, 1.3 equivalent), and with resulting mixture stir 15h down at 48 ℃.This reactant mixture is cooled to room temperature,, and uses CH with HCl aqueous solution (400mL) cancellation of 2N
2Cl
2(400mL, 2 * 200mL) extractions.With the organic facies drying (MgSO that merges
4), filter, and under vacuum, concentrate.The alcohol that flash chromatography (hexane → hexane-ether 10: 1 → 8: 1 → 6: 1 → 4: 1) provides is clarification grease (31.64g, 85% productive rate): IR (film) 3426 (br m), 2986 (m), 1713 (s), 1377 (m), 1345 (m), 1301 (m), 1232 (m), 1173 (s), 1095 (m), 1023 (m), 927 (m) cm
-1 1H NMR (400MHz, CDCl
3) δ 5.82 (m, 1H), 5.15 (m, 3H), 4.17 (m, 2H), 2.59 (m, 1H), 2.58 (d, J=3.4Hz, 2H), 2.29 (dd, J=14.2,8.6Hz, 1H), 1.24 (t, J=7.2Hz, 3H);
13C NMR (100MHz, CDCl
3) δ 172.08,130.89,125.65 (q, J=280Hz), 120.27,73.79 (q, J=28Hz), 61.55,38.97,35.65,13.82; High resolution mass spec m/z 227.0895[(M+H)
+C
9H
14O
3F
3Value of calculation: 227.0895].
This alcohol is volatile.After column chromatography, should thoroughly not concentrate by alcohol.Product that productive rate obtains by gross weight with by the NMR integration and the ratio between solvent are determined.
With alcohol (16.71g, 0.07386mol) and the mixture of pyridine (15.0mL, 2.5 equivalents) be cooled to-10 ℃ and in 11min, slowly handle (yellow mercury oxide) with thionyl chloride (11.3mL, 2.1 equivalents).The mixture of gained is warmed to 55 ℃ (heating the complex mixture that 17h obtains chlorizate down at 75 ℃) and stirs 12h.Reactant mixture is cooled to-5 ℃, water (200mL) cancellation is also used CH
2Cl
2(2 * 200mL, 2 * 150mL) extractions.The saturated NaHCO of organic facies that merges
3(2 * 200mL) and saline (200mL) washing, dry (MgSO
4) and under vacuum, concentrate.(pentane: ether 15: 1) ester that provides (11.90g, 77% productive rate) is yellow oil: IR (film) 2986 (w) to flash chromatography, 1731 (s), 1308 (s), 1265 (w), 1227 (m), 1197 (s), 1133 (s), 1025 (m), 920 (w), 896 (w) cm
-1 1H NMR (400MHz, CDCl
3) δ 6.36 (s, 1H), 5.79 (ddt, J=16.9,10.2,6.6Hz, 1H), 5.15 (dd, J=17.1,1.5Hz, 1H), 5.08 (dd, J=10.0,1.4Hz, 1H), 4.22 (q, J=7.1Hz, 2H), 3.44 (d, J=6.5Hz, 2H), 1.29 (t, J=7.1Hz, 3H);
13C NMR (100MHz, CDCl
3) δ 164.22,143.37 (q, J=29Hz), 132.71,123.21 (q, J=274Hz), 122.60 (q, J=6Hz), 117.32,60.85,30.54,13.85; High resolution mass spec m/z 209.0788[(M+H)
+C
9H
12O
2F
3Value of calculation: 227.0789].
This ester is volatile.Through after the column chromatography, this ester is not thoroughly concentrated.
To refrigerative (75 ℃) described ester (7.12g, CH 0.0342mol)
2Cl
2(120mL) in the solution, in 35min, add the CH of DIBAL-H (75mL, 2.2 equivalents)
2Cl
2Solution (1.0M) is warmed to room temperature with the solution of gained in 3h.Reactant mixture is cooled to 0 ℃, uses saturated NH
4Cl (12mL) cancellation and at stirring at room 20min.Reactant mixture is diluted dry (MgSO with ether (200mL)
4) and vacuum concentration.(pentane: ether 3: 1 → 1: 1) alcohol that provides (5.68g, 99%) is clarification grease: IR (film) 3331 (br s), 2929 (m) to flash chromatography, 1642 (m), 1445 (m), 1417 (w), 1348 (s), 1316 (s), 1217 (s), 1175 (s), 1119 (s), 1045 (m), 985 (s), 921 (m), 831 (w) cm
-1 1H NMR (400MHz, CDCl
3) δ 6.33 (td, J=6.1,1.6Hz, 1H), 5.75 (ddt, J=17.2,10.0,6.2Hz, 1H), 5.07 (m, 2H), 4.29 (ddd, J=6.3,4.3,2.1Hz, 2H), 2.95 (d, J=6.2Hz, 2H);
13C NMR (100MHz, CDCl
3) δ 134.45 (q, J=6Hz), 133.38,127.97 (q, J=29Hz), 123.76 (q, J=271Hz), 116.25,57.87,29.79.
With refrigerative (0 ℃) alcohol (5.97g, CH 0.0358mol)
2Cl
2(50mL) solution PPh
3(11.17g, 1.2 equivalents), imidazoles (3.55g, 1.5 equivalents) and I
2(9.10g, 1.1 equivalents) are handled and (are added I at last
2), (yellow muddy) mixture of gained is stirred 10min down at 0 ℃.The saturated Na of this reactant mixture
2S
2O
3Saturated NaHCO
3(1: 1=V: V, 200mL) solution cancellation and with pentane extraction (3 * 200mL).The saturated Na of organic facies that merges
2S
2O
3Saturated NaHCO
3(1: 1=V: V, 200mL) solution and saline (100mL) washing, dry (MgSO
4) and under vacuum, concentrate.The iodide that flash chromatography (pentane) provides (6.69g, 68%) are pale red grease (preserving in-78 ℃ of household freezers): IR (film) 3083 (w), 2982 (w), 1636 (w), 1558 (w), 1456 (w), 1367 (w), 1317 (s), 1216 (m), 1181 (s), 1151 (s), 1120 (s), 989 (m), 921 (m), 896 (m) cm
-1 1H NMR (400MHz, CDCl
3) δ 6.45 (td, J=8.9,1.5Hz, 1H), 5.79 (ddt, J=16.8,10.3,6.2Hz, 1H), 5.12 (m, 2H), 3.85 (ddd, J=8.9,2.9,1.4Hz, 2H), 3.00 (dt, J=6.1,1.4Hz, 2H);
13C NMR (100MHz, CDCl
3) δ 132.42,131.64 (q, J=6Hz), 129.63 (q, J=29Hz), 123.64 (q, J=272Hz), 117.00,29.32 ,-4.27; Low resolution mass spectrum m/z 298.7[(M+Na)
+C
7H
8F
3INa value of calculation: 299.0].
This allyl iodide is volatile.Through after the column chromatography, this allyl iodide is not thoroughly concentrated.
α-hydroxyoxazolidinones.4-benzyl-3-hydroxyacetyl-oxazolidines-2-ketone (16.28g to refrigerative (78 ℃) TES protection; 1.92 in THF equivalent) (160mL) solution; in 51min, drip LHMDS (42mL; 1.73 THF solution (1.0M) equivalent) stirs 35min with resulting mixture down at-78 ℃.(6.69g, THF 24.2mmol) (10mL) solution-treated slowly are warmed to ambient temperature overnight with the mixture of gained to this reactant mixture with allyl iodide in 15min.The saturated NaHCO of this reactant mixture
3(200mL) cancellation and with EtOAc extraction (3 * 200mL).The saturated NH of organic facies that merges
4Cl (150mL), saline (150mL) washing, dry (MgSO
4) and under vacuum, concentrate.Flash chromatography (hexane-EtOAc 6: 1 → 3: 1) provides alkylate mixture (13.6g), and it is used for the next step and needn't be further purified (not separating diastereomer in this stage).With the HOAc-water-THF solution of described alkylate (3: 1: 1=V: V: V, 200mL) at room temperature stir 4h.The reactant mixture vacuum concentration to remove HOAc, is used saturated NaHCO
3(400mL) cancellation and with EtOAc extraction (3 * 200mL).With the organic facies drying (MgSO that merges
4) and under vacuum, concentrate.Flash chromatography (hexane: EtOAc3: 1 → 2: 1) provide α-hydroxyoxazolidinones (7.55g, the productive rate in two steps is 81%) and be clarification grease: [α]
D 20(25 ℃)-48.2 ° (c 1.08, CHCl
3); IR (film) 3486 (br s), 3030 (m), 2983 (s), 2925 (m), 1790 (s), 1682 (s), 1481 (m), 1393 (m), 1360 (m), 1217 (m), 1171 (m), 1113 (m), 992 (m), 919 (m), 847 (w) cm
-1 1H NMR (400MHz, CDCl
3) δ 7.32 (m, 3H), 7.17 (m, 2H), 6.33 (td, J=7.2,1.5Hz, 1H), 5.77 (ddt, J=16.6,10.1,6.2Hz, 1H), 5.08 (m, 3H), 4.74 (ddt, J=4.8,3.7,4.4Hz, 1H), 4.33 (dd, J=8.6,8.6Hz, 1H), 4.26 (dd, J=9.2,3.4Hz, 1H), 3.42 (br d, J=6.4Hz, 1H), 3.24 (dd, J=13.5,3.4Hz, 1H), 2.99 (m, 2H), 2.79 (dd, J=13.5,9.4Hz, 1H), 2.70 (m, 1H), 2.50 (m, 1H);
13C NMR (125MHz, CDCl
3) δ 173.93,153.05,134.43,133.64,129.98 (q, J=6Hz), 129.82 (q, J=28Hz), 129.29,120.01,127.58,124.00 (q, J=272Hz), 116.34,69.60,67.31,54.95,37.78,32.29,29.84; High resolution mass spec m/z 384.1421[(M+H)
+C
19H
21NO
4F
3Value of calculation: 384.1423].
The Alpha-hydroxy amide.(MeO) THF (100mL) suspension of NHMe.HCl (10.1g, 5.25 equivalents) is used AlMe under 0 ℃
3(50mL, handle 5.1 toluene solution equivalent) (2.0M) drips, and resulting settled solution is at room temperature stirred 34min, slowly join refrigerative (0 ℃) α-hydroxyoxazolidinones (7.55g then, 19.7mmol) THF (70mL) solution in (muddiness → clarification, faint yellow).Resulting mixture is warmed to room temperature and stirs 12h.Reactant mixture is cooled to 0 ℃,, stirs 25min under the room temperature, with EtOAc extraction (3 * 200mL) by aqueous tartaric acid solution (100mL) cancellation of slow adding 1N.With the organic facies drying (MgSO that merges
4) and under vacuum, concentrate.The Alpha-hydroxy amide (5.12g, productive rate 97%) that flash chromatography (hexane: EtOAc 2: 1 → 1: 1) provides is clarification grease: [α]
D 20(24 ℃)-57.2 ° (c 1.03, CHCl
3); IR (film) 3432 (br s), 3084 (w), 2980 (m), 2943 (m), 1652 (s), 1464 (m), 1373 (m), 1318 (m), 1214 (m), 1171 (m), 1112 (m), 991 (m), 919 (m), 818 (w) cm
-1 1H NMR (400MHz, CDCl
3) δ 6.32 (td, J=7.3,1.5Hz, 1H), 5.74 (ddt, J=16.9,10.3,6.1Hz, 1H), 5.05 (m, 2H), 4.43 (dd, J=7.6,3.5Hz, 1H), 3.70 (s, 3H), 3.35 (br s, 1H), 3.24 (s, 3H), 2.94 (d, J=6.1Hz, 2H), 2.59 (m, 1H), 2.36 (m, 1H);
13C NMR (100MHz, CDCl
3) δ 173.43,133.68,130.59 (q, J=6Hz), 129.25 (q, J=28Hz), 124.05 (q, J=271Hz), 116.17,67.57,61.44,32.56,32.38,29.75; High resolution mass spec m/z 268.1161[(M+H)
+C
11H
17NO
3F
3Value of calculation: 268.1161].
Alpha-alcohol ketone.(4.87g adds the diethyl ether solution (3.0M) of MeMgBr (75mL, 12 equivalents) in THF 18.2mmol) (150mL) solution to refrigerative (0 ℃) Alpha-hydroxy amide.Behind the 5min, with the saturated NH of this reactant mixture
4Cl (250mL) cancellation and with EtOAc extraction (5 * 200mL).With the organic facies drying (MgSO that merges
4) and under vacuum, concentrate.The alpha-alcohol ketone that flash chromatography (hexane: EtOAc 4: 1 → 2: 1 → 1: 2) provides (2.16g, productive rate 53% are 73% based on the raw material meter productive rate that reclaims) is clarification grease, and provides raw material Alpha-hydroxy amide (1.30g, yield are 27%): [α]
D 20(23 ℃)+58.5 ° (c 1.30, CHCl
3); IR (film) 3460 (br s), 3085 (w), 2984 (m), 2926 (m), 1716 (s), 1679 (m), 1641 (m), 1417 (m), 1361 (m), 1319 (s), 1247 (m), 1216 (s), 1172 (s), 1113 (s), 1020 (m), 994 (m), 968 (w), 919 (m) cm
-1 1H NMR (500MHz, CDCl
3) δ 6.21 (t, J=7.0Hz, 1H), 5.75 (ddt, J=16.7,10.4,6.2Hz, 1H), 5.07 (m, 2H), 4.26 (dt, J=7.1,4.5Hz, 1H), 3.51 (d, J=4.7Hz, 1H), 2.96 (d, J=6.1Hz, 2H), 2.66 (m, 1H), 2.42 (m, 1H), 2.19 (s, 3H);
13C NMR (100MHz, CDCl
3) δ 208.53,133.43,129.80 (q, J=28Hz), 129.76 (q, J=6Hz), 123.85 (q, J=271Hz), 116.32,75.36,31.22,29.81,25.11; High resolution mass spec m/z 223.0945[(M+H)
+C
10H
14NO
2F
3Value of calculation: 223.0946].
Even this reaction uses excessive MeMgBr can not carry out fully.
Carbonic acid 1-(2 benzyloxies-1-Methylethyl)-5,5-diisopropoxy-2,4,4-trimethyl-3-oxo pentyl ester 2,2,2-three chloro-ethyl esters.7-benzyloxy-5-hydroxyl-1 under 0 ℃, 1-diisopropoxy-2,2,4,6-tetramethyl-heptan-3-ketone (1.0g, 2.4mmol) and pyridine (0.8mL, CH 7.3mmol)
2Cl
2(10.0mL) add chloro-carbonic acid 2,2 in the solution, (668.0 μ L, 4.9mmol), the mixture with gained is warmed to room temperature to the 2-trichloro ethyl ester then.Behind the 1h, with reactant mixture with the saline cancellation and use CH
2Cl
2Extraction.With the organic layer that merges through MgSO
4Dry and under reduced pressure concentrated.Crude product provides the product of wanting (1.285g, 92%) and is clarification grease by flash chromatography (gradient hexane to hexane/EtOAc 93: 7) purification:
1H NMR (400MHz, CDCl
3) δ 1.03-1.09 (m, 12H), 1.15 (d, J=1.8Hz, 3H), 1.17 (d, J=1.9Hz, 3H), 1.19-1.21 (m, 6H), 1.97-2.11 (m, 1H), 3.2 (dd, J=6.2 and 9.0Hz, 1H), 3.54 (dd, J=4.8 and 9.1Hz, 1H), 3.57-3.60 (m, 1H), 3.82 (qd, J=3.6 and 5.9Hz, 2H), 4.47 (s, 2H), 4.57 (s, 1H), 4.72 (d, J=11.9Hz, 1H), 4.81 (d, J=11.9Hz, 1H), 5.08 (t, J=6.0Hz, 1H), and 7.29-7.35 (m, 5H);
13C NMR (100MHz, CDCl
3) δ 11.9,15.0,18.8,21.4,21.7,22.3,23.2,23.4,35.7,42.5,53.4,53.9,69.4,70.9,71.4,73.3,81.3,94.7,103.4,127.5,127.6,128.2,138.2,154.0,215.6; IR (film, NaCl, cm
-1) 2966,1760,1698,1247; LRMS (ESI) C
27H
41O
7Cl
3Na[M+Na
+] value of calculation 605.2, experiment value 605.2; [α]
23 D=-20.4 (c=1.0, CHCl
3).
Carbonic acid 1-(2 benzyloxies-1-Methylethyl)-2,4,4-trimethyl-3,5-dioxo pentyl ester 2,2,2-three chloro-ethyl esters.To raw material (1.28g, 4: 1 THF/H 2.25mmol)
2Add in O (25mL) solution p-TsOH (111.0mg, 0.6mmol).Behind heating 5h under 70 ℃, (0 ℃) saturated NaHCO that the reactant mixture impouring is cold
3(12mL) extracts with EtOAc then in the aqueous solution.With the organic layer salt water washing that merges, through MgSO
4Dry and under reduced pressure concentrated.Crude product is clarification grease through the product (793.2mg, 76%) that flash chromatography (gradient hexane to hexane/EtOAc 84: 16) purification provides:
1H NMR (400MHz, CDCl
3) δ 0.90 (d, J=5.8Hz, 3H), 1.0 (d, J=6.9Hz, 3H), 1.24 (s, 6H), 1.97-2.04 (m, 1H), 3.24 (dd, J=4.8 and 9.2Hz, 1H), 3.34 (m, 1H), 3.42 (dd, J=5.8 and 9.2Hz, 1H), 4.35 (d, J=11.9Hz, 1H), 4.39 (d, J=11.9Hz, 1H), 4.64 (d, J=11.9Hz, 1H), 4.69 (d, J=11.9Hz, 1H), 4.96 (t, J=6.0Hz, 1H), 7.19-7.28 (m, 5H), 9.49 (s, 1H);
13CNMR (100MHz, CDCl
3)-12.0,14.8,19.5,19.6,35.4,43.3,60.9,71.1,73.3,80.37,94.5,127.7,127.8,128.3,137.9,154.1,201.0,210.1; IR (film, NaCl, cm
-1) 2973,2880,1758,1701,1453,1380,1248; LRMS (ESI) C
21H
27O
6Cl
3Na[M+Na
+] value of calculation 503.0, experiment value 503.0; [α]
23 D=-18.5 (c=0.8, CHCl
3).
9-benzyloxy-4,4,6,8-tetramethyl-3,5-dioxo-7-(2,2,2-trichlorine ethoxy carbonyl oxygen the base)-n-nonanoic acid tert-butyl ester.(1.17mmol is at Et to LDA under-78 ℃
20.3M among the O) adds tert-butyl acetate (1.0mmol, 135.0 μ l) in the solution.Behind the 30min, in 15min, slowly add raw material (464.0mg, Et 1mmol)
2O (2mL) solution.After stirring 1h, use saturated NH
4Cl aqueous solution cancellation reaction also extracts with EtOAc then.The organic layer salt water washing that merges is through MgSO
4Dry and under reduced pressure concentrated.Crude product is clarification grease with the product (1: 1 epimer mixture 461.4mg, 80%) that flash chromatography (gradient hexane to hexane/EtOAc 86: 14) purification provides:
1H NMR (400MHz, CDCl3) δ 0.87 (d, J=5.3Hz, 3H), 0.89 (d, J=5.5Hz, 3H), 1.02-1.10 (m, 18H), 1.38 (s, 18H), 1.97-2.2 (m, 2H), and 2.27-2.31 (m, 2H), 3.22-3.27 (m, 3H), 3.39-3.48 (m, 5H), and 4.03-4.06 (m, 1H), 4.11-4.14 (m, 1H), 4.38-4.45 (m, 4H), 4.58-4.73 (m, 4H), 4.97 (t, J=5.8Hz, 1H), 5.02 (t, J=5.8Hz, 1H), 7.18-7.27 (m, 10H);
13C NMR (100MHz, CDCl
3) δ 11.9,12.7,14.9,15.2,18.7,19.3,21.4,21.6,28.0,35.6,37.4,41.7,42.0,51.8,51.9,71.3,71.3,72.5,73.0,73.3,73.3,80.6,81.2,81.3,94.6,127.5,127.7,127.8,128.3,138.0,138.1,154.0,154.1,172.3,172.4,216.0,216.3; IR (film, NaCl, cm
-1) 3509,2975,1759,1707,1368,1248,1152; LRMS (ESI) C
27H
39O
8Cl
3Na[M+Na
+] value of calculation 619.1, experiment value 619.2.
To raw material (350.0mg, CH 0.6mmol)
2Cl
2Add in 0 ℃ of solution (10mL) Dess-Martin cross iodine alkane (periodinane) (398.0mg, 0.9mmol).This mixture is at room temperature stirred 1h be poured into sufficient 1: the 1 saturated Na of stirring then
2S
2O
3/ saturated NaHCO
3In the mixture.Layering behind the 30min.Water layer Et
2O extraction three times.Merge organic extract, use saturated NaHCO
3, the salt water washing, through MgSO
4Dry and concentrated under vacuum.Crude product is clarification grease with the product (258.4mg, 74%) that flash chromatography (gradient hexane to hexane/EtOAc 91: 9) purification provides:
1H NMR (400MHz, CDCl
3) δ 0.80 (d, J=6.9Hz, 3H), 0.87 (d, J=6.9Hz, 3H), 1.13 (s, 3H), 1.19 (s, 3H), 1.23 (s, 9H), 2.04-2.12 (m, 1H), 3.09-3.28 (m, 5H), 4.23 (s, 2H), 4.48 (d, J=11.9Hz, 1H), 4.55 (d, J=11.9Hz, 1H), 4.79 (dd, J=4.6 and 7.3Hz, 1H), 7.04-7.13 (m, 5H);
13CNMR (100MHz, CDCl
3) δ 11.7,14.6,20.7,21.5,27.9,35.5,42.2,43.4,63.3,71.3,73.3,79.9,81.5,90.5,94.5,127.6,127.7,128.2,138.0,154.0,166.2,202.9,210.0; IR (film, NaCl, cm
-1) 2977,1758,1697,1368,1248,1154; LRMS (ESI) C
27H
37O
8Cl
3Na[M+Na
+] value of calculation 617.1, experiment value 617.1; [α]
23 D=-49.1 (c=0.9, CHCl
3).
9-benzyloxy-3-hydroxyl-4,4,6,8-tetramethyl-5-oxo-7-(2,2,2-trichlorine ethoxy carbonyl oxygen the base)-n-nonanoic acid tert-butyl ester.With (R)-RuBINAP catalyst (16.8mg, 10.0pmol) filing of containers lining (bomb liner).Add HCl (555 μ L, 0.2N in methanol), and with the ultrasonic 15sec of this mixture.(59.4mg, methanol 0.1mmol) (555 μ L) solution add and this mixture are transferred in the Parr device with raw material then.With this container H
2Clean 5min, be forced into 1200psi then.Behind the 17h, reaction is got back under the atmospheric pressure and with the saturated NaHCO of its impouring
3In the aqueous solution.Water layer extracts three times with EtOAc.The organic extract that merges is through MgSO
4Dry and under reduced pressure concentrated.Crude product is clarification grease with the product (47.6mg, 80%) that flash chromatography (gradient hexane to hexane/EtOAc 88: 12) purification provides:
1H NMR (400MHz, CDCl
3) δ 1.06 (d, J=6.9Hz, 3H), 1.11 (d, J=6.8Hz, 3H), 1.14 (s, 3H), 1.18 (s, 3H), 1.47 (s, 9H), 2.05-2.12 (m, 1H), 2.35-2.40 (m, 1H), 3.31-3.37 (m, 2H), 3.51-3.54 (m, 2H), 4.11-4.14 (m, 1H), 4.46 (s, 2H), 4.72 (d, J=11.9Hz, 1H), 4.80 (d, J=11.9Hz, 1H), 5.05 (dd, J=5.0 and 6.7Hz, 1H), 7.27-7.35 (m, 5H);
13C NMR (100MHz, CDCl
3) δ 12.0,15.0,19.3,21.7,28.0,35.6,37.5,41.7,51.8,71.3,73.0,73.3,80.6,81.3,94.7,127.5,127.7,128.3,138.2,154.1,172.4,216; IR (film, NaCl, cm
-1) 3849,2974,2879,1758,1701,1454,1368,1248,1152,926,734; LRMS (ESI) C
27H
39O
8Cl
3Na[M+Na
+] value of calculation 619.1, experiment value 619.2; [α]
23 D=-13.0 (c=0.4, CHCl
3).
9-benzyloxy-4,4,6,8-tetramethyl-5-oxo-7-(2,2,2-trichlorine ethoxy carbonyl oxygen base)-3-(triethyl silicane oxygen base)-n-nonanoic acid tert-butyl ester.Under 0 ℃, in DMF (0.4mL) solution of raw material (37.6mg, 6.3 μ mol) and imidazoles (9.4mg, 13.8 μ mol), add TESCl (11.6 μ l, 69.3 μ mol).Behind the 3h, use saturated NaHCO
3Aqueous solution dilutes this mixture.Water layer hexane extraction three times.The organic extract salt water washing that merges is through MgSO
4Dry and under reduced pressure concentrated.Crude product is by flash chromatography (gradient hexane to hexane/EtOAc 93: 7) purification, with eluting order obtain product (22.9mg, 51%) and the raw material (12.9mg, 34%) that reclaims for clarifying grease:
1H NMR (400MHz, CDCl
3) δ 0.66 (q, J=7.9Hz, 6H), 0.96 (t, J=7.9Hz, 9H), 1.01 (s, 3H), 1.05 (d, J=5.2Hz, 3H), 1.07 (d, J=5.3Hz, 3H), 1.35 (s, 3H) .1.44 (s, 9H), 2.05-2.11 (m, 2H), 2.50 (dd, J=3.5 and 17.2Hz, 1H), 3.35 (dd, J=5.9 and 9.0Hz, 1H), 3.49 (dd, J=4.0 and 9.0Hz, 1H), 3.53 (dd, J=3.8 and 6.7Hz, 1H), 4.18 (dd, J=3.5 and 6.5Hz, 1H), 4.45 (s, 2H), 4.65 (d, J=11.9Hz, 1H), 4.79 (d, J=11.9Hz, 1H), 4.97 (dd, J=3.7 and 8.1Hz, 1H), 7.29-7.52 (m, 5H);
13C NMR (125MHz, CDCl
3) δ 5.3,7.3,10.9,14.9,21.3,22.6,28.4,35.9,41.1,42.7,53.7,71.9,73.7,75.7,80.1,80.9,95.1,127.9,128.0,128.7,138.6,154.3,171.7,215.7; IR (film, NaCl, cm
-1) 2956,2876,1732,1694,1456,1366,1257,1154,1098,988,835,774,741; LRMS (ESI) C
33H
53O
8SiCl
3Na[M+Na
+] value of calculation 733.2, experiment value 733.3.[α]
23 D=-16.1(c=0.1,CHCl
3)。
9-benzyloxy-3-(diethylmethyl silicon alkoxyl)-7-hydroxyl-4,4,6,8-tetramethyl-5-oxo-n-nonanoic acid tert-butyl ester.To 1 of raw material (22.9mg, 3.2 μ mol): add Zn (5.0mg, 7.8 μ mol, nanoscale) in 1THF/AcOH (1.4mL) solution.With the ultrasonic 15min of this mixture.Add more Zn (5.0mg, 7.8 μ mol, nanoscale), ultrasonic more subsequently 15min.This suspension filters by the celite pad, with the EtOAc washing for several times.The saturated NaHCO of filter liquor
3, the salt water washing, through MgSO
4Dry and concentrated under vacuum.By the short plug of silica gel, with 4: 1 eluting of hexane/EtOAc, the product that provides 17.1mg (99% yield) is a colorless oil with thick residue:
1HNMR (400MHz, CDCl
3) δ (m, 6H), 0.96 (t, J=7.9Hz, 9H), 0.97 (d, J=6.8Hz, 3H), 1.05 (d, J=6.8Hz, 3H), 1.11 (s, 3H), 1.26 (s, 3H), 1.44 (s, 9H), 1.84-1.90 (m, 1H), 2.21 (dd, J=6.7 and 17.0Hz, 1H), 2.36 (dd, J=6.7 and 17.0Hz, 1H), 3.24-3.29 (m, 1H), 3.44-3.52 (m, 2H), 3.67 (dd, J=3.9 and 8.9Hz, 1H), 4.36 (dd, J=3.5 and 6.5Hz, 1H), 4.50 (d, J=12.0Hz, 1H), 4.54 (d, J=12.0Hz, 1H), 7.32-7.36 (m, 5H);
13C NMR (100MHz, CDCl
3) δ 5.0,6.9,9.7,13.9,20.2,21.8,28.0,36.3,40.8,41.5,53.7,72.5,72.9,73.2,73.6,80.7,127.4,127.5,128.2,138.6,171.0,221.4; IR (film, NaCl, cm
-1) 3502,2959,2875,1731,1683,1456,1366,1154,1098,996,739; LRMS (ESI) C
30H
52O
6SiCl
3Na[M+Na
+] value of calculation 559.3, experiment value 559.3; [α]
23 D=-41.0 (c=0.4, CHCl
3).
9-benzyloxy-7-(tert-butyl group dimethyl-silicon alcoxyl base)-3-(diethylmethyl silicon alkoxyl)-4,4,6,8-tetramethyl-5-oxo-n-nonanoic acid tert-butyl ester.Under-78 ℃ to raw material (4.1mg, 7.6 μ mol) and 2,6-lutidines (10.0 μ l, CH 43.5mmol)
2Cl
2(0.2mL) add in the solution TBSOTf (10.0 μ l, 85.8mmol).Behind the 2h, add more 2, the 6-lutidines (10.0 μ l, 43.5mmol) and TBSOTf (10.0 μ l, 85.8mmol).Behind the 6h with the saturated NaHCO of this mixture
3The aqueous solution dilution.Water layer extracts three times with EtOAc.With the organic extract salt water washing that merges, through MgSO
4Dry and under reduced pressure concentrated.Crude product is clarification grease with the product (5.4mg, 82%) that flash chromatography (gradient hexane to hexane/EtOAc 91: 9) purification provides.Spectroscopic data accords with the value of having reported well.
With acid and alcohol and anhydrous benzene (5mL * 2) azeotropic and dry under fine vacuum before reaction.Under 0 ℃ to alcohol (639mg, CH 2.63mmol)
2Cl
2(13mL) add in the solution EDCI (576mg, 3.09mmol) and DMAP (366mg, 3.09mmol).At the CH that in this mixture, drips acid (1.11g is equivalent to 1.88mmol) under 0 ℃
2C1
2(5mL+2mL flushing) is more than the solution 16min.After stirring 1.5h under 0 ℃, this mixture is at room temperature stirred 3.5h.After reactant mixture concentrated, residue was by hurried column chromatography (SiO
2, hexane/EtOAc=30: 1 to 20: 1) and the ester (1.20g, 1.61mmol is by tert-butyl ester meter 86%) that provides of purification is colorless oil.
[α]
D 24-25.1 (c 1.30, CHCl
3); IR (film) ν 2955,2925,2872,1732,1696,1461,1378,1290,1243,1173,1091,985,873,773cm
-1 1H NMR (400MHz, CDCl
3) δ 0.06 (3H, s), 0.06 (3H, s), 0.58-0.66 (6H, m), 0.92 (9H, s), 0.95 (9H, t, J=8.0Hz), 1.02 (3H, d, J=6.5Hz), 1.03 (3H, d, J=6.5Hz), 1.07 (3H, s), 1.21 (3H, s), 1.67 (3H, s), 2.07 (3H, s), and 2.05-2.12 (1H, m), 2.30 (1H, dd, J=16.9,7.5Hz), 2.39 (1H, dt, J=14.8,6.7Hz), 2.49 (1H, dd, J=17.0,3.0Hz), 2.50 (1H, dt, J=14.8,6.7Hz), 2.70 (3H, s), 2.74-2.30 (2H, m), 3.07 (1H, dd, J=7.0Hz), 3.83 (1H, dd, J=7.1,2.0Hz), 4.35 (1H, dd, J=7.4,2.8Hz), 4.98-5.07 (4H, m), 5.16 (1H, brt, J=7.0Hz), 5.23 (1H, t, J=6.9Hz), 5.74 (1H, ddt, J=16.7,10.2,6.5Hz), 5.91 (1H, ddd, J=17.8,10.5,7.8Hz), 6.50 (1H, s), 6.95 (1H, s);
13C NMR (100MHz, CDCl
3) δ-3.7 ,-3.3,5.3 (3C), 7.2 (3C), 14.8,15.2,18.7,18.9,19.4,20.3,23.6,23.7,26.4 (3C), 31.7,36.7,40.1,43.8,46.4,53.3,74.2,76.5,79.6,115.5,115.6,116.5,120.5,121.3,135.8,136.1,137.4,140.2,152.9,164.7,171.5,218.4; LRMS (ESI) C
41H
71NO
5SSi
2Na[M+Na
+] value of calculation 768.5, experiment value 768.5; HRMSC
41H
72NO
5SSi
2[M+H
+] value of calculation 746.4670, experiment value 746.4680.
Toluene (70mL) solution of diene (26.9mg, 36.1 μ mol) is heated to refluxes and with toluene (2mL) solution-treated of Grubbs catalyst (3.1mg, 3.61 μ mol).This mixture is stirred 25min, be cooled to 0 ℃, filter by using hexane/EtOAc=2/1 washed silica gel pad.The filtrate that merges concentrated and by hurried column chromatography (SiO
2, hexane/Et
2O=40: 1 to 5: 1) purification provides product (9.9mg, 13.8 μ mol, 38%) and the cycloheptadiene (14.4mg, 22.3 μ mol, 62%) wanted and is colorless oil.
[α]
D 25-41.5 (c 0.715, CHCl
3); IR (film) ν 2955,2884,1737,1690,1467,1378,1249,1179,1102,1014,979,879,826,773cm
-1 1HNMR (400MHz, CDCl
3) δ 0.08 (3H, s), 0.12 (3H, s), 0.57 (6H, q, J=7.8Hz), 0.89 (9H, t, J=8.0Hz), 0.93 (9H, s), 1.04 (3H, s), 1.06 (3H, d, J=7.1Hz), 1.12 (3H, s), 1.17 (3H, d, J=7.1Hz), 1.68 (3H, s), 2.15 (3H, d, J=0.8Hz), 2.14-2.27 (2H, m), 2.45 (1H, dd, J=14.0,4.8Hz), 2.50 (1H, dd, J=14.9,3.2Hz), 2.64-2.74 (2H, m), 2.72 (3H, s), 3.02 (1H, quintet, J=7.0Hz), 3.10 (1H, dd, J=14.4,7.3Hz), 3.96 (1H, d, J=8.7Hz), 4.43 (1H, dd, J=8.3,2.9Hz), 5.22 (1H, dd, J=9.8,5.7Hz), 5.33-5.42 (2H, m), 5.69 (1H, dd, J=15.8,8.2Hz), 6.57 (1H, s), 6.96 (1H, s);
13C NMR (100MHz, CDCl
3) δ-3.3 ,-3.2,5.6 (3C), 7.1 (3C), 15.0,17.2,18.8,19.4,21.4,21.7,23.8,24.3,26.5 (3C), 33.2,35.6,41.3,41.8,48.2,54.0,74.4,77.4,79.3,116.4,120.5,121.0,129.3,132.1,137.8,138.0,152.7,164.8,170.7,216.8; LRMS (ESI) C
39H
68NO
5SSi
2[M+H
+] value of calculation 718.4, experiment value 718.3; HRMSC
39H
68NO
5SSi
2[M+H
+] 718.4357, experiment value 718.4355.
[α]
D 26-38.5 (c 0.400, CHCl
3); IR (film) ν 2955,2878,1741,1693,1472,1458,1385,1295,1253,1169,1098,988,871,837,775cm
-1 1HNMR (400MHz, CDCl
3) δ 0.07 (6H, s), 0.61-0.68 (6H, m), 0.93 (9H, s), 0.97 (9H, t, J=8.0Hz), 1.03 (3H, d, J=7.0Hz), 1.04 (3H, d, J=7.0Hz), 1.10 (3H, s), 1.21 (3H, s), 1.65 (3H, s), 1.75 (3H, s), 2.06-2.14 (1H, m), 2.31 (1H, dd, J=17.2,7.2Hz), 2.34-2.51 (2H, m), 2.49 (1H, dd, J=17.1,2.8Hz), 2.65-2.81 (2H, m), 3.07 (1H, quintet, J=7.0Hz), 3.84 (1H, dd, J=7.2,2.1Hz), 4.40 (1H, dd, J=7.2,2.8Hz), 4.98-5.09 (2H, m), 5.38-5.42 (1H, m), 5.65 (1H, t, J=5.9Hz), 5.93 (1H, ddd, J=17.9,10.1,7.8Hz);
13C NMR (100MHz, CDCl
3) δ-3.6 ,-3.3,5.4 (3C), 7.3 (3C), 15.3,18.7,19.0,20.0,22.1,23.8,25.8,26.4 (3C), 31.3,32.3,40.0,43.8,46.3,54.0,72.5,73.8,76.5,115.6,119.8,125.6,136.5,140.1,140.6,171.9,218.5; LRMS (ESI) C
35H
64O
5Si
2Na[M+Na
+] value of calculation 643.4, experiment value 643.3; HRMSC
35H
64O
5Si
2Na[M+Na
+] value of calculation 643.4190, experiment value 643.4219.
React through Wittig: under 0 ℃, in THF (0.4mL) solution of Wittig reagent (19.1mg, 54.7 μ mol), add KHMDS (toluene solution of 109 μ l 0.5M, 54.7 μ mol).This mixture is stirred 0.5h down at 0 ℃ be cooled to-78 ℃ then.In this mixture, drip THF (0.3mL) solution of ketone (5.7mg, 9.12 μ mol), the mixture that obtains is warmed to-20 ℃ at 1.5h.Use saturated NH
4Cl aqueous solution (2mL) cancellation should be reacted and be extracted (7mL * 3) with EtOAc.The organic layer that merges is through Na
2SO
4Dry and concentrated.Residue is by hurried column chromatography (SiO
2, hexane/Et
2O=10: 1) purification provides the inseparable alkene mixture (E/Z=9: 1) of 5.6mg.This mixture is passed through preparation TLC (hexane/Et
2O=4: 1) to provide the pure isomer of wanting (5.0mg, 6.96 μ mol, 76%) be colorless oil to purification.
1H NMR (400MHz, CDCl
3) δ 0.08 (3H, s), 0.12 (3H, s), 0.51 (6H, q, J=7.9Hz), 0.86 (9H, t, J=7.9Hz), 0.97 (9H, s), 1.01 (3H, s), 1.06 (3H, d, J=7.1Hz), 1.12 (3H, s), 1.18 (3H, d, J=7.1Hz), 1.69 (3H, s), 1.97 (3H, s), 2.10-2.18 (1H, m), 2.24-2.31 (1H, m), 2.38-2.59 (3H, m), 2.68-2.78 (1H, m), 2.72 (3H, s), 2.98-3.14 (2H, m), 3.97 (1H, d, J=9.0Hz), 4.45-4.48 (1H, m), 5.29-5.41 (2H, m), 5.73 (1H, dd, J=15.6,8.3Hz), 6.30 (1H, s), 6.73 (1H, d, J=8.7Hz), 6.56 (1H, s); LRMS (ESI) C
39H
68NO
5SSi
2[M+H
+] value of calculation 718.4, experiment value 718.1.
(298.8mg adds HF pyridine (3.2mL) in THF 0.416mmol) (6.5mL) solution, this mixture is at room temperature stirred 3h to the silyl ether in plastic tube under 0 ℃.Drip TMSOMe (30mL) cancellation reaction down at 0 ℃, this mixture is at room temperature stirred 3h.It is dry under fine vacuum to concentrate the back, and residue is with hurried column chromatography (SiO
2, hexane/Et
2O=1: 1) to provide alcohol (196.6mg, 0.402mmol, 97%) be colorless solid to purification.
[α]
D 25-96.6 (c 0.235, CHCl
3); IR (film) ν 3502,2970,2927,1733,1685,1506,1456,1375,1251,1152,1040,977cm
-1 1H NMR (400MHz, CDCl
3) δ 1.06 (3H, s), 1.11 (3H, d, J=7.0Hz), 1.22 (3H, d, J=6.8Hz), 1.28 (3H, s), 1.72 (3H, s), 2.10 (3H, s), 2.31-2.40 (2H, m), 2.43 (1H, dd, J=16.0,3.7Hz), 2.49 (1H, dd, J=16.0,9.2Hz), 2.55-2.68 (2H, m), 2.71 (3H, s), 2.98 (1H, dd, J=14.4,6.4Hz), 3.16 (1H, quintet, J=6.2Hz), 3.76 (1H, dd, J=5.9,3.2Hz), 4.30 (1H, dd, J=9.2,3.7Hz), 5.18 (1H, brt, J=7.3Hz), 5.32 (1H, dd, J=8.4,2.5Hz), 5.63 (1H, dd, J=15.7,6.4Hz), 5.60 (1H, ddd, J=15.7,6.9,5.1Hz), 6.60 (1H, s), 6.98 (1H, s);
13C NMR (100MHz, CDCl
3) δ 15.1,16.0,17.7,19.2,19.5,22.5,23.6,32.0,35.0,39.6,40.3,44.8,53.3,71.8,75.6,78.3,116.1,119.6,120.5,129.9,131.3,137.5,138.2,152.2,165.0,170.7,218.8; LRMS (ESI) C
27H
40NO
5S[M+H
+] value of calculation 490.3, experiment value 490.2; HRMS C
27H
40NO
5S[M+H
+] value of calculation 490.2627, experiment value 490.2602.
Under 50 ℃ to alkene (1.2mg, 2.5 μ mol) and TrisNHNH
2The ClCH of (29.3mg, 98 μ mol)
2CH
2Add Et in Cl (0.7mL) solution
3N (13.7 μ L, 98 μ mol).Reaction is by HPTLC monitoring (hexane/EtOAc/CH
2Cl
2=1/1/2).After stirring 7h, this mixture is cooled to room temperature, filters with the EtOAc dilution and by the silicagel pad of washing with EtOAc.After concentrating, residue is by preparation TLC (hexane/EtOAc/CH
2Cl
2=1/1/2) to provide reductive product (1.1mg, 2.2 μ mol, 91%) be white solid to purification.The spectroscopic data of this chemical compound is identical with the spectrum of the dEpoB that has reported.
With acid and alcohol and anhydrous benzene (5mL * 2) azeotropic and dry under fine vacuum before reaction.Under 0 ℃ to alcohol (10: 1 mixture of isomers, 240mg, CH 0.756mmol)
2Cl
2(5mL) add in the solution EDCI (192.7mg, 1.01mmol) and DMAP (122.8mg, 1.01mmol).Under 0 ℃, in 15min, in mixture, drip acid (314.6mg, CH 0.628mmol)
2Cl
2(2mL+1mL flushing) solution.After stirring 2h under 0 ℃, this mixture is at room temperature stirred 2h.After concentrating, carefully with residue with hurried column chromatography (SiO
2, hexane/EtOAc=20: 1 to 15: 1) and to give ester output (340.1mg, 0.425mmol is based on acid meter 68%) be colorless oil to purification.
[α]
D 24-27.5 (c 0.28, CHCl
3); IR (film) ν 2956,2878,1740,1692,1472,1378,1317,1253,1174,1118,988,915,872,837,775cm
-1 1HNMR (400MHz, CDCl
3) δ 0.06 (6H, s), 0.57-0.65 (6H, m), 0.92 (9H, s), 0.94 (9H, t, J=7.9Hz), 1.02 (3H, d, J=6.9Hz), 1.03 (3H, d, J=6.8Hz), 1.07 (3H, s), 1.22 (3H, s), 2.07-2.10 (1H, m), 2.09 (3H, s), 2.31 (1H, dd, J=16.9,7.3Hz), 2.51 (1H, dd, J=16.8,3.0Hz), 2.49-2.65 (2H, m), 2.71 (3H, s), 2.96-2.99 (2H, m), 3.06 (1H, quintet, J=7.1Hz), 3.83 (1H, dd, J=7.3,2.1Hz), 4.35 (1H, dd, J=7.2,3.0Hz), 4.98-5.12 (4H, m), 5.30 (1H, t, J=6.7Hz), 5.76 (1H, ddt, J=16.7,10.2,6.2Hz), 5.92 (1H, ddd, J=17.8,9.9,7.8Hz), 6.19 (1H, t, J=7.0Hz), 6.51 (1H, s), 6.97 (1H, s);
13C NMR (100MHz, CDCl
3) δ-3.7 ,-3.4,5.2 (3C), 7.1 (3C), 14.7,15.2,18.6,18.9,19.3,19.9,23.8,26.3 (3C), and 30.1,31.2,40.0,43.7,46.3,53.3,73.9,76.5,77.9,115.5,116.5,117.0,121.5,124.1[q,
1J (C, F)=273.4Hz], 129.6[q,
2J (C, F)=28.5Hz], 130.5[q,
3J (C, F)=6.1Hz], 133.6,136.3,140.1,152.4,164.8,171.3,218.3; LRMS (ESI) C
41H
68F
3NO
5SSi
2Na[M+Na
+] value of calculation 822.4, experiment value 822.4; HRMS C
41H
69F
3NO
5SSi
2[M+H
+] value of calculation 800.4387, experiment value 800.4374.
Toluene (142mL) solution of diene (57.6mg, 72.0 μ mol) is heated to refluxes and with toluene (2mL) solution-treated of Grubbs catalyst (6.1mg, 7.20 μ mol).This mixture is stirred 28min, be cooled to 0 ℃, filter by the silicagel pad of washing with hexane/EtOAc=2/1 (300mL).The filtrate that merges concentrated and by hurried column chromatography (SiO
2, hexane/Et
2O=40: 1 to 15: 2) purification provides product (12.0mg, 15.5 μ mol, 22%) and the cycloheptadiene (29.2mg, 43.3 μ mol, 60%) wanted and is colorless oil.
[α]
D 26-17.1 (c 0.14, CHCl
3); IR (film) ν 2955,2884,1743,1690,1472,1320,1173,1114,1038,1008,873,832,773cm
-1 1HNMR (400MHz, CDCl
3) δ 0.09 (3H, s), 0.12 (3H, s), 0.55 (6H, q, J=7.7Hz), 0.88 (9H, t, J=8.0Hz), 0.96 (9H, s), 1.01 (3H, s), 1.06 (3H, d, J=7.1Hz), 1.12 (3H, s), 1.20 (3H, d, J=7.1Hz), 2.07-2.17 (1H, m), 2.19 (3H, s), 2.38 (1H, dd, J=14.3,3.5Hz), 2.39-2.49 (1H, m), 2.50 (1H, dd, J=14.3,7.3Hz), 2.73 (3H, s), 2.77-2.91 (2H, m), 2.96-3.09 (2H, m), 3.98 (1H, dd, J=8.9Hz), 4.54 (1H, dd, J=7.3,3.4Hz), 5.28-5.38 (1H, m), 5.63 (1H, dd, J=9.6,2.3Hz), 5.77 (1H, dd, J=15.9,8.5Hz), 6.21-6.28 (1H, m), 6.60 (1H, s), 6.99 (1H, s);
13C NMR (100MHz, CDCl
3) δ-3.4 ,-3.3,5.5 (3C), 7.0 (3C), 14.6,17.1,18.7,19.4,19.9,21.3,24.8,26.4 (3C), and 29.6,32.8,42.0,42.1,48.2,54.1,73.4,76.9,77.8,117.0,121.6,124.3[q,
1J (C, F)=273.5Hz], 127.2,130.6[q,
2J (C, F)=28.2Hz], 130.8[q,
3J (C, F)=6.1Hz], 133.2,136.5,152.3,165.0,170.1,217.1; LRMS (ESI) C
39H
65F
3NO
5SSi
2[M+H
+] value of calculation 772.4, experiment value 772.4; HRMS C
39H
65F
3NO
5SSi
2[M+H
+] value of calculation 772.4074, experiment value 772.4102.
[α]
D 26-35.6 (c 0.365, CHCl
3); IR (film) ν 2956,2878,1737,1693,1472,1458,1305,1279,1252,1173,1116,988,871,775cm
-1 1HNMR (400MHz, CDCl
3) δ 0.08 (6H, s), 0.64 (6H, q, J=7.8Hz), 0.93 (9H, s), 0.96 (9H, t, J=7.8Hz), 1.04 (6H, d, J=7.0Hz), 1.10 (3H, s), 1.22 (3H, s), 1.70 (3H, s), and 2.05-2.14 (1H, m), 2.32 (1H, dd, J=17.0,7.1Hz), 2.50 (1H, dd, J=17.0,3.0Hz), 2.51-2.63 (2H, m), 2.87 (1H, dd, J=18.4,6.7Hz), 2.90-3.02 (1H, m), 3.07 (1H, quintet, J=7.1Hz), 3.85 (1H, dd, J=7.2,2.0Hz), 4.39 (1H, dd, J=7.1,2.9Hz), 4.98-5.08 (2H, m), 5.51 (1H, dd, J=8.1,3.8Hz), 5.67 (1H, t, J=5.9Hz), 5.93 (1H, ddd, J=17.8,10.5,7.8Hz), 6.29 (1H, t, J=5.5Hz);
13C NMR (100MHz, CDCl
3) δ-3.7 ,-3.4,5.3 (3C), 7.1 (3C), 15.3,18.7,18.9,19.6,21.3,23.9,24.1,26.3 (3C), and 30.3,40.0,43.7,46.3,53.4,70.9,73.7,76.5,115.5,123.4,123.8[q,
1J (C, F)=272.2Hz], 129.1[q,
3J (C, F)=6.1Hz], 131.5[q,
2J (C, F)=28.8Hz], 138.1,140.0,171.7,218.5; LRMS (ESI) C
35H
61F
3O
5Si
2Na[M+Na
+] value of calculation 697.4, experiment value 697.4; HRMS C
35H
61F
3O
5Si
2Na[M+Na
+] value of calculation 697.3907, experiment value 697.3892.
(1.78g slowly adds HF pyridine (12.5mL) in THF 2.31mmol) (25mL) solution, this mixture is at room temperature stirred 4h to the silyl ether in plastic tube under 0 ℃.Under 0 ℃, in 10min, react with dripping TMSOMe (80mL) cancellation.This mixture of vigorous stirring 2.5h at room temperature.Concentrate and behind high vacuum dry 2h, with residue by hurried column chromatography (SiO
2~50g, hexane/EtOAc=1: 1) purification, providing glycol (1.20g, 2.21mmol, 96%) is colorless solid.
[α]
D 25-54.6 (c 0.28, CHCl
3); IR (film) ν 3478,2974,2929,1736,1689,1449,1381,1318,1247,1169,1113,1039,983,867,736cm
-1 1HNMR (400MHz, CDCl
3) δ 1.05 (3H, s), 1.12 (3H, d, J=7.0Hz), 1.23 (3H, d, J=6.8Hz), 1.37 (3H, s), 2.04 (1H, brd, J=3.8Hz ,-OH), 2.12 (3H, s), 2.25-2.33 (1H, m), 2.38 (1H, dd, J=15.3,3.0Hz), 2.48 (1H, dd, J=15.4,9.8Hz), 2.54-2.61 (1H, m), 2.66-2.76 (1H, m), 2.71 (3H, s), 2.96 (1H, dd, J=16.5,4.5Hz), 3.02 (1H, dd, J=16.3,6.5Hz), 3.11 (1H, quintets, J=6.7Hz), 3.19 (1H, brs ,=OH), 3.74 (1H, brs), 4.35 (1H, brd, J=9.5Hz), 5.42 (1H, dd, J=6.2,4.1Hz), 5.60 (1H, ddd, J=15.8,5.6,4.5Hz), 5.66 (1H, dd, J=15.8,5.8Hz), 6.24 (1H, t, J=7.2Hz), 6.64 (1H, s), 7.00 (1H, s);
13CNMR (100MHz, CDCl
3) δ 15.1,16.1,17.7,18.5,19.3,22.5,28.8,31.1,39.6,39.7,45.0,53.7,71.4,75.3,76.8,116.7,120.2,124.3[q,
1J (C, F)=273.4Hz], 127.9,130.2[q,
3J (C, F)=6.0Hz], 130.6[q,
2J (C, F)=28.4Hz], 132.5,136.7,152.0,165.4,170.2,218.4; LRMS (ESI) C
27H
37F
3NO
5S[M+H
+] value of calculation 544.2, experiment value 544.1; HRMS C
27H
37F
3NO
5S[M+H
+] value of calculation 544.2345, experiment value 544.2346.
Under 50 ℃ to glycol (1.22mg, 2.24 μ mol) and TrisNHNH
2The ClCH of (26.7mg, 89.6 μ mol)
2CH
2Add Et in Cl (1mL) solution
3N (12.5 μ L, 89.6 μ mol).Reaction is by HPTLC monitoring (hexane/EtOAc/CH
2Cl
2=1/1/2).After stirring 6.5h, in mixture, add TrisNHNH again
2(26.7mg, 89.6 μ mol) and Et
3N (12.5 μ L, 89.6 μ mol).After stirring 14h, this mixture is cooled to room temperature, filters with the EtOAc dilution and by the silicagel pad of washing with EtOAc.After concentrating, residue is with preparing TLC (hexane/EtOAc/CH
2Cl
2=1/1/2) to provide reductive product (1.16mg, 2.13 μ mol, 94%) be white solid to purification.
[α]
D 24-75.1 (c 0.35, CHCl
3); IR (film) ν 3483,2968,1337,1685,1466,1381,1322,1247,1168,1113,1010,833,736cm
-1 1H NMR (400MHz, CDCl
3) δ 1.03 (3H, d, J=7.0Hz), 1.08 (3H, s), 1.19 (3H, d, J=6.8Hz), 1.25-1.35 (2H, m), 1.37 (3H, s), 1.42-1.55 (2H, m), 1.65-1.82 (2H, m), 2.10 (3H, d, J=0.8Hz), and 2.21-2.47 (2H, m), 2.27 (1H, dd, J=14.2,2.6Hz), 2.48 (1H, dd, J=14.3,10.8Hz), 2.70 (3H, s), 2.70-2.28 (1H, m), 3.02 (1H, d, J=2.0Hz ,-OH), 3.19 (1H, qd, J=6.9,2.2Hz), 3.65 (1H, d, J=6.2Hz,-OH), and 3.69-3.72 (1H, m), 4.34 (1H, ddd, J=10.8,6.2,2.6Hz), 5.28 (1H, dd, J=10.2,2.2Hz), 6.12 (1H, dd, J=10.2,5.2Hz), 6.61 (1H, s), 6.98 (1H, s);
13CNMR (100MHz, CDCl
3) δ 13.0,15.9,16.0,17.7,19.1,23.0,25.6,26.2,31.3,32.3,37.4,39.8,41.6,53.9,72.3,73.6,77.7,116.2,119.9,124.3[q,
1J (C, F)=274.4Hz], 129.8[q,
3J (C, F)=6.1Hz], 132.6[q,
2J (C, F)=27.8Hz], 138.3,151.7,165.4,170.2,220.7; LRMS (ESI) C
27H
39F
3NO
5S[M+H
+] value of calculation 546.3, experiment value 546.2; HRMS C
27H
39F
3NO
5S[M+H
+] value of calculation 546.2501, experiment value 544.2496.
With acid and alcohol and anhydrous benzene (3mL * 2) azeotropic and dry under fine vacuum before reaction.Under 0 ℃ to alcohol (68.0mg, CH 0.173mmol)
2Cl
2(1.3mL) add in the solution EDCI (37.8mg, 0.197mmol) and DMAP (24.1mg, 0.197mmol).Under 0 ℃, in 5min, in mixture, drip acid (72.6mg, CH 0.123mmol)
2Cl
2(0.7mL) solution.After stirring 1h under 0 ℃, this mixture is at room temperature stirred 2.5h.After concentrating, with residue with hurried column chromatography (SiO
2, hexane/EtOAc=30: 1) purification is a colorless oil to ester output (99.5mg, 0.114mmol is by tert-butyl ester meter 92%).
[α]
D 25-23.4 (c 0.56, CHCl
3); IR (film) ν 2955,2931,2880,1735,1696,1506,1472,1386,1362,1294,1254,1174,1104,988,878,776,742cm
-1 1H NMR (400MHz, CDCl
3) δ 0.06 (3H, s), 0.06 (3H, s), 0.14 (6H, s), 0.63 (6H, q, J=8.0Hz), 0.92 (9H, s), 0.94 (9H, t, J=8.0Hz), 0.97 (9H, s), 1.02 (3H, d, J=6.6Hz), 1.05 (3H, d, J=6.5Hz), 1.07 (3H, s), 1.21 (3H, s), 1.67 (3H, s), 2.06 (3H, d, J=0.8Hz), and 2.05-2.14 (1H, m), 2.30 (1H, dd, J=16.9,7.5Hz), 2.33-2.53 (2H, m), 2.50 (1H, dd, J=16.9,2.7Hz), 2.76-2.80 (2H, m), 3.07 (1H, quintet, J=7.0Hz), 3.83 (1H, dd, J=7.0,2.2Hz), 4.35 (1H, dd, J=7.4,2.8Hz), 4.97 (2H, s), 4.97-5.07 (4H, m), 5.16 (1H, t, J=7.2Hz), 5.24 (1H, t, J=6.9Hz), 5.74 (1H, ddt, J=16.6,10.0,6.5Hz), 5.91 (1H, ddd, J=17.6,9.9,7.7Hz), 6.50 (1H, s), 7.06 (1H, s);
13C NMR (100MHz, CDCl
3) δ-5.2 (2C) ,-3.7 ,-3.3,5.3 (3C), 7.2 (3C), 14.7,15.2,18.5,18.7,18.9,20.3,23.6,23.7,26.0 (3C), 26.4 (3C), 31.7,36.7,40.1,43.8,46.4,53.3,63.4,74.2,76.5,79.6,115.5,115.6,116.6,120.5,121.3,135.8,136.1,137.4,140.1,153.0,171.5,172.2,218.4; LRMS (ESI) C
47H
86NO
6SSi
3[M+H
+] value of calculation 876.6, experiment value 876.5; HRMS C
47H
86NO
6SSi
3[M+H
+] value of calculation 876.5484, experiment value 876.5482.
Toluene (158mL) solution of diene (69.7mg, 79.5 μ mol) is heated to refluxes and with toluene (2mL) solution-treated of Grubbs catalyst (6.7mg, 7.95 μ mol).This mixture is stirred 11min, be cooled to 0 ℃, filter by the silicagel pad of washing with hexane/EtOAc=3/1 (280mL).The filtrate that merges concentrated and by hurried column chromatography (SiO
2, hexane/Et
2O=20: 1 to 15: 1) purification provides product (18.4mg, 21.7 μ mol, 27%) and the cycloheptadiene (28.3mg, 45.5 μ mol, 57%) wanted and is colorless oil.
[α]
D 24-40.4 (c 0.26, CHCl
3); IR (film) ν 2955,2930,2879,1740,1694,1472,1387,1362,1253,1200,1107,1007,838,776,742cm
-1 1HNMR (400MHz, CDCl
3) δ 0.08 (3H, s), 0.12 (3H, s), 0.15 (6H, s), 0.57 (6H, q, J=7.9Hz), 0.88 (9H, t, J=8.0Hz), 0.95 (9H, s), 0.97 (9H, s), 1.04 (3H, s), 1.06 (3H, d, J=7.1Hz), 1.12 (3H, s), 1.17 (3H, d, J=7.0Hz), 1.69 (3H, s), 2.06-2.30 (2H, m), 2.14 (3H, s), 2.45 (1H, dd, J=15.6,3.6Hz), 2.50 (1H, dd, J=14.9,3.1Hz), 2.63-2.75 (2H, m), 2.97-3.06 (1H, m), 3.10 (1H, dd, J=14.6,7.7Hz), 3.97 (1H, d, J=8.5Hz), 4.44 (1H, dd, J=8.4,2.9Hz), 4.97 (2H, s), 5.22 (1H, dd, J=8.7,5.2Hz), 5.33-5.44 (2H, m), 5.70 (1H, dd, J=15.6,8.1Hz), 6.57 (1H, s), 7.07 (1H, s);
13C NMR (125MHz, CDCl
3) δ-5.2 ,-3.3 ,-3.2,5.6,7.2,7.3,15.0,17.2,18.5,18.8,21.4,23.9,24.4,26.0,26.5,33.3,35.6,41.4,41.8,48.2,54.0,63.5,74.4,78.1,79.3,116.6,120.6,121.0,129.3,132.1,137.8,137.9,153.0,170.7,172.3,216.8; LRMS (ESI) C
45H
82NO
6SSi
3[M+H
+] value of calculation 848.5, experiment value 848.5; HRMS (ESI) C
45H
82NO
6SSi
3[M+H
+] value of calculation 848.5171, experiment value 848.516l.
Under 0 ℃, in THF (2mL) solution of the silyl ether in plastic tube (61.8mg, 72.8 μ mol), add HF pyridine (1mL), this mixture is at room temperature stirred 3.2h.Drip TMSOMe (15mL) cancellation reaction down at 0 ℃.At room temperature stir this mixture 2h.Concentrate and after high vacuum dry, with residue by hurried column chromatography (SiO
2, hexane/EtOAc=1: 3) purification, providing triol (32.4mg, 64.1 μ mol, 88%) is white solid.
[α]
D 25-108.4 (c 0.285, CHCl
3); IR (film) ν 3422,2968,2919,2729,1689,1449,1377,1252,1152,1064,978cm
-1 1H NMR (400MHz, CDCl
3) δ 1.05 (3H, s), 1.12 (3H, d, J=6.9Hz), 1.22 (3H, d, J=6.8Hz), 1.32 (3H, s), 1.72 (3H, s), 2.08 (3H, s), 2.31-2.40 (3H, m), 2.43 (1H, dd, J=15.5,3.5Hz), 2.49 (1H, dd, J=15.5,9.5Hz), 2.55-2.67 (2H, m), 2.95 (1H, dd, J=14.6,6.3Hz), 3.13 (1H, quintet, J=6.6Hz), 3.34 (1H, brs ,-OH), 3.75 (1H, dd, J=6.6,2.4Hz), 4.06 (1H, brs,-OH), 4.33 (1H, dd, J=9.4,3.0Hz), 4.92 (2H, s), 5.18 (1H, t, J=6.9Hz), 5.33 (1H, dd, J=8.0,2.5Hz), 5.52 (1H, dd, J=15.8,6.4Hz), 5.59 (1H, ddd, J=15.8,6.6,5.0Hz), 6.63 (1H, s), 7.13 (1H, s);
13CNMR (100MHz, CDCl
3) δ 15.3,16.3,17.8,19.2,22.8,23.7,31.9,35.1,39.7,40.2,45.0,53.4,61.8,71.7,75.8,78.1,116.7,119.0,120.5,130.0,131.2,137.6,138.9,152.5,170.0,170.7,218.7; LRMS (ESI) C
27H
39NO
6SNa[M+Na
+] value of calculation 528.2, experiment value 528.0; HRMS C
27H
40NO
6S[M+H
+] value of calculation 506.2576, experiment value 506.2552.
Will thick acid (4.65g is equivalent to 7.27mmol) and alcohol (2.18g, 9.84mmol) and the anhydrous benzene azeotropic, dry 20min under the fine vacuum before reaction then.Under 0 ℃ to alcohol (2.18g, CH 9.84mmol)
2Cl
2(65mL) add in the solution EDCI (2.09g, 10.9mmol) and DMAP (1.33g, 10.9mmol).Under 0 ℃, in 20min, in mixture, drip the CH of thick acid (4.65g is equivalent to 7.27mmol)
2Cl
2(20mL+5mL flushing) solution.After stirring 40min under 0 ℃, this mixture is at room temperature stirred 4h.After concentrating, with residue with hurried column chromatography (SiO
2~160g, hexane/EtOAc=20: 1) purification is a colorless oil to ester output (4.85mg, 6.87mmol is from tert-butyl ester meter 94%).
[α]
D 25-22.7 (c 0.26, CHCl
3); IR (film) ν 2958,2936,2800,1748,1732,1693,1473,1416,1360,1317,1296,1254,1174,1119,989,916,872,838,776cm
-1 1H NMR (400MHz, CDCl
3) δ 0.08 (3H, s), 0.08 (3H, s), 0.60 (6H, q, J=7.8Hz), 0.93 (9H, s), 0.94 (9H, t, J=8.0Hz), 1.04 (3H, d, J=7.0Hz), 1.04 (3H, d, J=7.0Hz), 1.11 (3H, s), 1.23 (3H, s), 2.05-2.14 (1H, m), 2.17 (3H, s), 2.40 (1H, dd, J=16.9,7.0Hz), 2.59 (1H, dd, J=17.0,3.6Hz), 2.56-2.64 (2H, m), and 2.90-3.01 (2H, m), 3.06 (1H, quintets, J=7.0Hz), 3.85 (1H, dd, J=7.3,2.0Hz), 4.38 (1H, d, J=7.0,3.4Hz), 4.97-5.14 (5H, m), 5.75 (1H, ddt, J=16.0,9.9,6.2Hz), 5.92 (1H, ddd, J=17.8,10.5,7.8Hz), 6.21 (1H, td, J=7.2,1.5Hz);
13C NMR (100MHz, CDCl
3) δ-3.7 ,-3.4,5.2 (3C), 7.1 (3C), 15.4,18.7,18.9,19.5,23.9,26.3 (3C), and 26.6,28.5,30.0,39.8,43.7,46.3,53.3,73.6,76.5,77.1,115.6,117.8,124.0[q,
1J (C, F)=273.5Hz], 129.2[q,
3J (C, F)=6.1Hz], 130.6[q,
2J (C, F)=28.7Hz], 133.4,140.0,171.8,204.6,218.4; LRMS (ESI) C
36H
63F
3O
6Si
2Na[M+Na
+] value of calculation 727.4, experiment value 727.3; HRMS C
36H
64F
3O
6Si
2[M+H
+] value of calculation 705.4194, experiment value 705.4193.
(510.0mg, toluene 0.723mmol) (500mL) solution are heated to and reflux and with Grubbs catalyst (92.1mg, toluene 0.109mmol) (10mL) solution-treated with diene.This mixture is being stirred 17min and is being cooled to 0 ℃ and remain on 0 ℃ before filtering by silicagel pad immediately under the reflux state.Second batch of diene (510.0mg, 0.723mmol) same processing simultaneously.The reactant mixture that merges filters by the silicagel pad (100g) of washing with hexane/EtOAc=3/1 (1.4L).The filtrate that merges concentrated and by hurried column chromatography (SiO
2~65g, hexane/Et
2O=10: 1 to 5: 1) to provide macrolide (742.4mg, 1.10mmol, 76%) be colourless amorphous grease to purification.
[α]
D 25-7.5 (c 0.12, CHCl
3); IR (film) ν 2956,2979,1748,1732,1695,1472,1415,1384,1252,1170,1119,1018,986,876,835cm
-1 1HNMR (400MHz, CDCl
3) δ 0.08 (3H, s), 0.10 (3H, s), 0.60 (6H, q, J=7.8Hz), 0.93 (9H, s), 0.94 (9H, t, J=7.8Hz), 1.03 (3H, d, J=7.1Hz), 1.08 (3H, s), 1.13 (3H, d, J=7.0Hz), 1.17 (3H, s), 2.26 (3H, s), 2.25-2.34 (1H, m), 2.64 (1H, dd, J=15.5,5.0Hz), 2.68-2.75 (2H, m), 2.76 (1H, dd, J=15.6,6.4Hz), 2.85 (1H, dd, J=15.6,5.7Hz), 2.97 (1H, dq, J=8.3,6.9Hz), 3.04 (1H, dd, J=15.6,6.3Hz), 3.92 (1H, dd, J=8.3,1.2Hz), 4.36 (1H, t, J=5.3Hz), and 5.30-5.39 (2H, m), 5.58 (1H, dd, J=15.5,8.0Hz), 6.13 (1H, brt, J=7.2Hz);
13C NMR (100MHz, CDCl
3) δ-3.6 ,-3.6,5.4 (3C), 7.0 (3C), 17.5,18.5,19.0,21.6,23.5,26.3 (3C), and 26.5,28.6,29.1,41.0,42.3,47.3,54.1,74.2,76.8,77.7,124.0[q,
1J (C, F)=273.7Hz], 126.0,128.7[q,
3J (C, F)=5.9Hz], 132.2[q,
2J (C, F)=28.1Hz], 133.8,170.5,204.1,216.1; LRMS (ESI) C
34H
59F
3O
6Si
2Na[M+Na
+] value of calculation 699.4, experiment value 699.4; HRMS C
34H
60F
3O
6Si
2[M+H
+] value of calculation 677.3881, experiment value 677.3892.
Through Wittig reaction: with ketone and benzene (5mL * 2) azeotropic dry 0.5h under fine vacuum then.Under 0 ℃ in 5min to Wittig salt (907mg, drip in THF 2.59mmol) (19mL) solution t-BuOK (the THF solution of the 1.0M of 2.4mL, 2.43mmol).Under 0 ℃, this mixture is stirred 0.5h and be cooled to-78 ℃ then.(1.10g, THF 1.62mmol) (13mL) solution are warmed to-20 ℃ with the mixture that obtains in 2h to drip ketone in 10min in this mixture.Use saturated NH
4Cl aqueous solution (15mL) cancellation should be reacted and be extracted (50mL * 3) with EtOAc.The organic layer that merges is with saline (20mL) washing, through Na
2SO
4Dry and concentrated.Residue is with hurried column chromatography (SiO
2, hexane/Et
2O=20: 1 to 10: 1) purification provides 16 (E)-isomers (940mg, 1.22mmol, 75%) and undesired 16 (the Z)-isomers (140.9mg, 0.182mmol, 11%) wanted and is colourless amorphous grease.
[α]
D 2562.7 (c 0.33, CHCl
3); IR (film) ν 2955,2878,1743,1692,1472,1379,1320,1253,1169,1114,1007,956,877,835,775cm
-1 1HNMR (400MHz, CDCl
3) δ 0.09 (3H, s), 0.13 (3H, s), 0.49 (6H, q, J=7.8Hz), 0.85 (9H, t, J=7.8Hz), 0.97 (9H, s), 0.99 (3H, s), 1.06 (3H, d, J=7.1Hz), 1.11 (3H, s), 1.20 (3H, d, J=7.1Hz), 2.00 (3H, s), 2.03-2.13 (1H, m), 2.35 (1H, dd, J=14.3,3.0Hz), 2.46 (1H, dd, J=14.3,7.8Hz), 2.41-2.50 (1H, m), 2.73 (3H, s), 2.71-2.90 (2H, m), 2.98-3.12 (2H, m), 3.99 (1H, d, J=9.2Hz), 4.56 (1H, dd, J=7.7,2.8Hz), 5.33 (1H, ddd, J=15.6,8.9,4.1Hz), 5.82 (1H, dd, J=15.6,8.4Hz), 6.29 (1H, s), 6.33-6.40 (1H, m), 6.94 (1H, m), 7.09 (1H, brd, J=8.4Hz);
13C NMR (100MHz, CDCl
3) δ-3.2 ,-3.2,5.5 (3C), 7.0 (3C), 17.2,18.7,19.3,19.6,20.0,22.3,24.9,26.4 (3C), and 29.7,32.9,41.9,42.0,48.6,54.0,72.2,73.3,77.0,116.7,120.7,124.5[q,
1J (C, F)=273.3Hz], 127.9,129.7[q,
2J (C, F)=28.0Hz], 131.9[q,
3J (C, F)=6.1Hz], 132.9,136.6,152.1,165.4,170.2,217.4; LRMS (ESI) C
39H
65F
3NO
5SSi
2[M+H
+] value of calculation 772.4, experiment value 772.4; HRMS C
39H
65F
3NO
5SSi
2[M+H
+] value of calculation 772.4074, experiment value 772.4044.
CH with deH-dEpoB (12.2mg, 24.9 μ mol)
2Cl
2(1.25mL) solution is cooled to-78 ℃ and handle with refrigerative DMDO solution (78 ℃, 0.06M in the acetone, 914 μ l, 54.8 μ mol).This mixture is warmed to-50 ℃ and stir down 2.7h at-50 ℃.Excessive DMDO passes through to add dimethyl sulfide (117 μ l) and cancellation down at-50 ℃, and this mixture is stirred 0.5h under this temperature.Remove under the vacuum and desolvate.(hexane/EtOAc=1/2) purification provides beta epoxide thing (3.0mg, 5.93 μ mol, 24%) and α-epoxide (7.9mg, 15.6 μ mol, 63%), is colorless solid with the preparation thin layer chromatography.
[α]
D 25-78.5 (c 0.33, CHCl
3); IR (film) ν 3454,2974,2928,1734,1689,1450,1379,1250,1152,1061,978,735cm
-1 1H NMR (400MHz, CDCl
3) δ 1.03 (3H, s), 1.11 (3H, d, J=7.0Hz), 1.14 (3H, d, J=6.9Hz), 1.34 (3H, s), 1.36 (3H, s), 2.00 (1H, ddd, J=15.1,7.3,4.0Hz), 2.14 (1H, dt, J=15.1,5.2Hz), 2.14 (3H, s), 2.21 (1H, dd, J=14.6,8.0Hz), 2.33 (1H, dd, J=14.7,4.8Hz), 2.47 (1H, dd, J=13.8,3.3Hz), 2.59 (1H, dd, J=13.8,9.4Hz), 2.73 (3H, s), 2.77 (1H, brs, OH), 2.93 (1H, dd, J=7.3,4.8Hz), 3.34 (1H, qd, J=6.9,3.8Hz), 3.75-3.82 (1H, m), (4.12-4.24 2H, m comprise OH), 5.54 (1H, ddd, J=15.7,7.4,5.0Hz), and 5.54-5.60 (1H, m), 5.64 (1H, dd, J=15.7,5.6Hz), 6.94 (1H, s), 7.01 (1H, s);
1H NMR (500MHz, CD
2Cl
2) δ 0.91 (3H, s), 1.01 (3H, d, J=6.9Hz), 1.03 (3H, d, J=6.9Hz), 1.22 (3H, s), 1.27 (3H, s), 1.96-2.02 (1H, m), 2.04 (3H, d, J=0.7Hz), 2.16-2.23 (2H, m), 2.33 (1H, dd, J=14.2,3.1Hz), 2.30-2.35 (1H, m), 2.44 (1H, dd, J=14.4,10.3Hz), 2.69 (3H, s), 2.77 (1H, t, J=5.9Hz), 3.24 (1H, qd, J=6.9,4.5Hz), 3.63 (1H, t, J=4.1Hz), and 4.18-4.26 (1H, m), 5.37 (1H, t, J=4.5Hz), 5.48 (1H, dtd, J=15.7,6.7,0.5Hz), 5.58 (1H, dd, J=15.7,6.2Hz), 6.58 (1H, s), 7.00 (1H, s);
13C NMR (100MHz, CDCl
3) δ 14.4,16.3 (2C), 19.3,19.7,21.6,22.6,31.8,35.9,38.7,39.6,44.1,52.8,60.8,61.8,74.0,75.7,75.9,116.5,119.6,124.3,135.8,136.2,152.1,165.2,170.8,221.5; LRMS C
27H
40NO
6S[M+H
+] value of calculation 506.3, experiment value 506.3; HRMS (ESI) C
27H
40NO
6S[M+H
+] value of calculation 506.2576, experiment value 506.2566.
[α]
D 25-53.9 (c 0.700, CHCl
3); IR (film) ν 3460,2976,2928,1735,1688,1506,1451,1378,1252,1186,1151,1087,1042,976,879,735cm
-1 1H NMR (400MHz, CDCl
3) δ 1.00 (3H, s), 1.04 (3H, d, J=6.9Hz), 1.12 (3H, d, J=7.0Hz), 1.35 (3H, s), 1.35 (3H, s), 1.87 (1H, dt, J=15.0,9.2Hz), 2.03 (1H, dd, J=13.9,9.2Hz), 2.13 (3H, s), 2.13-2.19 (1H, m), 2.36 (1H, dd, J=13.9,3.4Hz), 2.39 (1H, dd, J=12.2,2.1Hz), 2.42-2.51 (1H, m), 2.49 (1H, dd, J=12.4,10.9Hz), 2.69 (1H, d, J=2.7Hz), 2.72 (3H, s), 3.06 (1H, dd, J=9.7,3.1Hz), 3.54 (1H, q d, J=7.0,1.8Hz), 3.76-3.80 (1H, m), 4.07-4.14 (1H, m), 4.31 (1H, d, J=4.1Hz), 5.52 (1H, dd, J=15.5,8.7Hz), 5.60 (1H, ddd, J=15.1,9.4,3.4Hz), 5.71 (1H, d, J=8.4Hz), 6.63 (1H, s), 6.99 (1H, s);
13CNMR (100MHz, CDCl
3) δ 13.7,15.3,15.7,18.5,19.4,21.2,22.4,32.5,35.5,39.1,43.4,43.8,51.9,61.3,64.8,73.5,75.9,76.4,116.7,120.1,124.3,137.5,137.7,152.3,165.2,171.0,222.3; LRMS (ESI) C
27H
39NO
6SNa[M+Na
+] value of calculation 528.2, experiment value 528.2; HRMS C
27H
40NO
6S[M+H
+] value of calculation 506.2576, experiment value 506.2583.
Under 50 ℃ to epoxide (0.7mg, 1.38 μ mol) and TrisNHNH
2The ClCH of (20.6mg, 69 μ mol)
2CH
2Add Et in Cl (0.4mL) solution
3N (9.6 μ L, 69 μ mol).Reaction is by HPTLC monitoring (hexane/EtOAc=1/2).After stirring 6h, this mixture is cooled to room temperature, filters with the EtOAc dilution and by the silicagel pad of washing with EtOAc.After concentrating, (it is white solid that the purification of hexane/EtOAc=1/2) provides reductive product (0.5mg, 0.985 μ mol, 71%) to residue with preparing TLC.
The spectroscopic data of this chemical compound is identical with the spectrum of the dEpoB that has reported.
Under 50 ℃ to epoxide (14.0mg, 27.7 μ mol) and TrisNHNH
2(165mg, ClCH 0.554mmol)
2CH
2Add Et in Cl (3.3mL) solution
3N (77.0 μ L, 0.554mmol).Reaction is by HPTLC monitoring (hexane/EtOAc=1/2).After stirring 6h, this mixture is cooled to room temperature, filters with the EtOAc dilution and by the silicagel pad of washing with EtOAc.After concentrating, (it is colorless solid that the purification of hexane/EtOAc=1/2) provides reductive product (12.3mg, 24.2 μ mol, 87%) to residue with preparing TLC.
[α]
D 24-13.8 (c 0.61, CHCl
3); IR (film) ν 3475,2971,2875,1735,1689,1456,1382,1253,1181,1151,1056,980,884,735cm
-1 1HNMR (400MHz, CDCl
3) δ 0.95 (3H, d, J=7.1Hz), 1.04 (3H, s), 1.11 (3H, d, J=7.0Hz), 1.28 (3H, s), 1.37 (3H, s), 1.25-1.44 (2H, m), 1.45-1.59 (2H, m), 1.71-1.82 (3H, m), 1.86 (1H, dt, J=15.3,9.5Hz), 2.10 (1H, dd, J=15.3,3.6Hz), 2.13 (3H, s), 2.40 (1H, dd, J=12.5,2.5Hz), 2.49 (1H, dd, J=12.5,11.0Hz), 2.74 (3H, s), 2.80 (1H, brs, OH), 3.07 (1H, dd, J=10.3,3.3Hz), 3.34 (1H, qd, J=7.0,0.5Hz), 3.89 (1H, brs, OH), 4.03-4.09 (1H, m), and 4.12-4.17 (1H, m), 5.69 (1H, d, J=9.1Hz), 6.63 (1H, s), 7.00 (1H, s);
13CNMR (100MHz, CDCl
3) δ 12.9,15.4,16.3,18.8,19.3,21.6,22.0,23.0,31.5,32.1,33.6,38.6,38.9,42.6,51.7,62.6,65.5,71.2,74.5,76.3,116.6,119.9,138.0,152.2,165.2,170.6,222.7; LRMS (ESI) C
27H
41NO
6SNa[M+Na
+] value of calculation 530.3, experiment value 530.2; HRMS C
27H
42NO
6S[M+H
+] value of calculation 508.2733, experiment value 508.2754.
With ketone and benzene (5mL * 2) azeotropic dry 0.5h under fine vacuum then.Under 0 ℃ in 5min to Wittig salt (1.19g, drip in THF 2.27mmol) (18mL) solution t-BuOK (the THF solution of the 1.0M of 2.2 L, 2.20mmol).Under 0 ℃, this mixture is stirred 20min and is cooled to-78 ℃ then.(1.06g, THF 1.51mmol) (10mL+2mL flushing) solution is warmed to-20 ℃ with the mixture that obtains in 2h to drip ketone in 10min in this mixture.Use saturated NH
4Cl aqueous solution (15mL) cancellation should be reacted and be extracted (50mL * 3) with EtOAc.The organic layer that merges is with saline (20mL) washing, through Na
2SO
4Dry and concentrated.Residue is with hurried column chromatography (SiO
2~65g, hexane/Et
2O=30: 1 to 20: 1) purification provides 16 (E)-isomers (1.01g, 1.11mmol, 74%) and undesired 16 (the Z)-isomers (154.5mg, 0.182mmol, 11%) wanted and is colourless amorphous grease.
[α]
D 24-19.0 (c 0.10, CHCl
3); IR (film) ν 2954,2930,2880,1744,1692,1472,1381,1321,1252,1171,1114,1038,1006,837,776cm
-1 1HNMR (400MHz, CDCl
3) δ 0.09 (3H, s), 0.12 (3H, s), 0.15 (6H, s), 0.55 (6H, q, J=7.8Hz), 0.87 (9H, t, J=8.0Hz), 0.96 (9H, s), 0.97 (9H, s), 1.01 (3H, s), 1.06 (3H, d, J=7.1Hz), 1.12 (3H, s), 1.20 (3H, d, J=7.1Hz), 2.07-2.16 (1H, m), 2.18 (3H, d, J=1.0Hz), 2.38 (1H, dd, J=14.4,3.3Hz), 2.34-2.46 (1H, m), 2.49 (1H, dd, J=14.4,7.4Hz), 2.78-2.90 (2H, m), 2.97-3.09 (2H, m), 3.98 (1H, d, J=8.9Hz), 4.54 (1H, dd, J=7.3,3.3Hz), 4.97 (2H, s), 5.33 (1H, ddd, J=15.8,8.6,4.9Hz), 5.63 (1H, dd, J=9.6,2.4Hz), 5.78 (1H, dd, J=15.8,8.2Hz), 6.22-6.27 (1H, m), 6.60 (1H, s), 7.09 (1H, s);
13C NMR (100MHz, CDCl
3) δ-5.3 (2C) ,-3.4 ,-3.3,5.5 (3C), 7.0 (3C), 14.6,17.1,18.4,18.7,19.8,21.3,24.8,25.9 (3C), 26.4 (3C), 29.6,32.9,42.0,42.1,48.2,54.1,63.4,73.4,76.9,77.8,117.2,121.7,124.3[q
1J (C, F)=273.6Hz], 127.2,130.7[q,
2J (C, F)=27.5Hz], 130.8[q,
3J (C, F)=6.2Hz], 133.2,136.4,152.6,170.1,172.4,217.1; LRMS (ESI) C
45H
78F
3NO
6SSi
3Na[M+Na
+] value of calculation 924.5, experiment value 924.5; HRMS C
45H
79F
3NO
6SSi
3[M+H
+] value of calculation 902.4888, experiment value 902.4887.
[α]
D 2665.7 (c 1.76, CHCl
3); IR (film) ν 2955,2931,2879,1743,1692,1472,1380,1321,1253,1170,1113,1007,836,776cm
-1 1HNMR (400MHz, CDCl
3) δ 0.07 (3H, s), 0.13 (3H, s), 0.16 (6H, s), 0.48 (6H, q, J=7.8Hz), 0.84 (9H, t, J=7.9Hz), 0.97 (18H, s), 0.98 (3H, s), 1.06 (3H, d, J=7.1Hz), 1.11 (3H, s), 1.20 (3H, d, J=7.2Hz), 2.00 (3H, s), 2.03-2.11 (1H, m), 2.33 (1H, dd, J=14.1,2.8Hz), 2.43 (1H, dd, J=14.0,7.8Hz), 2.40-2.48 (1H, m), 2.76-2.89 (2H, m), and 2.97-3.10 (2H, m), 3.99 (1H, d, J=9.3Hz), 4.57 (1H, dd, J=7.8,2.6Hz), 4.95 (1H, d, J=14.6Hz), 5.00 (1H, d, J=14.6Hz), 5.33 (1H, ddd, J=15.6,9.1,3.8Hz), 5.82 (1H, dd, J=15.6,8.3Hz), 6.30 (1H, s), 6.32-6.38 (1H, m), 7.04 (1H, s), 7.11 (1H, dd, J=11.0,2.3Hz);
13C NMR (100MHz, CDCl
3) δ-5.3 (2C) ,-3.2 ,-3.2,5.5 (3C), 7.0 (3C), 17.2,18.4,18.8,19.3,19.8,22.4,25.1,25.9 (3C), 26.5 (3C), 29.7,33.0,41.9,42.1,48.6,54.0,63.5,72.1,73.3,76.9,117.0,120.8,124.5[q
1J (C, F)=273.5Hz], 127.9,129.7[q,
2J (C, F)=27.6Hz], 131.9[q,
3J (C, F)=6.1Hz], 132.9,136.4,152.4,170.1,172.9,217.5; LRMS (ESI) C
45H
78F
3NO
6SNa[M+Na
+] value of calculation 924.5, experiment value 924.5.
(1.04g slowly adds HF pyridine (11mL) in THF 2.25mmol) (22mL) solution, this mixture is at room temperature stirred 4.3h to the silyl ether in plastic tube under 0 ℃.Under 0 ℃, in 10min, drip TMSOMe (75mL) cancellation reaction.This mixture of vigorous stirring 4.2h at room temperature.Concentrate and behind high vacuum dry 1h, with residue by hurried column chromatography (SiO
2~25g, hexane/EtOAc=3: 4 to 1: 2) purification, providing triol (615.7mg, 1.00mmol, 96%) is colourless powder.
[α]
D 25-57.7 (c 1.20, CHCl
3); IR (film) ν 3441,2974,2932,1734,1685,1507,1456,1374,1318,1248,1169,1112,1054,982,888,737cm
-1 1HNMR (400MHz, CDCl
3) δ 1.04 (3H, s), 1.12 (3H, d, J=6.9Hz), 1.25 (3H, d, J=6.8Hz), 1.36 (3H, s), 1.90 (1H, d, J=6.6Hz, OH), 2.08 (3H, s), 2.23-2.32 (1H, m), 2.34 (1H, dd, J=15.7,2.4Hz), 2.49 (1H, d d, J=15.7,10.1Hz), 2.59-2.69 (2H, m), 2.95-3.01 (2H, m), 3.04 (1H, quintet, J=6.8Hz), 3.72 (1H, td, J=7.0,3.0Hz), 3.78 (1H, d, J=5.7Hz, OH), 4.38 (1H, ddd, J=10.1,5.7,2.4Hz), 4.90 (2H, d, J=6.1Hz), 5.10 (1H, t, J=6.1Hz, OH), 5.44 (1H, t, J=4.7Hz), 5.60 (1H, dd, J=15.9,4.4Hz), 5.66 (1H, dd, J=15.9,5.0Hz), 6.28 (1H, t, J=6.7Hz), 6.73 (1H, s), 7.16 (1H, s);
13C NMR (100MHz, CDCl
3) δ 16.0,16.5,17.4,17.5,22.9,28.5,30.3,39.0,39.6,45.6,54.0,60.9,70.6,75.6,75.7,116.8,119.2,124.2[q,
1J (C, F)=273.6Hz], 127.9,129.8[q,
2J (C, F)=28.4Hz], 130.3[q,
3J (C, F)=5.9Hz], 131.2,137.0,152.2,169.8,170.0,218.3; LRMS (ESI) C
27H
37F
3NO
6SNa[M+H
+] value of calculation 560.2, experiment value 560.1; HRMS C
27H
37F
3NO
6S[M+H
+] value of calculation 560.2294, experiment value 560.2299.
Under 0 ℃, in THF (1mL) solution of the silyl ether in plastic tube (42.8mg, 55.4 μ mol), slowly add HF pyridine (0.5mL), and this mixture is at room temperature stirred 4.3h.Under 0 ℃, in 10min, drip TMSOMe (3.2mL) cancellation reaction.This mixture of vigorous stirring 1.5h at room temperature.Concentrate and behind high vacuum dry 1h, with residue by hurried column chromatography (SiO
2, hexane/EtOAc=1: 1) purification, providing glycol (23.6mg, 43.4 μ mol, 78%) is colorless oil.
[α]
D 2531.6 (c 1.00, CHCl
3); IR (film) ν 2955,2878,1743,1692,1471,1379,1320,1253,1169,1114,1007,877,835,741cm
-1 1HNMR (400MHz, CDCl
3) δ 1.04 (3H, s), 1.11 (3H, d, J=6.9Hz), 1.20 (3H, d, J=6.9Hz), 1.30 (3H, s), 1.93 (3H, brs), 2.22 (1H, d, J=4.3Hz, OH), 2.25-2.33 (1H, m), and 2.38-2.41 (2H, m), 2.51-2.59 (2H, m), 2.70 (3H, s), 2.80-2.90 (1H, m), 2.94 (1H, dd, J=15.6,4.7Hz), 3.06 (1H, dd, J=15.6,7.4Hz), 3.19 (1H, quintet, J=6.6Hz), 3.71-3.76 (1H, m), 4.26-4.32 (1H, m), 5.57 (1H, ddd, J=15.8,7.2,5.0Hz), 5.67 (1H, dd, J=15.8,6.8Hz), 6.27 (1H, s), 6.33 (1H, dd, J=7.6,6.3Hz), 6.76 (1H, dd, J=8.3,2.9Hz), 6.94 (1H, s);
13CNMR (100MHz, CDCl
3) δ 14.5,17.9,19.2,19.5,19.8,22.2,28.7,32.4,39.8 (2C), 44.7,53.3,71.9,74.1,75.1,117.0,120.4,124.4[q,
1J (C, F)=272.7Hz], 128.4,130.1[q,
2J (C, F)=28.9Hz], 131.5[q,
3J (C, F)=5.9Hz], 133.0,136.9,152.2,165.5,170.7,218.5; LRMS (ESI) C
27H
36F
3NO
5SNa[M+Na
+] value of calculation 566.2, experiment value 566.3.
Under 0 ℃ to alcohol (18.9mg, 33.8 μ mol) and Et
3N (18.8 μ L, CH 0.135mmol)
2Cl
2(1mL) add TsCl (12.9mg, 67.5 μ mol) in the solution, add DMAP (2.1mg, 16.9 μ mol) subsequently.After stirring 1.5h under the room temperature, this mixture is filtered by silicagel pad (EtOAc flushing).After concentrating, (purification of hexane/EtOAc=1/1) provides tosylate (8.5mg, 11.9 μ mol, 35%) and chloride (4.3mg, 7.44 μ mol, 22%) is colourless powder with preparing TLC for residue.
1H NMR (400MHz, CDCl
3) δ 1.06 (3H, s), 1.12 (3H, d, J=7.0Hz), 1.23 (3H, d, J=6.7Hz), 1.33 (3H, s), 1.99 (1H, d, J=5.5Hz), 2.10 (3H, s), 2.25-2.34 (1H, m), 2.41 (1H, dd, J=15.5,3.3Hz), 2.47 (3H, s), 2.48 (1H, dd, J=15.7,9.4Hz), 2.51-2.63 (1H, m), 2.63 (1H, d, J=6.1Hz, OH), 2.64-2.75 (1H, m), 2.91-3.05 (2H, m), 3.10 (1H, quintet, J=6.8Hz), 3.70-3.75 (1H, m), 4.30 (1H, ddd, J=9.3,6.1,3.2Hz), 5.32 (2H, s), 5.41 (1H, dd, J=5.8,4.5Hz), 5.57 (1H, ddd, J=15.8,6.4,4.6Hz), 5.65 (1H, dd, J=15.8,6.0Hz), 6.21 (1H, t, J=7.1Hz), 6.59 (1H, s), 7.18 (1H, s), 7.37 (2H, d, J=8.1Hz), 7.84 (2H, d, J=8.3Hz); LRMS (ESI) C
34H
42F
3NO
8S
2Na[M+Na
+] value of calculation 736.2, experiment value 736.3.
IR (film) ν 3494,2975,2935,1734,1689,1319,1248,1170,1113,1040,979,738cm
-1 1H NMR (400MHz, CDCl
3) δ 1.06 (3H, s), 1.12 (3H, d, J=6.9Hz), 1.23 (3H, d, J=6.7Hz), 1.34 (3H, s), 2.00 (1H, d, J=5.6Hz, OH), 2.15 (3H, s), 2.25-2.35 (1H, m), 2.41 (1H, dd, J=15.5,3.2Hz), 2.49 (1H, dd, J=15.5,9.4Hz), 2.53-2.62 (1H, m), 2.69 (1H, d, J=6.1Hz, OH), 2.66-2.76 (1H, m), 2.92-3.05 (2H, m), 3.11 (1H, quintet, J=6.4Hz), 3.70-3.76 (1H, m), 4.32 (1H, ddd, J=9.2,5.9,3.1Hz), 4.85 (2H, s), 5.43 (1H, dd, J=6.0,4.4Hz), 5.59 (1H, ddd, J=15.9,6.4,4.5Hz), 5.66 (1H, dd, J=15.9,6.1Hz), 6.23 (1H, t, J=6.8Hz), 6.63 (1H, s), 7.20 (1H, s); LRMS (ESI) C
27H
35ClF
3NO
5SNa[M+Na
+] value of calculation 600.2, experiment value 600.2.
Under 0 ℃, in THF (1mL) solution of triol (50.4mg, 90.1 μ mol), add (PhO)
2PON
3(27.2 μ l, 0.126mmol).Behind the 5min, (16.2 μ l 0.108mmol), stir 2h with this mixture down at 0 ℃, at room temperature stir 20.5h then to add DBU.This mixture extracts (three times) with EtOAc dilution and water (2mL) cancellation with EtOAc, and the organic layer of merging is through Na
2SO
4Dry.After concentrating, residue is passed through hurried column chromatography (SiO
2, hexane/EtOAc=3: 2) purification, providing azide (45.6mg, 78 μ mol, 87%) is colourless powder.
[α]
D 24-60.3 (c 0.345, CHCl
3); IR (film) ν 3492,2975,2931,2105,1732,1688,1319,1248,1169,1113,982,733cm
-1 1H NMR (400MHz, CDCl
3) δ 1.05 (3H, s), 1.12 (3H, d, J=7.0Hz), 1.23 (3H, d, J=6.8Hz), 1.33 (3H, s), 2.01 (1H, d, J=5.5Hz, OH), 2.17 (3H, s), 2.25-2.35 (1H, m), 2.41 (1H, dd, J=15.5,3.2Hz), 2.49 (1H, dd, J=15.5,9.5Hz), 2.54-2.60 (1H, m), 2.66 (1H, d, J=6.0Hz), 2.65-2.76 (1H, m), 2.96 (1H, dd, J=16.0,4.2Hz), 3.03 (1H, dd, J=16.1,6.7Hz), 3.11 (1H, quintets, J=6.8Hz), and 3.71-3.76 (1H, m), 4.31 (1H, ddd, J=9.2,5.9,3.2Hz), 4.65 (2H, s), 5.43 (1H, dd, J=6.0,4.3Hz), 5.58 (1H, ddd, J=15.8,6.4,4.6Hz), 5.66 (1H, dd, J=15.8,6.1Hz), 6.23 (1H, t, J=7.3Hz), 6.63 (1H, s), 7.18 (1H, s);
13C NMR (100MHz, CDCl
3) δ 15.4,15.9,17.8,18.6,22.8,28.7,30.9,39.5,39.7,45.1,51.3,53.5,71.5,75.4,76.8,118.2,119.6,122.7[q,
1J (C, F)=273.6Hz], 127.9,130.0[q,
3J (C, F)=6.1Hz], 130.6[q,
2J (C, F)=27.9Hz], 132.3,137.2,153.1,163.9,170.0,218.3; LRMS (ESI) C
27H
35F
3N
4O
5SNa[M+Na
+] value of calculation 607.2, experiment value 607.2; HRMS C
27H
36F
3N
4O
5S[M+H
+] value of calculation 585.2359, experiment value 585.2344.
In DMF (0.4mL) solution of tosylate (8.9mg, 12.5 μ mol), add NaN
3(12.2mg, 0.188mmol).At room temperature stir 21h, the saturated NH of this mixture
4Cl (aqueous solution) cancellation is with EtOAc extraction (three times).After concentrating, (hexane/EtOAc=1: 1) to provide azide (6.9mg, 11.8 μ mol, 94%) be colourless powder to purification to residue with preparing TLC.
In THF (0.6mL) solution of azide (21.0mg, 35.9 μ mol), add PMe
3(1.0M in THF, 43.1 μ L, 43.1 μ mol).Behind the 2min, add entry (0.1mL) and mixture is at room temperature stirred 3h.Add more PMe
3(1.0M in THF, 7.2 μ L, 7.2 μ mol), and at room temperature mixture is stirred 1.5h.The NH of adding 28%
4OH aqueous solution (54.5 μ L).After stirring 1h under the room temperature, mixture is directly used preparation TLC (CH
2Cl
2/ MeOH=100: 7.5) to provide amine (15.9mg, 28.5 μ mol, 79%) be colourless powder to purification.
[α]
D 26-64.2 (c 0.815, CHCl
3); IR (film) ν 3504,3363,2975,2931,1733,1688,1450,1383,1318,1248,1169,1113,1054,984,736cm
-1 1HNMR (400MHz, CDCl
3) δ 1.05 (3H, s), 1.12 (3H, d, J=7.0Hz), 1.23 (3H, d, J=6.8Hz), 1.34 (3H, s), 2.12 (3H, d, J=0.7Hz), and 2.24-2.35 (1H, m), 2.39 (1H, dd, J=15.4,3.0Hz), 2.49 (1H, dd, J=15.4,9.8Hz), 2.54-2.63 (1H, m), and 2.66-2.76 (1H, m), 2.97 (1H, dd, J=16.2,4.2Hz), 3.03 (1H, dd, J=16.3,6.5Hz), 3.10 (1H, quintet, J=6.8Hz), 3.74 (1H, dd, J=6.7,3.5Hz), 4.18 (2H, s), 4.34 (1H, dd, J=9.8,2.9Hz), 5.43 (1H, dd, J=6.0,4.3Hz), 5.55-5.64 (1H, m), 5.67 (1H, dd, J=15.9,5.8Hz), 6.24 (1H, brt, J=7.3Hz), 6.66 (1H, s), 7.10 (1H, s);
13C NMR (100MHz, CDCl
3) δ 15.3,16.1,17.7,18.2,22.6,28.7,30.9,39.4,39.7,43.9,45.1,53.8,71.2,75.3,76.6,116.8,120.1,124.2[q,
1J (C, F)=273.5Hz], 127.8,130.2[q,
3J (C, F)=6.1Hz], 130.4[q,
2J (C, F)=28.6Hz], 132.2,136.6,152.3,170.1,172.7,218.4; LRMS (ESI) C
27H
38F
3N
2O
5S [M+H
+] value of calculation 559.2, experiment value 559.2; HRMSC
27H
38F
3N
2O
5S[M+H
+] value of calculation 559.2454, experiment value 559.2440.
CH to the amine that stirred (15.9mg, 28.5 μ mol)
3(37% aqueous solution, 31.4 μ L 0.143mmol), add NaBH subsequently to add HCHO in CN (0.78mL) solution
3CN (1.0M in THF, 85.5 μ L.85.5μmol)。20min at room temperature stirs the mixture.Add AcOH (1), 40min stirs the mixture under the room temperature.Mixture is directly used preparation TLC (CH
2Cl
2/ MeOH=100: 8) to provide dimethylamine (15.6mg, 26.6 μ mol, 93%) be colourless powder to purification.
[α]
D 24-49.9 (c 0.74, CHCl
3); IR (film) ν 3424,2974,1729,1689,1468,1318,1247,1169,1112,754cm
-1 1H NMR (400MHz, CDCl
3) δ 1.05 (3H, s), 1.12 (3H, d, J=6.9Hz), 1.23 (3H, d, J=6.8Hz), 1.33 (3H, s), 2.17 (3H, s), 2.24-2.35 (1H, m), 2.43 (1H, dd, J=15.7,3.6Hz), 2.49 (1H, dd, J=15.6,9.1Hz), 2.55-2.64 (2H, m comprise OH), 2.68-2.77 (1H, m), 2.80 (3H, s), 2.81 (3H, s), and 2.92-3.06 (2H, m), 3.10 (1H, quintets, J=6.8Hz), and 3.69-3.76 (1H, m), 4.25-4.34 (1H, m), 4.33 (2H, s), 5.42 (1H, t, J=5.5Hz), 5.57 (1H, dt, J=15.8,6.3Hz), 5.66 (1H, dd, J=15.7,6.4Hz), 6.22 (1H, brt, J=7.2Hz), 6.64 (1H, s), 7.30 (1H, s);
13C NMR (100MHz, CDCl
3) δ 15.3,15.8,17.8,18.8,22.3,28.8,30.9,39.6,39.6,45.2,49.7,49.7,53.4,61.5,71.7,75.4,77.4,119.2,120.2,124.2[q,
1J (C, F)=273.5Hz], 127.8,129.9[q,
3J (C, F)=6.2Hz], 130.7[q,
2J (C, F)=28.4Hz], 132.4,137.6,154.2,157.2,170.0,218.3; LRMS (ESI) C
29H
42F
3N
2O
5S[M+H
+] value of calculation 580.2, experiment value 580.2.
Fusing point; Two equal not re-crystallizations of sample, but pass through SiO
2Purification.
Claims (56)
1. the chemical compound of following formula and pharmacy acceptable derivates thereof:
R wherein
1Be hydrogen or low alkyl group;
R
2For replacing or unsubstituted aryl, heteroaryl, aralkyl or heteroarylalkyl part;
R
5And R
6Be hydrogen or blocking group independently of one another;
X is O, S, C (R
7)
2Or NR
7, the R under every kind of situation wherein
7Be hydrogen or low alkyl group independently;
A-B represents CR
A=CR
B-, C (R
A)
2-C (R
B)
2-or-C ≡ C-;
C-D representative-CR
C=CR
D-,-C (R
C)
2-C (R
D)
2-or-C ≡ C-;
The R under every kind of situation wherein
ABe hydrogen independently; Halogen;-OR
A '-SR
A '-N (R
A ')
2-C (O) OR
A '-C (O) R
A '-CONHR
A '-O (C=O) R
A '-O (C=O) OR
A '-NR
A '(C=O) R
A 'N
3N
2R
A 'Cyclic acetal; Or the aliphatic of ring-type or acyclic, straight or branched, assorted aliphatic, aryl or heteroaryl, the optional replacement: hydrogen with one or more following groups; Halogen;-OR
A '-SR
A '-N (R
A ')
2-C (O) OR
A '-C (O) R
A '-CONHR
A '-O (C=O) R
A '-O (C=O) OR
A '-NR
A '(C=O) R
A 'N
3N
2R
A 'Cyclic acetal; Or the replacement of ring-type or acyclic, straight or branched or unsubstituted aliphatic, assorted aliphatic, aryl or heteroaryl moieties;
For every kind of situation, R
BBe hydrogen independently; Halogen;-OR
B '-SR
B '-N (R
B ')
2-C (O) OR
B '-C (O) R
B '-CONHR
B '-O (C=O) R
B '-O (C=O) OR
B '-NR
B '(C=O) R
B 'N
3N
2R
B 'Cyclic acetal; Or the aliphatic of ring-type or acyclic, straight or branched, assorted aliphatic, aryl or heteroaryl, the optional replacement: hydrogen with one or more following groups; Halogen;-OR
B '-SR
B '-N (R
B ')
2-C (O) OR
B '-C (O) R
B '-CONHR
B '-O (C=O) R
B '-O (C=O) OR
B '-NR
B '(C=O) R
B 'N
3N
2R
B 'Cyclic acetal; Or the replacement of ring-type or acyclic, straight or branched or unsubstituted aliphatic, assorted aliphatic, aryl or heteroaryl moieties;
For every kind of situation, R
CBe hydrogen independently; Halogen;-OR
C '-SR
C '-N (R
C ')
2-C (O) OR
C '-C (O) R
C '-CONHR
C '-O (C=O) R
C '-O (C=O) OR
C '-NR
C '(C=O) R
C 'N
3N
2R
C 'Cyclic acetal; Or the aliphatic of ring-type or acyclic, straight or branched, assorted aliphatic, aryl or heteroaryl, the optional replacement: hydrogen with one or more following groups; Halogen;-OR
C '-SR
C '-N (R
C ')
2-C (O) OR
C '-C (O) R
C '-CONHR
C '-O (C=O) R
C '-O (C=O) OR
C '-NR
C '(C=O) R
C 'N
3N
2R
C 'Cyclic acetal; Or the replacement of ring-type or acyclic, straight or branched or unsubstituted aliphatic, assorted aliphatic, aryl or heteroaryl moieties;
For every kind of situation, R
DBe hydrogen independently; Halogen;-OR
D '-SR
D '-N (R
D ')
2-C (O) OR
D '-C (O) R
D '-CONHR
D '-O (C=O) R
D '-O (C=O) OR
D '-NR
D '(C=O) R
D 'N
3N
2R
D 'Cyclic acetal; Or the aliphatic of ring-type or acyclic, straight or branched, assorted aliphatic, aryl or heteroaryl, the optional replacement: hydrogen with one or more following groups; Halogen;-OR
D '-SR
D '-N (R
D ')
2-C (O) OR
D '-C (O) R
D '-CONHR
D '-O (C=O) R
D '-O (C=O) OR
D '-NR
D '(C=O) R
D 'N
3N
2R
D 'Cyclic acetal; Or the replacement of ring-type or acyclic, straight or branched or unsubstituted aliphatic, assorted aliphatic, aryl or heteroaryl moieties; Perhaps
R wherein
A, R
B, R
COr R
DIn any two lump together and can form annulus and can pass through oxygen, sulfur, carbon or the nitrogen-atoms connection, perhaps any two adjacent R
A, R
B, R
COr R
DGroup lumps together, and can form replacement of 3-6 unit or unsubstituted aliphatic, assorted aliphatic, aryl or heteroaryl ring;
The R under every kind of situation wherein
A ', R
B ', R
C 'Or R
D 'Be hydrogen independently; Blocking group; Straight or branched, replacement or not replacement, ring-type or acyclic, aliphatic, assorted aliphatic, aryl, heteroaryl, aralkyl, arylalkenyl, sweet-smelling alkynyl, arylalkenyl, sweet-smelling alkynyl or heteroarylalkyl, impure aromatic ene base or hetaryne base section.
2. the chemical compound of following formula and its pharmacy acceptable derivates:
Wherein X is O, S, C (R
7)
2Or NR
7, the R under every kind of situation wherein
7Be hydrogen or low alkyl group independently;
Y is O or S;
R
5And R
6Be hydrogen or blocking group independently of one another;
R
8Be independently hydrogen, halogen ,-OR
9,-SR
9,-N (R
9)
2,-CZ
3,-CHZ
2,-CH
2Z, wherein Z is F, Br, Cl, I, OR
B ', NHR
B ', N (R
B ')
2Or SR
B '-(CV
2)
nOR
9,-(CV
2)
nN (R
9)
2,-(CV
2)
nSR
9The R of ,-(C=O)
9,-O (C=O) R
9The OR of ,-(C=O)
9,-O (C=O) OR
9-NH (C=O) R
9,-NH (C=O) OR
9The NHR of ,-(C=O)
9, or the aliphatic of ring-type or acyclic, straight or branched, assorted aliphatic, aryl, heteroaryl, aralkyl or heteroarylalkyl part, the optional following group that replaces with one or more appearance: halogen ,-OR
9,-SR
9,-N (R
9)
2,-(CV
2)
nOR
9,-(CV
2)
nN (R
9)
2,-(CV
2)
nSR
9The R of ,-(C=O)
9,-O (C=O) R
9The OR of ,-(C=O)
9,-O (C=O) OR
9-NH (C=O) R
9,-NH (C=O) OR
9The NHR of ,-(C=O)
9, or ring-type or acyclic, straight or branched, replacement or unsubstituted aliphatic, assorted aliphatic, aryl, heteroaryl, aralkyl or heteroarylalkyl part,
The R under every kind of situation wherein
9Be hydrogen independently; Blocking group; Ring-type or acyclic, straight or branched, replacement or unsubstituted aliphatic, assorted aliphatic, aryl or heteroaryl moieties; Or Epothilones, NSC-703147 or its analog; Polymer; Saccharide; The photoaffinity label; Or radioactive marker;
Wherein the V under every kind of situation is hydrogen, halogen, hydroxyl, sulfo-, amino, alkylamino or protected hydroxyl, sulfo-or amino independently; T under every kind of situation is 0,1 or 2 independently; N under every kind of situation is 0-10 independently;
A-B represents CR
A=CR
B-, C (R
A)
2-C (R
B)
2-or-C ≡ C-;
C-D representative-CR
C=CR
D-, C (R
C)
2-C (R
D)
2-or-C ≡ C-;
The R under every kind of situation wherein
ABe hydrogen independently; Halogen;-OR
A '-SR
A '-N (R
A ')
2-C (O) OR
A '-C (O) R
A '-CONHR
A '-O (C=O) R
A '-O (C=O) OR
A '-NR
A '(C=O) R
A 'N
3N
2R
A 'Cyclic acetal; Or the aliphatic of ring-type or acyclic, straight or branched, assorted aliphatic, aryl or heteroaryl, the optional replacement: hydrogen with one or more following groups; Halogen;-OR
A '-SR
A '-N (R
A ')
2-C (O) OR
A '-C (O) R
A '-CONHR
A '-O (C=O) R
A '-O (C=O) OR
A '-NR
A '(C=O) R
A 'N
3N
2R
A 'Cyclic acetal; Or the replacement of ring-type or acyclic, straight or branched or unsubstituted aliphatic, assorted aliphatic, aryl or heteroaryl moieties;
For every kind of situation, R
BBe hydrogen independently; Halogen;-OR
B '-SR
B '-N (R
B ')
2-C (O) OR
B '-C (O) R
B '-CONHR
B '-O (C=O) R
B '-O (C=O) OR
B '-NR
B '(C=O) R
B 'N
3N
2R
B 'Cyclic acetal; Or the aliphatic of ring-type or acyclic, straight or branched, assorted aliphatic, aryl or heteroaryl, the optional replacement: hydrogen with one or more following groups; Halogen;-OR
B '-SR
B '-N (R
B ')
2-C (O) OR
B '-C (O) R
B '-CONHR
B '-O (C=O) R
B '-O (C=O) OR
B '-NR
B '(C=O) R
B 'N
3N
2R
B 'Cyclic acetal; Or the replacement of ring-type or acyclic, straight or branched or unsubstituted aliphatic, assorted aliphatic, aryl, or heteroaryl moieties;
For every kind of situation, R
CBe hydrogen independently; Halogen;-OR
C '-SR
C '-N (R
C ')
2-C (O) OR
C '-C (O) R
C '-CONHR
C '-O (C=O) R
C '-O (C=O) OR
C '-NR
C '(C=O) R
C 'N
3N
2R
C 'Cyclic acetal; Or the aliphatic of ring-type or acyclic, straight or branched, assorted aliphatic, aryl or heteroaryl, the optional replacement: hydrogen with one or more following groups; Halogen;-OR
C '-SR
C '-N (R
C ')
2-C (O) OR
C '-C (O) R
C '-CONHR
C '-O (C=O) R
C '-O (C=O) OR
C '-NR
C '(C=O) R
C 'N
3N
2R
C 'Cyclic acetal; Or the replacement of ring-type or acyclic, straight or branched or unsubstituted aliphatic, assorted aliphatic, aryl or heteroaryl moieties;
For every kind of situation, R
DBe hydrogen independently; Halogen;-OR
D '-SR
D '-N (R
D ')
2-C (O) OR
D '-C (O) R
D '-CONHR
D '-O (C=O) R
D '-O (C=O) OR
D '-NR
D '(C=O) R
D 'N
3N
2R
D 'Cyclic acetal; Or the aliphatic of ring-type or acyclic, straight or branched, assorted aliphatic, aryl or heteroaryl, the optional replacement: hydrogen with one or more following groups; Halogen;-OR
D '-SR
D '-N (R
D ')
2-C (O) OR
D '-C (O) R
D '-CONHR
D '-O (C=O) R
D '-O (C=O) OR
D '-NR
D '(C=O) R
D 'N
3N
2R
D 'Cyclic acetal; Or the replacement of ring-type or acyclic, straight or branched or unsubstituted aliphatic, assorted aliphatic, aryl, or heteroaryl moieties; Perhaps
R wherein
A, R
B, R
COr R
DIn any two lump together and can form annulus and can pass through oxygen, sulfur, carbon or the nitrogen-atoms connection, perhaps any two adjacent R
A, R
B, R
COr R
DGroup lumps together, and can form replacement of 3-6 unit or unsubstituted aliphatic, assorted aliphatic, aryl or heteroaryl ring;
The R under every kind of situation wherein
A ', R
B ', R
C 'Or R
D 'Be hydrogen independently; Blocking group; Straight or branched, replacement or not replacement, ring-type or acyclic, aliphatic, assorted aliphatic, aryl, heteroaryl, aralkyl, arylalkenyl, sweet-smelling alkynyl, arylalkenyl, sweet-smelling alkynyl or heteroarylalkyl, impure aromatic ene base or hetaryne base section.
3. the chemical compound of claim 2, wherein A-B is-CH=C (R
B)-.
4. the chemical compound of claim 2, wherein A-B is
5. the chemical compound of claim 2, wherein R
BBe methyl.
6. the chemical compound of claim 2, wherein R
BFor-CF
3
7. claim 2,3 or 4 chemical compound, wherein R
8Be methyl.
8. claim 2,3 or 4 chemical compound, wherein R
8For-CH
2OH.
9. claim 2,3 or 4 chemical compound, wherein R
8For-CH
2NH
2
10. claim 2,3 or 4 chemical compound, wherein C-D is
Wherein Z is O, S, NR
ZOr C (R
Z)
2, R wherein
ZBe hydrogen, halogen, lower acyl or low alkyl group.
11. the chemical compound of claim 10, wherein Z is NH.
12. the chemical compound of claim 10, wherein Z is CH
2
13. the chemical compound of claim 10, wherein Z is O.
14. the chemical compound of claim 10, wherein Z is S.
15. claim 2,3 or 4 chemical compound, wherein C-D is
Or
Wherein Z is O, S, NR
ZOr C (R
Z)
2, R wherein
ZBe hydrogen, halogen, lower acyl or low alkyl group.
16. the chemical compound of claim 15, wherein Z is NH.
17. the chemical compound of claim 15, wherein Z is CH
2
18. the chemical compound of claim 2, wherein Y is S.
19. the chemical compound of claim 2, wherein Y is O.
20. claim 2,3 or 4 chemical compound, wherein C-D is-C (R
C)
2-C (R
D)
2-.
21. the chemical compound of claim 20, the wherein R under every kind of situation
CAnd R
DBe selected from hydrogen, low alkyl group, hydroxyl, halogen and lower alkoxy.
22. the chemical compound of claim 20, the wherein R under every kind of situation
CAnd R
DBe selected from hydrogen and methyl.
23. the chemical compound of claim 20, wherein each R
CBe methyl and each R
DBe hydrogen.
24. the chemical compound of claim 20, wherein each R
CBe hydrogen and each R
DBe methyl.
25. the chemical compound of claim 20, one of them R
CBe hydrogen and another R
CBe methyl.
26. the chemical compound of claim 20, one of them R
DBe hydrogen and another R
DBe methyl.
27. the chemical compound of claim 1 is selected from the chemical compound of following formula:
29. the chemical compound of claim 1 is selected from the chemical compound of following formula:
33. be used for the treatment of the pharmaceutical composition of cancer, it comprises the chemical compound and the acceptable excipient of pharmacy of claim 1.
34. the pharmaceutical composition of claim 33, but further comprise Li Mofu.
35. the pharmaceutical composition of claim 33, but further comprise Li Mofu and ethanol.
36. the pharmaceutical composition of claim 33, wherein said chemical compound is suspended in 1: but Li Mofu/ethanol of 1.
37. the pharmaceutical composition of claim 33 further comprises other cytotoxic agent.
38. be used for the treatment of the pharmaceutical composition of cancer, it comprises: claim 1 chemical compound or the acceptable salt of its pharmacy of treatment effective dose; With pharmaceutically acceptable carrier or diluent, the treatment effective dose of wherein said chemical compound is such amount: it is enough to send the every kg object of about chemical compound of 0.001 to about 40mg body weight.
39. be used for the treatment of the pharmaceutical composition of cancer, it comprises claim 1 chemical compound; With the acceptable excipient of pharmacy; Wherein said pharmaceutical composition is suitable for the object oral administration.
40. be used for the treatment of the pharmaceutical composition of cancer, it comprises claim 2 chemical compound; With the acceptable excipient of pharmacy; Wherein said pharmaceutical composition is suitable for the object oral administration.
41. the pharmaceutical composition of claim 40, wherein R
8For-CH
2OH.
42. the pharmaceutical composition of claim 40, wherein R
BFor-CHF
2,-CH
2F or-CF
3
43. the pharmaceutical composition of claim 40, wherein C-D is-CH=CH-, and wherein this pair key is an anti-configuration.
44. the pharmaceutical composition of claim 40, wherein said chemical compound as shown in the formula:
45. the pharmaceutical composition of claim 40, wherein said compositions are solid form.
46. the pharmaceutical composition of claim 40, wherein said compositions are liquid form.
47. the treatment method for cancer, it comprises that chemical compound with the claim 1 of treatment effective dose is to its object administration of needs.
48. the method for claim 47, wherein the treatment effective dose of chemical compound is such amount, and it is enough to send the chemical compound every kg body weight of about 0.001mg to about 40mg.
49. the method for claim 47, wherein the treatment effective dose of chemical compound is such amount, and it is enough to send the chemical compound every kg body weight of about 0.1mg to about 25mg.
50. the treatment method for cancer, it comprises the following formula: compound of treatment effective dose to its object oral administration of needs:
51. prepare the method for following formula: compound:
R wherein
1Be hydrogen or low alkyl group;
R
2For replacing or unsubstituted aryl, heteroaryl, aralkyl or heteroarylalkyl part;
R
5And R
6Be hydrogen or blocking group independently of one another;
X is O, S, C (R
7)
2Or NR
7, the R under every kind of situation wherein
7Be hydrogen or low alkyl group independently; With
For every kind of situation, R
BBe hydrogen independently; Halogen;-OR
B '-SR
B '-N (R
B ')
2-CY
3,-CHY
2,-CH
2Y, wherein Y is F, Br, Cl, I, OR
B ', NHR
B ', N (R
B ')
2Or SR
B '-C (O) OR
B '-C (O) R
B '-CONHR
B '-O (C=O) R
B '-O (C=O) OR
B '-NR
B '(C=O) R
B 'N
3N
2R
B 'Cyclic acetal; Or the aliphatic of ring-type or acyclic, straight or branched, assorted aliphatic, aryl or heteroaryl, the optional replacement: hydrogen with one or more following groups; Halogen;-OR
B '-SR
B '-N (R
B ')
2-C (O) OR
B '-C (O) R
B '-CONHR
B '-O (C=O) R
B '-O (C=O) OR
B '-NR
B '(C=O) R
B 'N
3N
2R
B 'Cyclic acetal; Or the replacement of ring-type or acyclic, straight or branched or unsubstituted aliphatic, assorted aliphatic, aryl or heteroaryl moieties; Or be Epothilones, NSC-703147 or its analog; Or be polymer; Saccharide; Photoaffinity label or radioactive marker; The R under every kind of situation wherein
B 'Be hydrogen independently; Blocking group; Straight or branched, replacement or not replacement, ring-type or acyclic aliphatic, assorted aliphatic, aryl, heteroaryl, aralkyl, arylalkenyl, sweet-smelling alkynyl, heteroarylalkyl, impure aromatic ene base or hetaryne base section;
It is in the presence of metal and Reducing agent with the following formula: compound isomerization:
52. the method for claim 51, wherein said metal are transition metal.
53. the method for claim 51, wherein said metal are palladium.
54. the method for claim 51, wherein said Reducing agent is selected from LiAlH
4, NaBH
4And NaBH
3CN.
55. prepare the method for following formula: compound:
R wherein
1Be hydrogen or low alkyl group;
R
2For replacing or unsubstituted aryl, heteroaryl, aralkyl or heteroarylalkyl part;
R
5And R
6Be hydrogen or blocking group independently of one another;
X is O, S, C (R
7)
2Or NR
7, the R under every kind of situation wherein
7Be hydrogen or low alkyl group independently; With
For every kind of situation, R
BBe hydrogen independently; Halogen;-OR
B '-SR
B '-N (R
B ')
2-CY
3,-CHY
2,-CH
2Y, wherein Y is F, Br, Cl, I, OR
B ', NHR
B ', N (R
B ')
2Or SR
B '-C (O) OR
B '-C (O) R
B '-CONHR
B '-O (C=O) R
B '-O (C=O) OR
B '-NR
B '(C=O) R
B 'N
3N
2R
B 'Cyclic acetal; Or the aliphatic of ring-type or acyclic, straight or branched, assorted aliphatic, aryl or heteroaryl, the optional replacement: hydrogen with one or more following groups; Halogen;-OR
B '-SR
B '-N (R
B ')
2-C (O) OR
B '-C (O) R
B '-CONHR
B '-O (C=O) R
B '-O (C=O) OR
B '-NR
B '(C=O) R
B 'N
3N
2R
B 'Cyclic acetal; Or the replacement of ring-type or acyclic, straight or branched or unsubstituted aliphatic, assorted aliphatic, aryl, or heteroaryl moieties; Or be Epothilones, NSC-703147 or its analog; Or be polymer; Saccharide, photoaffinity label or radioactive marker; The R under every kind of situation wherein
B 'Be hydrogen independently; Blocking group; Straight or branched, replacement or not replacement, ring-type or acyclic aliphatic, assorted aliphatic, aryl, heteroaryl, aralkyl, arylalkenyl, sweet-smelling alkynyl, heteroarylalkyl, impure aromatic ene base or hetaryne base section;
It is with following formula: compound and Cabbeen or carbenoid reagent reacting:
56. the method for claim 55, wherein Cabbeen is CH
2N
2
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54840204P | 2004-02-27 | 2004-02-27 | |
US60/548,402 | 2004-02-27 | ||
US10/921,109 | 2004-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1976699A true CN1976699A (en) | 2007-06-06 |
Family
ID=38126278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200580013480 Pending CN1976699A (en) | 2004-02-27 | 2005-02-28 | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1976699A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110689927A (en) * | 2019-09-26 | 2020-01-14 | 中山大学 | Drug resistance key gene screening method and device, electronic equipment and storage medium |
-
2005
- 2005-02-28 CN CN 200580013480 patent/CN1976699A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110689927A (en) * | 2019-09-26 | 2020-01-14 | 中山大学 | Drug resistance key gene screening method and device, electronic equipment and storage medium |
CN110689927B (en) * | 2019-09-26 | 2021-11-23 | 中山大学 | Drug resistance key gene screening method and device, electronic equipment and storage medium |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1759115A (en) | Synthesis of epothilones, intermediates thereto, analogues and uses thereof | |
CN1205208C (en) | C-21 modified epothilones | |
CN1192031C (en) | Epothilones derivatives, their synthesis and uses | |
CN1160343C (en) | Aminothiazole inhibitors of cyclin dependent protein kinasses of cells | |
CN1040327C (en) | Optionally substituted pyrido [2,3-d] pyrimidine-2,4(1H,3H)-diones and pyrido [2,3-d] pyrimidine-2(1H,3H)-ones | |
CN100338061C (en) | Alkyne-aryl phosphodiesterase-4 inhibitors | |
CN1086386C (en) | Novel multi-drug resistance modifier | |
CN1582277A (en) | Amide derivatives as glycogen synthase kinase 3-beta inhibitors | |
CN1582285A (en) | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (GSK3 inhibitors) | |
CN1153771C (en) | Glucocorticoid-selective antiinflammatory agents | |
CN1349534A (en) | 6-alkenyl-, 6-alkinyl-and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations | |
CN1444582A (en) | Heterocyclic compound, their preparation and use | |
CN1489583A (en) | Novel physiologically active substance | |
CN1281441A (en) | Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors | |
CN1498212A (en) | New spirotricyclic derivatives and their use as phosphodiesterase-7-inhibitors | |
CN1956982A (en) | Selective inhibitors against Cdk4 and Cdk6 having aminothiazole skeleton | |
CN1832939A (en) | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | |
CN1429210A (en) | Substituted thioacetamides | |
CN1227555A (en) | Cytokine production inhibitors triazepine compounds, and intermediates thereof | |
CN1524080A (en) | Phthalatyinone-piperidino-derivatives as pde4 inhibitors | |
CA2761663A1 (en) | 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof, and therapeutic use thereof | |
CN101061111A (en) | DNA-PK inhibitors | |
CN1255161A (en) | Protease inhibitors | |
JP2007525519A (en) | Synthesis and use of epothilone, its intermediates and analogues | |
CN1340053A (en) | Epothilon derivatives, method for the production and the use as pharmaceuticals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |